TABLE OF CONTENTS

| ​ | Title of each class                                                                               | ​ | ​ | Name of each exchange on which registered | ​ |
|---------|---------------------------------------------------------------------------------------------------|---------|---------|-------------------------------------------|---------|
| ​ | American Depositary Shares, each representing 12 Ordinary Shares, par value £0.001 per share | ​ | ​ | The Nasdaq Global Market                  | ​ |
| ​ | Large accelerated filer ☒ | ​ | ​ | Accelerated filer ☐ | ​ | ​ | Non-accelerated filer ☐ | ​ | ​ | Emerging growth company ☐​ | ​ |
|---------|---------------------------------|---------|---------|---------------------------|---------|---------|-------------------------------|---------|---------|----------------------------------------|---------|

----

TABLE OF CONTENTS​

| ​                                                                  | ​ | ​ | Page    |
|--------------------------------------------------------------------------|---------|---------|---------|
| GENERAL INFORMATION                                                      | ​ | ​ | ​ | ​ | 1 |
| PRESENTATION OF FINANCIAL AND OTHER DATA                                 | ​ | ​ | ​ | ​ | 1 |
| INFORMATION REGARDING FORWARD-LOOKING STATEMENTS                         | ​ | ​ | ​ | ​ | 1 |
| NOTE REGARDING EXPANDED ACCESS STUDIES                                   | ​ | ​ | ​ | ​ | 3 |
| PART I                                                                   | ​ | ​ | ​ | ​ | ​ |
| Item 1Identity of Directors, Senior Management and Advisers ​ | ​ | ​ | ​ | ​ | 4 |
| Item 2Offer Statistics and Expected Timetable ​               | ​ | ​ | ​ | ​ | 4 |
| Item 3Key Information ​                                       | ​ | ​ | ​ | ​ | 4 |
| A.Selected Financial Data ​                                        | ​ | ​ | ​ | ​ | 4 |
| B.Capitalization and Indebtedness ​                                | ​ | ​ | ​ | ​ | 6 |
| C.Reasons for the Offer and Use of Proceeds ​                      | ​ | ​ | ​ | ​ | 6 |
| D.Risk Factors ​                                                   | ​ | ​ | ​ | ​ | 7 |
| Item 4Information on the Company ​                            | ​ | ​ | ​ | ​ | 38 |
| A.History and Development of the Company ​                         | ​ | ​ | ​ | ​ | 38 |
| B.Business ​                                                       | ​ | ​ | ​ | ​ | 38 |
| C.Organizational Structure ​                                       | ​ | ​ | ​ | ​ | 84 |
| D.Property, Plant and Equipment ​                                  | ​ | ​ | ​ | ​ | 85 |
| Item 4A.Unresolved Staff Comments ​                           | ​ | ​ | ​ | ​ | 85 |
| Item 5.Operating and Financial Review and Prospects ​         | ​ | ​ | ​ | ​ | 86 |
| A.Operating Results ​                                              | ​ | ​ | ​ | ​ | 86 |
| B.Liquidity and Capital Resources ​                                | ​ | ​ | ​ | ​ | 101 |
| C.Research and Development, Patents and Licenses, etc. ​           | ​ | ​ | ​ | ​ | 102 |
| D.Trend information ​                                              | ​ | ​ | ​ | ​ | 103 |
| E.Off Balance Sheet Arrangements ​                                 | ​ | ​ | ​ | ​ | 104 |
| F.Tabular Disclosure of Contractual Obligations ​                  | ​ | ​ | ​ | ​ | 105 |
| G.Safe Harbor ​                                                    | ​ | ​ | ​ | ​ | 105 |
| Item 6Directors, Senior Management and Employees ​            | ​ | ​ | ​ | ​ | 106 |
| A.Directors and Senior Management ​                                | ​ | ​ | ​ | ​ | 106 |
| B.Compensation ​                                                   | ​ | ​ | ​ | ​ | 109 |
| C.Board Practices ​                                                | ​ | ​ | ​ | ​ | 124 |
| D.Employees ​                                                      | ​ | ​ | ​ | ​ | 126 |
| E.Share Ownership ​                                                | ​ | ​ | ​ | ​ | 126 |
| Item 7Major Shareholders and Related Party Transactions ​     | ​ | ​ | ​ | ​ | 127 |
| A.Major Shareholders ​                                             | ​ | ​ | ​ | ​ | 127 |
| B.Related Party Transactions ​                                     | ​ | ​ | ​ | ​ | 128 |
| C.Interests of Experts and Counsel ​                               | ​ | ​ | ​ | ​ | 129 |
| Item 8Financial Information ​                                 | ​ | ​ | ​ | ​ | 129 |
| A.Consolidated Statements and Other Financial Information ​        | ​ | ​ | ​ | ​ | 129 |
| B.Significant Changes ​                                            | ​ | ​ | ​ | ​ | 129 |

----

TABLE OF CONTENTS​

| ​                                                                                           | ​ | ​ | Page    |
|---------------------------------------------------------------------------------------------------|---------|---------|---------|
| Item 9The Offer and Listing ​                                                          | ​ | ​ | ​ | ​ | 129 |
| A.Offer and Listing Details ​                                                               | ​ | ​ | ​ | ​ | 129 |
| B.Plan of Distribution ​                                                                    | ​ | ​ | ​ | ​ | 130 |
| C.Markets ​                                                                                 | ​ | ​ | ​ | ​ | 130 |
| D.Selling Shareholders ​                                                                    | ​ | ​ | ​ | ​ | 130 |
| E.Dilution ​                                                                                | ​ | ​ | ​ | ​ | 130 |
| F.Expenses of the Issue ​                                                                   | ​ | ​ | ​ | ​ | 130 |
| Item 10Additional Information ​                                                        | ​ | ​ | ​ | ​ | 130 |
| A.Share Capital ​                                                                           | ​ | ​ | ​ | ​ | 130 |
| B.Memorandum and Articles of Association ​                                                  | ​ | ​ | ​ | ​ | 130 |
| C.Material Contracts ​                                                                      | ​ | ​ | ​ | ​ | 130 |
| D.Exchange Controls ​                                                                       | ​ | ​ | ​ | ​ | 130 |
| E.Taxation ​                                                                                | ​ | ​ | ​ | ​ | 131 |
| F.Dividends and Paying Agents ​                                                             | ​ | ​ | ​ | ​ | 138 |
| G.Statement by Experts ​                                                                    | ​ | ​ | ​ | ​ | 138 |
| H.Documents on Display ​                                                                    | ​ | ​ | ​ | ​ | 138 |
| I.Subsidiary Information ​                                                                  | ​ | ​ | ​ | ​ | 138 |
| Item 11Quantitative and Qualitative Disclosures About Market Risk ​                    | ​ | ​ | ​ | ​ | 138 |
| Item 12Description of Securities Other than Equity Securities ​                        | ​ | ​ | ​ | ​ | 139 |
| A.Debt Securities ​                                                                         | ​ | ​ | ​ | ​ | 139 |
| B.Warrants and Rights ​                                                                     | ​ | ​ | ​ | ​ | 139 |
| C.Other Securities ​                                                                        | ​ | ​ | ​ | ​ | 139 |
| D.American Depositary Shares ​                                                              | ​ | ​ | ​ | ​ | 139 |
| PART II                                                                                           | ​ | ​ | ​ | ​ | ​ |
| Item 13.Defaults, Dividend Arrearages and Delinquencies ​                              | ​ | ​ | ​ | ​ | 141 |
| Item 14.Material Modifications To The Rights of Security Holders and Use of Proceeds ​ | ​ | ​ | ​ | ​ | 141 |
| Item 15.Controls and Procedures ​                                                      | ​ | ​ | ​ | ​ | 141 |
| A.Disclosure Controls and Procedures ​                                                      | ​ | ​ | ​ | ​ | 141 |
| B.Management’s Annual Report on Internal Control over Financial Reporting ​           | ​ | ​ | ​ | ​ | 141 |
| C.Attestation Report of the Registered Public Accounting Firm ​                             | ​ | ​ | ​ | ​ | 142 |
| D.Changes in Internal Control Over Financial Reporting ​                                    | ​ | ​ | ​ | ​ | 143 |
| Item 16A.Audit Committee Financial Expert ​                                            | ​ | ​ | ​ | ​ | 143 |
| Item 16B.Code of Ethics ​                                                              | ​ | ​ | ​ | ​ | 143 |
| Item 16C.Principal Accountant Fees and Services ​                                      | ​ | ​ | ​ | ​ | 143 |
| Item 16D.Exemptions From the Listing Standards For Audit Committees ​                  | ​ | ​ | ​ | ​ | 144 |
| Item 16E.Purchases of Equity Securities by the Issuer and Affiliated Purchasers ​      | ​ | ​ | ​ | ​ | 144 |
| Item 16F.Change in the Registrant’s Certifying Accountant ​                      | ​ | ​ | ​ | ​ | 144 |
| Item 16G.Corporate Governance ​                                                        | ​ | ​ | ​ | ​ | 144 |
| Item 16H.Mine Safety Disclosure ​                                                      | ​ | ​ | ​ | ​ | 144 |
| PART III                                                                                          | ​ | ​ |
| Item 17Financial Statements ​                                                          | ​ | ​ | ​ | ​ | 145 |
| Item 18Financial Statements ​                                                          | ​ | ​ | ​ | ​ | 145 |
| Item 19Exhibits ​                                                                      | ​ | ​ | ​ | ​ | 145 |

----

TABLE OF CONTENTS​​​

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS​​​​

| ​                                    | ​ | ​ | Year Ended September 30,         | ​ |
|--------------------------------------------|---------|---------|---------------------------------------|---------|
| ​                                    | ​ | ​ | 2017                                  | ​ | ​ | 2017(1) | ​ | ​ | 2016(1) | ​ | ​ | 2015(1) | ​ | ​ | 2014(1) | ​ | ​ | 2013(1)(2) | ​ |
| ​                                    | ​ | ​ | $                                     | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ |
| ​                                    | ​ | ​ | (in thousands, except per share data) | ​ |
| Income Statement Data:                     | ​ | ​ | ​                               | ​ | ​ | ​ | ​ |
| Revenue                                    | ​ | ​ | ​                               | ​ | 11,004 | ​ | ​ | ​ | ​ | ​ | 8,238 | ​ | ​ | ​ | ​ | ​ | 10,315 | ​ | ​ | ​ | ​ | ​ | 28,540 | ​ | ​ | ​ | ​ | ​ | 30,045 | ​ | ​ | ​ | ​ | ​ | 27,295 | ​ | ​ |
| Cost of sales                              | ​ | ​ | ​                               | ​ | (4,730) | ​ | ​ | ​ | ​ | ​ | (3,541) | ​ | ​ | ​ | ​ | ​ | (2,719) | ​ | ​ | ​ | ​ | ​ | (2,618) | ​ | ​ | ​ | ​ | ​ | (2,060) | ​ | ​ | ​ | ​ | ​ | (1,276) | ​ | ​ |
| Research and development expenditure       | ​ | ​ | ​                               | ​ | (148,576) | ​ | ​ | ​ | ​ | ​ | (111,229) | ​ | ​ | ​ | ​ | ​ | (99,815) | ​ | ​ | ​ | ​ | ​ | (76,785) | ​ | ​ | ​ | ​ | ​ | (43,475) | ​ | ​ | ​ | ​ | ​ | (32,697) | ​ | ​ |
| Sales, general and administrative expenses | ​ | ​ | ​                               | ​ | (55,700) | ​ | ​ | ​ | ​ | ​ | (41,699) | ​ | ​ | ​ | ​ | ​ | (19,939) | ​ | ​ | ​ | ​ | ​ | (12,569) | ​ | ​ | ​ | ​ | ​ | (7,337) | ​ | ​ | ​ | ​ | ​ | (3,555) | ​ | ​ |
| Net foreign exchange (losses)/gains        | ​ | ​ | ​                               | ​ | (6,739) | ​ | ​ | ​ | ​ | ​ | (5,045) | ​ | ​ | ​ | ​ | ​ | 25,551 | ​ | ​ | ​ | ​ | ​ | 6,202 | ​ | ​ | ​ | ​ | ​ | 3,188 | ​ | ​ | ​ | ​ | ​ | (237) | ​ | ​ |
| Operating loss                             | ​ | ​ | ​                               | ​ | (204,741) | ​ | ​ | ​ | ​ | ​ | (153,276) | ​ | ​ | ​ | ​ | ​ | (86,607) | ​ | ​ | ​ | ​ | ​ | (57,230) | ​ | ​ | ​ | ​ | ​ | (19,639) | ​ | ​ | ​ | ​ | ​ | (10,470) | ​ | ​ |
| Interest expense                           | ​ | ​ | ​                               | ​ | (995) | ​ | ​ | ​ | ​ | ​ | (745) | ​ | ​ | ​ | ​ | ​ | (173) | ​ | ​ | ​ | ​ | ​ | (75) | ​ | ​ | ​ | ​ | ​ | (61) | ​ | ​ | ​ | ​ | ​ | (64) | ​ | ​ |
| Interest and other income                  | ​ | ​ | ​                               | ​ | 2,159 | ​ | ​ | ​ | ​ | ​ | 1,616 | ​ | ​ | ​ | ​ | ​ | 608 | ​ | ​ | ​ | ​ | ​ | 244 | ​ | ​ | ​ | ​ | ​ | 130 | ​ | ​ | ​ | ​ | ​ | 178 | ​ | ​ |
| Loss before tax                            | ​ | ​ | ​                               | ​ | (203,577) | ​ | ​ | ​ | ​ | ​ | (152,405) | ​ | ​ | ​ | ​ | ​ | (86,172) | ​ | ​ | ​ | ​ | ​ | (57,061) | ​ | ​ | ​ | ​ | ​ | (19,570) | ​ | ​ | ​ | ​ | ​ | (10,356) | ​ | ​ |
| Tax benefit                                | ​ | ​ | ​                               | ​ | 27,673 | ​ | ​ | ​ | ​ | ​ | 20,717 | ​ | ​ | ​ | ​ | ​ | 22,515 | ​ | ​ | ​ | ​ | ​ | 12,498 | ​ | ​ | ​ | ​ | ​ | 4,911 | ​ | ​ | ​ | ​ | ​ | 5,807 | ​ | ​ |
| Loss for the year                          | ​ | ​ | ​                               | ​ | (175,904) | ​ | ​ | ​ | ​ | ​ | (131,688) | ​ | ​ | ​ | ​ | ​ | (63,657) | ​ | ​ | ​ | ​ | ​ | (44,563) | ​ | ​ | ​ | ​ | ​ | (14,659) | ​ | ​ | ​ | ​ | ​ | (4,549) | ​ | ​ |
| ​                                    |

----

TABLE OF CONTENTS

| ​                           | ​ | ​ | Year Ended September 30,         | ​ |
|-----------------------------------|---------|---------|---------------------------------------|---------|
| ​                           | ​ | ​ | 2017                                  | ​ | ​ | 2017(1) | ​ | ​ | 2016(1) | ​ | ​ | 2015(1) | ​ | ​ | 2014(1) | ​ | ​ | 2013(1)(2) | ​ |
| ​                           | ​ | ​ | $                                     | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ |
| ​                           | ​ | ​ | (in thousands, except per share data) | ​ |
| Loss per share                    | ​ | ​ | ​                               | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Basic                             | ​ | ​ | ​                               | ​ | (0.58) | ​ | ​ | ​ | ​ | ​ | (0.43) | ​ | ​ | ​ | ​ | ​ | (0.24) | ​ | ​ | ​ | ​ | ​ | (0.18) | ​ | ​ | ​ | ​ | ​ | (0.07) | ​ | ​ | ​ | ​ | ​ | (0.03) | ​ | ​ |
| Diluted                           | ​ | ​ | ​                               | ​ | (0.58) | ​ | ​ | ​ | ​ | ​ | (0.43) | ​ | ​ | ​ | ​ | ​ | (0.24) | ​ | ​ | ​ | ​ | ​ | (0.18) | ​ | ​ | ​ | ​ | ​ | (0.07) | ​ | ​ | ​ | ​ | ​ | (0.03) | ​ | ​ |
| Weighted average number of shares | ​ | ​ | ​                               | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Basic                             | ​ | ​ | ​                               | ​ | 303.6 | ​ | ​ | ​ | ​ | ​ | 303.6 | ​ | ​ | ​ | ​ | ​ | 270.4 | ​ | ​ | ​ | ​ | ​ | 246.4 | ​ | ​ | ​ | ​ | ​ | 210.4 | ​ | ​ | ​ | ​ | ​ | 151.5 | ​ | ​ |
| Diluted                           | ​ | ​ | ​                               | ​ | 304.1 | ​ | ​ | ​ | ​ | ​ | 304.1 | ​ | ​ | ​ | ​ | ​ | 277.5 | ​ | ​ | ​ | ​ | ​ | 254.2 | ​ | ​ | ​ | ​ | ​ | 219.9 | ​ | ​ | ​ | ​ | ​ | 158.2 | ​ | ​ |
| ​                          | ​ | ​ | As at September 30, | ​ |
|----------------------------------|---------|---------|--------------------------|---------|
| ​                          | ​ | ​ | 2017                     | ​ | ​ | 2017(1) | ​ | ​ | 2016(1) | ​ | ​ | 2015(1) | ​ | ​ | 2014(1)(3) | ​ | ​ | 2013(1) | ​ |
| ​                          | ​ | ​ | $                        | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ |
| ​                          | ​ | ​ | (in thousands)           | ​ |
| Balance Sheet Data:              | ​ | ​ | ​                  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Non-current assets               | ​ | ​ | ​                  | ​ | 75,079 | ​ | ​ | ​ | ​ | ​ | 56,207 | ​ | ​ | ​ | ​ | ​ | 48,659 | ​ | ​ | ​ | ​ | ​ | 34,606 | ​ | ​ | ​ | ​ | ​ | 17,126 | ​ | ​ | ​ | ​ | ​ | 11,581 | ​ | ​ |
| Current assets                   | ​ | ​ | ​                  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Inventories                      | ​ | ​ | ​                  | ​ | 5,669 | ​ | ​ | ​ | ​ | ​ | 4,244 | ​ | ​ | ​ | ​ | ​ | 4,248 | ​ | ​ | ​ | ​ | ​ | 4,756 | ​ | ​ | ​ | ​ | ​ | 4,777 | ​ | ​ | ​ | ​ | ​ | 4,661 | ​ | ​ |
| Trade and other receivables      | ​ | ​ | ​                  | ​ | 41,795 | ​ | ​ | ​ | ​ | ​ | 31,289 | ​ | ​ | ​ | ​ | ​ | 25,878 | ​ | ​ | ​ | ​ | ​ | 15,514 | ​ | ​ | ​ | ​ | ​ | 7,108 | ​ | ​ | ​ | ​ | ​ | 4,633 | ​ | ​ |
| Cash and cash equivalents        | ​ | ​ | ​                  | ​ | 322,154 | ​ | ​ | ​ | ​ | ​ | 241,175 | ​ | ​ | ​ | ​ | ​ | 374,392 | ​ | ​ | ​ | ​ | ​ | 234,872 | ​ | ​ | ​ | ​ | ​ | 164,491 | ​ | ​ | ​ | ​ | ​ | 38,069 | ​ | ​ |
| Total current assets             | ​ | ​ | ​                  | ​ | 369,618 | ​ | ​ | ​ | ​ | ​ | 276,708 | ​ | ​ | ​ | ​ | ​ | 404,518 | ​ | ​ | ​ | ​ | ​ | 255,142 | ​ | ​ | ​ | ​ | ​ | 176,376 | ​ | ​ | ​ | ​ | ​ | 47,363 | ​ | ​ |
| Total assets                     | ​ | ​ | ​                  | ​ | 444,697 | ​ | ​ | ​ | ​ | ​ | 332,915 | ​ | ​ | ​ | ​ | ​ | 453,177 | ​ | ​ | ​ | ​ | ​ | 289,748 | ​ | ​ | ​ | ​ | ​ | 193,502 | ​ | ​ | ​ | ​ | ​ | 58,944 | ​ | ​ |
| Current liabilities              | ​ | ​ | ​                  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Trade and other payables         | ​ | ​ | ​                  | ​ | (44,238) | ​ | ​ | ​ | ​ | ​ | (33,119) | ​ | ​ | ​ | ​ | ​ | (31,170) | ​ | ​ | ​ | ​ | ​ | (24,022) | ​ | ​ | ​ | ​ | ​ | (12,376) | ​ | ​ | ​ | ​ | ​ | (9,440) | ​ | ​ |
| Current tax liabilities          | ​ | ​ | ​                  | ​ | (1,119) | ​ | ​ | ​ | ​ | ​ | (838) | ​ | ​ | ​ | ​ | ​ | (883) | ​ | ​ | ​ | ​ | ​ | (366) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Obligations under finance leases | ​ | ​ | ​                  | ​ | (274) | ​ | ​ | ​ | ​ | ​ | (205) | ​ | ​ | ​ | ​ | ​ | (211) | ​ | ​ | ​ | ​ | ​ | (111) | ​ | ​ | ​ | ​ | ​ | (126) | ​ | ​ | ​ | ​ | ​ | (100) | ​ | ​ |
| Deferred revenue                 | ​ | ​ | ​                  | ​ | (3,082) | ​ | ​ | ​ | ​ | ​ | (2,307) | ​ | ​ | ​ | ​ | ​ | (2,686) | ​ | ​ | ​ | ​ | ​ | (3,269) | ​ | ​ | ​ | ​ | ​ | (4,827) | ​ | ​ | ​ | ​ | ​ | (3,181) | ​ | ​ |
| Non-current liabilities          | ​ | ​ | ​                  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Trade and other payables         | ​ | ​ | ​                  | ​ | (12,364) | ​ | ​ | ​ | ​ | ​ | (9,256) | ​ | ​ | ​ | ​ | ​ | (9,423) | ​ | ​ | ​ | ​ | ​ | (8,445) | ​ | ​ | ​ | ​ | ​ | (7,927) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Obligations under finance leases | ​ | ​ | ​                  | ​ | (6,352) | ​ | ​ | ​ | ​ | ​ | (4,755) | ​ | ​ | ​ | ​ | ​ | (4,959) | ​ | ​ | ​ | ​ | ​ | (1,540) | ​ | ​ | ​ | ​ | ​ | (1,781) | ​ | ​ | ​ | ​ | ​ | (1,905) | ​ | ​ |
| Deferred revenue                 | ​ | ​ | ​                  | ​ | (5,690) | ​ | ​ | ​ | ​ | ​ | (4,260) | ​ | ​ | ​ | ​ | ​ | (5,355) | ​ | ​ | ​ | ​ | ​ | (6,725) | ​ | ​ | ​ | ​ | ​ | (7,881) | ​ | ​ | ​ | ​ | ​ | (8,916) | ​ | ​ |
| Share capital                    | ​ | ​ | ​                  | ​ | 406 | ​ | ​ | ​ | ​ | ​ | 304 | ​ | ​ | ​ | ​ | ​ | 302 | ​ | ​ | ​ | ​ | ​ | 261 | ​ | ​ | ​ | ​ | ​ | 237 | ​ | ​ | ​ | ​ | ​ | 178 | ​ | ​ |
| Share premium                    | ​ | ​ | ​                  | ​ | 743,450 | ​ | ​ | ​ | ​ | ​ | 556,570 | ​ | ​ | ​ | ​ | ​ | 556,477 | ​ | ​ | ​ | ​ | ​ | 349,275 | ​ | ​ | ​ | ​ | ​ | 220,551 | ​ | ​ | ​ | ​ | ​ | 84,005 | ​ | ​ |
| Net assets/Total equity          | ​ | ​ | ​                  | ​ | 371,578 | ​ | ​ | ​ | ​ | ​ | 278,175 | ​ | ​ | ​ | ​ | ​ | 398,490 | ​ | ​ | ​ | ​ | ​ | 245,270 | ​ | ​ | ​ | ​ | ​ | 158,584 | ​ | ​ | ​ | ​ | ​ | 35,402 | ​ | ​ |
| ​                                             | ​ | ​ | Year Ended September 30, | ​ |
|-----------------------------------------------------|---------|---------|-------------------------------|---------|
| ​                                             | ​ | ​ | 2017                          | ​ | ​ | 2017(1) | ​ | ​ | 2016(1) | ​ | ​ | 2015(1) | ​ | ​ | 2014(1) | ​ | ​ | 2013(1) | ​ |
| ​                                             | ​ | ​ | $                             | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ |
| ​                                             | ​ | ​ | (in thousands)                | ​ |
| Cash Flow Data:                                     | ​ | ​ | ​                       | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Net cash outflow from operating activities          | ​ | ​ | ​                       | ​ | (147,259) | ​ | ​ | ​ | ​ | ​ | (110,245) | ​ | ​ | ​ | ​ | ​ | (84,594) | ​ | ​ | ​ | ​ | ​ | (46,471) | ​ | ​ | ​ | ​ | ​ | (12,626) | ​ | ​ | ​ | ​ | ​ | (7,468) | ​ | ​ |
| Net cash outflow from investing activities          | ​ | ​ | ​                       | ​ | (20,387) | ​ | ​ | ​ | ​ | ​ | (15,262) | ​ | ​ | ​ | ​ | ​ | (8,756) | ​ | ​ | ​ | ​ | ​ | (17,791) | ​ | ​ | ​ | ​ | ​ | (7,095) | ​ | ​ | ​ | ​ | ​ | (2,076) | ​ | ​ |
| Net cash (outflow)/inflow from financing activities | ​ | ​ | ​                       | ​ | (2,742) | ​ | ​ | ​ | ​ | ​ | (2,053) | ​ | ​ | ​ | ​ | ​ | 206,807 | ​ | ​ | ​ | ​ | ​ | 128,419 | ​ | ​ | ​ | ​ | ​ | 144,267 | ​ | ​ | ​ | ​ | ​ | 18,253 | ​ | ​ |

----

TABLE OF CONTENTS​​

| ​                                   | ​ | ​ | Noon Buying Rate | ​ | ​ |
|-------------------------------------------|---------|---------|------------------|---------|---------|
| ​                                   | ​ | ​ | Period End       | ​ | ​ | Average(1) | ​ | ​ | High | ​ | ​ | Low | ​ | ​ |
| Year ended September 30:             | ​ | ​ | ​          | ​ | ​ | ​ |
| 2012                                      | ​ | ​ | ​          | ​ | 1.6132  | ​ | ​ | ​ | ​ | ​ | 1.5768 | ​ | ​ | ​ | ​ | ​ | 1.6263 | ​ | ​ | ​ | ​ | ​ | 1.5301 | ​ | ​ | ​ |
| 2013                                      | ​ | ​ | ​          | ​ | 1.6179  | ​ | ​ | ​ | ​ | ​ | 1.5609 | ​ | ​ | ​ | ​ | ​ | 1.6275 | ​ | ​ | ​ | ​ | ​ | 1.4837 | ​ | ​ | ​ |
| 2014                                      | ​ | ​ | ​          | ​ | 1.6220  | ​ | ​ | ​ | ​ | ​ | 1.6570 | ​ | ​ | ​ | ​ | ​ | 1.7165 | ​ | ​ | ​ | ​ | ​ | 1.5904 | ​ | ​ | ​ |
| 2015                                      | ​ | ​ | ​          | ​ | 1.5116  | ​ | ​ | ​ | ​ | ​ | 1.5447 | ​ | ​ | ​ | ​ | ​ | 1.6216 | ​ | ​ | ​ | ​ | ​ | 1.4648 | ​ | ​ | ​ |
| 2016                                      | ​ | ​ | ​          | ​ | 1.3015  | ​ | ​ | ​ | ​ | ​ | 1.4228 | ​ | ​ | ​ | ​ | ​ | 1.5475 | ​ | ​ | ​ | ​ | ​ | 1.2874 | ​ | ​ | ​ |
| 2017                                      | ​ | ​ | ​          | ​ | 1.3402  | ​ | ​ | ​ | ​ | ​ | 1.2680 | ​ | ​ | ​ | ​ | ​ | 1.3578 | ​ | ​ | ​ | ​ | ​ | 1.2118 | ​ | ​ | ​ |
| 2018 (through November 24, 2017)          | ​ | ​ | ​          | ​ | 1.3336  | ​ | ​ | ​ | ​ | ​ | 1.3191 | ​ | ​ | ​ | ​ | ​ | 1.3336 | ​ | ​ | ​ | ​ | ​ | 1.3063 | ​ | ​ | ​ |
| Month:                                    | ​ | ​ | ​          | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| May 2017                             | ​ | ​ | ​          | ​ | 1.2905  | ​ | ​ | ​ | ​ | ​ | 1.2929 | ​ | ​ | ​ | ​ | ​ | 1.3018 | ​ | ​ | ​ | ​ | ​ | 1.2795 | ​ | ​ | ​ |
| June 2017                            | ​ | ​ | ​          | ​ | 1.2995  | ​ | ​ | ​ | ​ | ​ | 1.2810 | ​ | ​ | ​ | ​ | ​ | 1.2995 | ​ | ​ | ​ | ​ | ​ | 1.2628 | ​ | ​ | ​ |
| July 2017                            | ​ | ​ | ​          | ​ | 1.3196  | ​ | ​ | ​ | ​ | ​ | 1.2996 | ​ | ​ | ​ | ​ | ​ | 1.3196 | ​ | ​ | ​ | ​ | ​ | 1.2851 | ​ | ​ | ​ |
| August 2017                          | ​ | ​ | ​          | ​ | 1.2888  | ​ | ​ | ​ | ​ | ​ | 1.2952 | ​ | ​ | ​ | ​ | ​ | 1.3236 | ​ | ​ | ​ | ​ | ​ | 1.2787 | ​ | ​ | ​ |
| September 2017                       | ​ | ​ | ​          | ​ | 1.3402  | ​ | ​ | ​ | ​ | ​ | 1.3340 | ​ | ​ | ​ | ​ | ​ | 1.3578 | ​ | ​ | ​ | ​ | ​ | 1.2972 | ​ | ​ | ​ |
| October 2017                         | ​ | ​ | ​          | ​ | 1.3281  | ​ | ​ | ​ | ​ | ​ | 1.3202 | ​ | ​ | ​ | ​ | ​ | 1.3304 | ​ | ​ | ​ | ​ | ​ | 1.3063 | ​ | ​ | ​ |
| November 2017 (through November 24, 2017) | ​ | ​ | ​          | ​ | 1.3336  | ​ | ​ | ​ | ​ | ​ | 1.3178 | ​ | ​ | ​ | ​ | ​ | 1.3336 | ​ | ​ | ​ | ​ | ​ | 1.3067 | ​ | ​ | ​ |

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​​​

----

TABLE OF CONTENTS

| Product/Product Candidates | ​                                                     | ​ | Indication                               | ​                                  | ​ | Partner(s)               | ​                                                                                    | ​ | Status                                                                                                                              | ​ | ​ | Expected Next Steps                                                                                                                    | ​ |
|----------------------------|-------------------------------------------------------------|---------|------------------------------------------|------------------------------------------|---------|--------------------------|--------------------------------------------------------------------------------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------|---------|---------|----------------------------------------------------------------------------------------------------------------------------------------|---------|
| Epidiolex (CBD)            | ​                                                     | ​ | Childhood-onset epilepsy                 | ​                                  | ​ | We retain global rights. | ​                                                                                    | ​ | Positive results in Phase 3 trials in Dravet syndrome and LGS. NDA submitted in October 2017 for Dravet syndrome and LGS. | ​ | ​ | MAA submission late 2017. PDUFA date expected to be mid-2018. Data from second Phase 3 Dravet syndrome trial expected in H2 2018. | ​ |
| ​                    | Initial targets: Dravet syndrome and LGS Follow-up targets: | ​ |
| ​                    | ​                                                     | ​ | TSC                                      | ​                                  | ​ | ​                  | ​                                                                                    | ​ | Phase 3 trial in TSC underway.                                                                                                 | ​ | ​ | Data from Phase 3 TSC trial expected in H2 2018.                                                                                  | ​ |
| ​                    | ​                                                     | ​ | IS                                       | ​                                  | ​ | ​                  | ​                                                                                    | ​ | Two-part Phase 2/3 trial in IS commenced in Q4 2016.                                                                           | ​ | ​ | Data from Part A expected Q1 2018. Decision on whether to proceed to second pivotal part of trial                                 | ​ |
| GWP42006 (CBDV)            | ​                                                     | ​ | Epilepsy                                 | ​                                  | ​ | We retain global rights  | ​                                                                                    | ​ | Phase 2 trial ongoing in adults with focal seizures.                                                                           | ​ | ​ | Phase 2 data expected Q1 2018.                                                                                                    | ​ |
| ​                    | ASD                                                         | ​ | ​                                  | FDA orphan designation in Rett syndrome. | ​ | ​                  | A Phase 2 placebo-controlled trial in this condition is expected to commence in 2018. | ​ |
| Intravenous GWP42003       | ​                                                     | ​ | Neonatal Hypoxic-Ischemic Encephalopathy | ​                                  | ​ | We retain global rights  | ​                                                                                    | ​ | Phase 1 trial in healthy volunteers complete.                                                                                  | ​ | ​ | Phase 2 trial in planning.                                                                                                        | ​ |
| Product/Product Candidates | ​ | ​ | Indication               | ​ | ​ | Partner(s)                                                              | ​ | ​ | Status                                                                                                          | ​ | ​ | Expected Next Steps                                | ​ |
|----------------------------|---------|---------|--------------------------|---------|---------|-------------------------------------------------------------------------|---------|---------|-----------------------------------------------------------------------------------------------------------------|---------|---------|----------------------------------------------------|---------|
| Sativex (nabiximols)       | ​ | ​ | MS spasticity (ex- U.S.) | ​ | ​ | Almirall, Bayer, Ipsen and Neopharm                                     | ​ | ​ | Approved in numerous countries                                                                                  | ​ | ​ |
| ​                    | ​ | ​ | MS spasticity (U.S.)     | ​ | ​ | We are in late stage negotiations for the return of rights from Otsuka. | ​ | ​ | Single additional Phase 3 trial in planning                                                                | ​ | ​ | Open IND for single additional Phase 3 trial. | ​ |
| Combination of CBD and THC | ​ | ​ | Glioblastoma             | ​ | ​ | We retain global rights                                                 | ​ | ​ | Phase 2 trial complete and reported in February 2017. Data presented at ASCO. FDA orphan designation. | ​ | ​ | Open IND for pivotal clinical program              | ​ |
| GWP42003                   | ​ | ​ | Schizophrenia            | ​ | ​ | We retain global rights                                                 | ​ | ​ | Positive Phase 2 proof-of-concept.                                                                         | ​ | ​ | Next steps under consideration                     | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| ​      | ​ | ​ | CBD 10mg/kg/day | ​ | ​ | Placebo | ​ |
|--------------|---------|---------|-----------------|---------|---------|---------|---------|
| Overall      | ​ | ​ | ​         | ​ | 40%     | ​ | ​ | ​ | ​ | ​ | 13% | ​ | ​ |
| On clobazam  | ​ | ​ | ​         | ​ | 46%     | ​ | ​ | ​ | ​ | ​ | 19% | ​ | ​ |
| Off clobazam | ​ | ​ | ​         | ​ | 33%     | ​ | ​ | ​ | ​ | ​ | 8% | ​ | ​ |
| ​      | ​ | ​ | CBD 20mg/kg/day | ​ | ​ | Placebo | ​ |
|--------------|---------|---------|-----------------|---------|---------|---------|---------|
| Overall      | ​ | ​ | ​         | ​ | 45%     | ​ | ​ | ​ | ​ | ​ | 19% | ​ | ​ |
| On clobazam  | ​ | ​ | ​         | ​ | 56%     | ​ | ​ | ​ | ​ | ​ | 24% | ​ | ​ |
| Off clobazam | ​ | ​ | ​         | ​ | 35%     | ​ | ​ | ​ | ​ | ​ | 13% | ​ | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| ​                                                       | ​ | ​ | Week 12 (n=343) | ​ | ​ | Week 24 (n=331) | ​ | ​ | Week 48 (n=224) | ​ | ​ | Week 72 (n=157) | ​ | ​ | Week 96 (n=112) | ​ |
|---------------------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Median percentage change in convulsive seizure frequency | ​ | ​ | ​         | ​ | -51.4   | ​         | ​ | ​ | ​         | ​ | -47.7   | ​         | ​ | ​ | ​         | ​ | -44.5 | ​ | ​ | ​ | ​ | ​ | -50.7 | ​ | ​ | ​ | ​ | ​ | -44.1 | ​ | ​ |
| ​                                                  | ​ | ​ | Week 12 (n=431) | ​ | ​ | Week 24 (n=412) | ​ | ​ | Week 48 (n=282) | ​ | ​ | Week 72 (n=197) | ​ | ​ | Week 96 (n=138) | ​ |
|----------------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Median percentage change in total seizure frequency | ​ | ​ | ​         | ​ | -48.0   | ​         | ​ | ​ | ​         | ​ | -45.7   | ​         | ​ | ​ | ​         | ​ | -47.1 | ​ | ​ | ​ | ​ | ​ | -53.1 | ​ | ​ | ​ | ​ | ​ | -49.0 | ​ | ​ |
| ​                                                       | ​ | ​ | Week 12 (n=108) | ​ | ​ | Week 24 (n=91) | ​ | ​ | Week 48 (n=74) | ​ | ​ | Week 72 (n=67) | ​ | ​ | Week 96 (n=53) | ​ |
|---------------------------------------------------------------|---------|---------|-----------------|---------|---------|----------------|---------|---------|----------------|---------|---------|----------------|---------|---------|----------------|---------|
| Median percentage change in convulsive seizure frequency | ​ | ​ | ​         | ​ | -50.3   | ​        | ​ | ​ | ​        | ​ | -45.5   | ​        | ​ | ​ | ​        | ​ | -36.4 | ​ | ​ | ​ | ​ | ​ | -41.2 | ​ | ​ | ​ | ​ | ​ | -48.3 | ​ | ​ |
| ​                                                  | ​ | ​ | Week 12 (n=118) | ​ | ​ | Week 24 (n=99) | ​ | ​ | Week 48 (n=83) | ​ | ​ | Week 72 (n=74) | ​ | ​ | Week 96 (n=57) | ​ |
|----------------------------------------------------------|---------|---------|-----------------|---------|---------|----------------|---------|---------|----------------|---------|---------|----------------|---------|---------|----------------|---------|
| Median percentage change in total seizure frequency | ​ | ​ | ​         | ​ | -44.3   | ​        | ​ | ​ | ​        | ​ | -45.5   | ​        | ​ | ​ | ​        | ​ | -42.5 | ​ | ​ | ​ | ​ | ​ | -48.2 | ​ | ​ | ​ | ​ | ​ | -49.6 | ​ | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| ​ | CBD (Cannabidiol)                               | ​ | ​ | CBN (Cannabinol)                                        | ​ |
|---------|-------------------------------------------------|---------|---------|---------------------------------------------------------|---------|
| ​ | CBDV (Cannabidivarin)                           | ​ | ​ | CBNV (Cannabinovarin)                                   | ​ |
| ​ | CBDA (Cannabidiol — Acid)     | ​ | ​ | D8-THC (Delta-8 Tetrahydrocannabinol)                   | ​ |
| ​ | CBDVA (Cannabidivarin — Acid) | ​ | ​ | THC (Delta-9 Tetrahydrocannabinol)                      | ​ |
| ​ | CBC (Cannabichromene)                           | ​ | ​ | THCA (Tetrahydrocannabinol — Acid)    | ​ |
| ​ | CBG (Cannabigerol)                              | ​ | ​ | THCV (Tetrahydrocannabivarin)                           | ​ |
| ​ | CBGA (Cannabigerol — Acid)    | ​ | ​ | THCVA (Tetrahydrocannabivarin — Acid) | ​ |
| ​ | CBGV (Cannabigerovarin)                         | ​ | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​

| Name of undertaking                       | ​ | ​ | Country of registration | ​ | ​ | Activity                            | ​ | ​ | % holding  | ​ |
|-------------------------------------------|---------|---------|-------------------------|---------|---------|-------------------------------------|---------|---------|------------|---------|
| GW Pharma Limited                         | ​ | ​ | England and Wales       | ​ | ​ | Research and Development            | ​ | ​ | 100​ | ​ |
| GW Research Limited                       | ​ | ​ | England and Wales       | ​ | ​ | Research and Development            | ​ | ​ | 100​ | ​ |
| Greenwich Biosciences, Inc.               | ​ | ​ | United States           | ​ | ​ | Pharmaceutical development services | ​ | ​ | 100​ | ​ |
| GWP Trustee Company Limited               | ​ | ​ | England and Wales       | ​ | ​ | Employee Share Ownership            | ​ | ​ | 100​ | ​ |
| GW Pharmaceuticals Australia Pty. Limited | ​ | ​ | Australia               | ​ | ​ | Dormant                             | ​ | ​ | 100​ | ​ |
| Cannabinoid Research Institute Limited    | ​ | ​ | England and Wales       | ​ | ​ | Dormant                             | ​ | ​ | 100​ | ​ |
| Guernsey Pharmaceuticals Limited          | ​ | ​ | Guernsey                | ​ | ​ | Dormant                             | ​ | ​ | 100​ | ​ |
| G-Pharm Limited                           | ​ | ​ | England and Wales       | ​ | ​ | Dormant                             | ​ | ​ | 100​ | ​ |

----

TABLE OF CONTENTS​​

| Type                       | ​ | ​ | Location                  | ​ | ​ | Size (sq ft) | ​ | ​ | Expiry                     | ​ |
|----------------------------|---------|---------|---------------------------|---------|---------|--------------|---------|---------|----------------------------|---------|
| Executive office           | ​ | ​ | Andover, United Kingdom   | ​ | ​ | 3,113        | ​ | ​ | April 2020​     | ​ |
| Executive office           | ​ | ​ | London, United Kingdom    | ​ | ​ | 2,680        | ​ | ​ | September 2020​ | ​ |
| Executive office           | ​ | ​ | Cambridge, United Kingdom | ​ | ​ | 12,120       | ​ | ​ | May 2021​       | ​ |
| Executive office           | ​ | ​ | Carlsbad, United States   | ​ | ​ | 21,895       | ​ | ​ | November 2022​  | ​ |
| Executive office           | ​ | ​ | Carlsbad, United States   | ​ | ​ | 4,911        | ​ | ​ | January 2019​   | ​ |
| Executive office           | ​ | ​ | Durham, United States     | ​ | ​ | 256          | ​ | ​ | October 2017​   | ​ |
| Executive office           | ​ | ​ | Southern United Kingdom   | ​ | ​ | 17,222       | ​ | ​ | December 2025​  | ​ |
| Research and manufacturing | ​ | ​ | Southern United Kingdom   | ​ | ​ | 64,620       | ​ | ​ | January 2019​   | ​ |
| Research and manufacturing | ​ | ​ | Southern United Kingdom   | ​ | ​ | 15,222       | ​ | ​ | November 2027​  | ​ |
| Research and manufacturing | ​ | ​ | Southern United Kingdom   | ​ | ​ | 3,261        | ​ | ​ | September 2029​ | ​ |
| Research and manufacturing | ​ | ​ | Southern United Kingdom   | ​ | ​ | 20,172       | ​ | ​ | May 2036​       | ​ |
| Research and manufacturing | ​ | ​ | Southern United Kingdom   | ​ | ​ | 7,050        | ​ | ​ | December 2019​  | ​ |
| Growing facility           | ​ | ​ | Eastern United Kingdom    | ​ | ​ | 1,960,000    | ​ | ​ | August 2021​    | ​ |
| Growing facility           | ​ | ​ | Eastern United Kingdom    | ​ | ​ | 815,022      | ​ | ​ | February 2020​  | ​ |
| Growing facility           | ​ | ​ | Northern United Kingdom   | ​ | ​ | 914,760      | ​ | ​ | December 2018​  | ​ |
| Growing facility           | ​ | ​ | Southern United Kingdom   | ​ | ​ | 163,350      | ​ | ​ | January 2018​   | ​ |

29

----

TABLE OF CONTENTS​​

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| ​                                    | ​ | ​ | Year Ended September 30,               | ​ | ​   | Change 2017 vs. 2016 |
|--------------------------------------------|---------|---------|---------------------------------------------|---------|-----------|----------------------|
| ​                                    | ​ | ​ | 2017                                        | ​ | ​   | 2017                 | ​ | ​ | 2016 | ​ | ​ | Increase/(Decrease) |
| ​                                    | ​ | ​ | $                                           | ​ | ​   | £               | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | % |
| ​                                    | ​ | ​ | (in thousands, except for percentages) |
| Revenue                                    | ​ | ​ | ​                                     | ​ | 11,004    | ​              | ​ | ​ | ​ | ​ | 8,238 | ​ | ​ | ​ | ​ | ​ | 10,315 | ​ | ​ | ​ | ​ | ​ | (2,077) | ​ | ​ | ​ | ​ | ​ | (20)% |
| Cost of sales                              | ​ | ​ | ​                                     | ​ | (4,730)   | ​              | ​ | ​ | ​ | ​ | (3,541) | ​ | ​ | ​ | ​ | ​ | (2,719) | ​ | ​ | ​ | ​ | ​ | (822) | ​ | ​ | ​ | ​ | ​ | 30% |
| Research and development expenditure       | ​ | ​ | ​                                     | ​ | (148,576) | ​              | ​ | ​ | ​ | ​ | (111,229) | ​ | ​ | ​ | ​ | ​ | (99,815) | ​ | ​ | ​ | ​ | ​ | (11,414) | ​ | ​ | ​ | ​ | ​ | 11% |
| Sales, general and administrative expenses | ​ | ​ | ​                                     | ​ | (55,700)  | ​              | ​ | ​ | ​ | ​ | (41,699) | ​ | ​ | ​ | ​ | ​ | (19,939) | ​ | ​ | ​ | ​ | ​ | (21,760) | ​ | ​ | ​ | ​ | ​ | 109% |
| Net foreign exchange (losses)/gains        | ​ | ​ | ​                                     | ​ | (6,739)   | ​              | ​ | ​ | ​ | ​ | (5,045) | ​ | ​ | ​ | ​ | ​ | 25,551 | ​ | ​ | ​ | ​ | ​ | (30,596) | ​ | ​ | ​ | ​ | ​ | (120)% |
| Operating loss                             | ​ | ​ | ​                                     | ​ | (204,741) | ​              | ​ | ​ | ​ | ​ | (153,276) | ​ | ​ | ​ | ​ | ​ | (86,607) | ​ | ​ | ​ | ​ | ​ | (66,669) | ​ | ​ | ​ | ​ | ​ | 77% |
| Interest expense                           | ​ | ​ | ​                                     | ​ | (995)     | ​              | ​ | ​ | ​ | ​ | (745) | ​ | ​ | ​ | ​ | ​ | (173) | ​ | ​ | ​ | ​ | ​ | (572) | ​ | ​ | ​ | ​ | ​ | 331% |
| Interest and other income                  | ​ | ​ | ​                                     | ​ | 2,159     | ​              | ​ | ​ | ​ | ​ | 1,616 | ​ | ​ | ​ | ​ | ​ | 608 | ​ | ​ | ​ | ​ | ​ | 1,008 | ​ | ​ | ​ | ​ | ​ | 166% |
| Loss before tax                            | ​ | ​ | ​                                     | ​ | (203,577) | ​              | ​ | ​ | ​ | ​ | (152,405) | ​ | ​ | ​ | ​ | ​ | (86,172) | ​ | ​ | ​ | ​ | ​ | (66,233) | ​ | ​ | ​ | ​ | ​ | 77% |
| Tax benefit                                | ​ | ​ | ​                                     | ​ | 27,673    | ​              | ​ | ​ | ​ | ​ | 20,717 | ​ | ​ | ​ | ​ | ​ | 22,515 | ​ | ​ | ​ | ​ | ​ | (1,798) | ​ | ​ | ​ | ​ | ​ | (8)% |
| Loss for the year                          | ​ | ​ | ​                                     | ​ | (175,904) | ​              | ​ | ​ | ​ | ​ | (131,688) | ​ | ​ | ​ | ​ | ​ | (63,657) | ​ | ​ | ​ | ​ | ​ | (68,031) | ​ | ​ | ​ | ​ | ​ | 107% |
| ​                                    |
| ​                                          | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2017 vs. 2016 | ​ |
|--------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                          | ​ | ​ | 2017                                        | ​ | ​ | 2017                 | ​ | ​ | 2016 | ​ | ​ | Increase/ (Decrease) | ​ |
| ​                                          | ​ | ​ | $                                           | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                          | ​ | ​ | (in thousands, except for percentages) | ​ |
| Product sales                                    | ​ | ​ | ​                                     | ​ | 8,324   | ​              | ​ | ​ | ​ | ​ | 6,232 | ​ | ​ | ​ | ​ | ​ | 5,208 | ​ | ​ | ​ | ​ | ​ | 1,024 | ​ | ​ | ​ | ​ | ​ | 20% | ​ | ​ |
| Research and development fees                    | ​ | ​ | ​                                     | ​ | 699     | ​              | ​ | ​ | ​ | ​ | 523 | ​ | ​ | ​ | ​ | ​ | 3,837 | ​ | ​ | ​ | ​ | ​ | (3,314) | ​ | ​ | ​ | ​ | ​ | (86)% | ​ | ​ |
| License, collaboration and technical access fees | ​ | ​ | ​                                     | ​ | 1,834   | ​              | ​ | ​ | ​ | ​ | 1,373 | ​ | ​ | ​ | ​ | ​ | 1,172 | ​ | ​ | ​ | ​ | ​ | 201 | ​ | ​ | ​ | ​ | ​ | 17% | ​ | ​ |
| Development and approval milestone fees          | ​ | ​ | ​                                     | ​ | 147     | ​              | ​ | ​ | ​ | ​ | 110 | ​ | ​ | ​ | ​ | ​ | 98 | ​ | ​ | ​ | ​ | ​ | 12 | ​ | ​ | ​ | ​ | ​ | 12% | ​ | ​ |
| Total revenue                                    | ​ | ​ | ​                                     | ​ | 11,004  | ​              | ​ | ​ | ​ | ​ | 8,238 | ​ | ​ | ​ | ​ | ​ | 10,315 | ​ | ​ | ​ | ​ | ​ | (2,077) | ​ | ​ | ​ | ​ | ​ | (20)% | ​ | ​ |
| ​                                          |

----

TABLE OF CONTENTS

| ​                                             | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2017 vs. 2016 | ​ |
|-----------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                             | ​ | ​ | 2017                                        | ​ | ​ | 2017                 | ​ | ​ | 2016 | ​ | ​ | Increase/ (Decrease) | ​ |
| ​                                             | ​ | ​ | $                                           | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                             | ​ | ​ | (in thousands, except for percentages) | ​ |
| GW-funded research and development                  | ​ | ​ | ​                                     | ​ | 147,876 | ​              | ​ | ​ | ​ | ​ | 110,705 | ​ | ​ | ​ | ​ | ​ | 95,978 | ​ | ​ | ​ | ​ | ​ | 14,727 | ​ | ​ | ​ | ​ | ​ | 15% | ​ | ​ |
| Development partner-funded research and development | ​ | ​ | ​                                     | ​ | 700     | ​              | ​ | ​ | ​ | ​ | 524 | ​ | ​ | ​ | ​ | ​ | 3,837 | ​ | ​ | ​ | ​ | ​ | (3,313) | ​ | ​ | ​ | ​ | ​ | (86)% | ​ | ​ |
| Total research and development expenditure          | ​ | ​ | ​                                     | ​ | 148,576 | ​              | ​ | ​ | ​ | ​ | 111,229 | ​ | ​ | ​ | ​ | ​ | 99,815 | ​ | ​ | ​ | ​ | ​ | 11,414 | ​ | ​ | ​ | ​ | ​ | 11% | ​ | ​ |
| ​                                             |

----

TABLE OF CONTENTS

| ​                                                   | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2017 vs. 2016 | ​ |
|-----------------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                                   | ​ | ​ | 2017                                        | ​ | ​ | 2017                 | ​ | ​ | 2016 | ​ | ​ | Increase/(Decrease) | ​ |
| ​                                                   | ​ | ​ | $                                           | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                                   | ​ | ​ | (in thousands, except for percentages) | ​ |
| Sativex U.S. development program                          | ​ | ​ | ​                                     | ​ | 127     | ​              | ​ | ​ | ​ | ​ | 95 | ​ | ​ | ​ | ​ | ​ | 3,500 | ​ | ​ | ​ | ​ | ​ | (3,405) | ​ | ​ | ​ | ​ | ​ | (97)% | ​ | ​ |
| Otsuka research collaboration expenses                    | ​ | ​ | ​                                     | ​ | 573     | ​              | ​ | ​ | ​ | ​ | 429 | ​ | ​ | ​ | ​ | ​ | 337 | ​ | ​ | ​ | ​ | ​ | 92 | ​ | ​ | ​ | ​ | ​ | 27% | ​ | ​ |
| Total development partner-funded research and development | ​ | ​ | ​                                     | ​ | 700     | ​              | ​ | ​ | ​ | ​ | 524 | ​ | ​ | ​ | ​ | ​ | 3,837 | ​ | ​ | ​ | ​ | ​ | (3,313) | ​ | ​ | ​ | ​ | ​ | (86)% | ​ | ​ |
| ​                                                   |

----

TABLE OF CONTENTS

| ​                                          | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2017 vs. 2016 | ​ |
|--------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                          | ​ | ​ | 2017                                        | ​ | ​ | 2017                 | ​ | ​ | 2016 | ​ | ​ | Increase/Decrease | ​ |
| ​                                          | ​ | ​ | $                                           | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                          | ​ | ​ | (in thousands, except for percentages) | ​ |
| Product sales                                    | ​ | ​ | ​                                     | ​ | 8,325   | ​              | ​ | ​ | ​ | ​ | 6,232 | ​ | ​ | ​ | ​ | ​ | 5,208 | ​ | ​ | ​ | ​ | ​ | 1,024 | ​ | ​ | ​ | ​ | ​ | 20% | ​ | ​ |
| License, collaboration and technical access fees | ​ | ​ | ​                                     | ​ | 1,834   | ​              | ​ | ​ | ​ | ​ | 1,373 | ​ | ​ | ​ | ​ | ​ | 1,172 | ​ | ​ | ​ | ​ | ​ | 201 | ​ | ​ | ​ | ​ | ​ | 17% | ​ | ​ |
| Development and approval milestone fees          | ​ | ​ | ​                                     | ​ | 147     | ​              | ​ | ​ | ​ | ​ | 110 | ​ | ​ | ​ | ​ | ​ | 98 | ​ | ​ | ​ | ​ | ​ | 12 | ​ | ​ | ​ | ​ | ​ | 12% | ​ | ​ |
| Total revenue                                    | ​ | ​ | ​                                     | ​ | 10,306  | ​              | ​ | ​ | ​ | ​ | 7,715 | ​ | ​ | ​ | ​ | ​ | 6,478 | ​ | ​ | ​ | ​ | ​ | 1,237 | ​ | ​ | ​ | ​ | ​ | 19% | ​ | ​ |
| Cost of sales                                    | ​ | ​ | ​                                     | ​ | (4,730) | ​              | ​ | ​ | ​ | ​ | (3,541) | ​ | ​ | ​ | ​ | ​ | (2,719) | ​ | ​ | ​ | ​ | ​ | (822) | ​ | ​ | ​ | ​ | ​ | 30% | ​ | ​ |
| Segmental result                                 | ​ | ​ | ​                                     | ​ | 5,576   | ​              | ​ | ​ | ​ | ​ | 4,174 | ​ | ​ | ​ | ​ | ​ | 3,759 | ​ | ​ | ​ | ​ | ​ | 415 | ​ | ​ | ​ | ​ | ​ | 11% | ​ | ​ |
| ​                                          |

----

TABLE OF CONTENTS

| ​                                             | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2017 vs. 2016 | ​ |
|-----------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                             | ​ | ​ | 2017                                        | ​ | ​ | 2017                 | ​ | ​ | 2016 | ​ | ​ | Increase/(Decrease) | ​ |
| ​                                             | ​ | ​ | $                                           | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                             | ​ | ​ | (in thousands, except for percentages) | ​ |
| Research and development fees                       | ​ | ​ | ​                                     | ​ | 127     | ​              | ​ | ​ | ​ | ​ | 95 | ​ | ​ | ​ | ​ | ​ | 3,500 | ​ | ​ | ​ | ​ | ​ | (3,405) | ​ | ​ | ​ | ​ | ​ | (97)% | ​ | ​ |
| Research and development expenditure:               | ​ | ​ | ​                                     | ​ | ​ | ​              | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| GW-funded research and development                  | ​ | ​ | ​                                     | ​ | (16)    | ​              | ​ | ​ | ​ | ​ | (12) | ​ | ​ | ​ | ​ | ​ | (625) | ​ | ​ | ​ | ​ | ​ | 613 | ​ | ​ | ​ | ​ | ​ | (98)% | ​ | ​ |
| Development partner-funded research and development | ​ | ​ | ​                                     | ​ | (127)   | ​              | ​ | ​ | ​ | ​ | (95) | ​ | ​ | ​ | ​ | ​ | (3,500) | ​ | ​ | ​ | ​ | ​ | 3,405 | ​ | ​ | ​ | ​ | ​ | (97)% | ​ | ​ |
| Total research and development expenditure          | ​ | ​ | ​                                     | ​ | (143)   | ​              | ​ | ​ | ​ | ​ | (107) | ​ | ​ | ​ | ​ | ​ | (4,125) | ​ | ​ | ​ | ​ | ​ | 4,018 | ​ | ​ | ​ | ​ | ​ | (97)% | ​ | ​ |
| Segmental result                                    | ​ | ​ | ​                                     | ​ | (16)    | ​              | ​ | ​ | ​ | ​ | (12) | ​ | ​ | ​ | ​ | ​ | (625) | ​ | ​ | ​ | ​ | ​ | 613 | ​ | ​ | ​ | ​ | ​ | (98)% | ​ | ​ |
| ​                                             |
| ​                                             | ​ | ​ | Year Ended September 30,               | ​ | ​   | Change 2017 vs. 2016 | ​ |
|-----------------------------------------------------|---------|---------|---------------------------------------------|---------|-----------|----------------------|---------|
| ​                                             | ​ | ​ | 2017                                        | ​ | ​   | 2017                 | ​ | ​ | 2016 | ​ | ​ | Increase/(Decrease) | ​ |
| ​                                             | ​ | ​ | $                                           | ​ | ​   | £               | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                             | ​ | ​ | (in thousands, except for percentages) | ​ |
| Research and development fees                       | ​ | ​ | ​                                     | ​ | 573       | ​              | ​ | ​ | ​ | ​ | 428 | ​ | ​ | ​ | ​ | ​ | 337 | ​ | ​ | ​ | ​ | ​ | 91 | ​ | ​ | ​ | ​ | ​ | 27% | ​ | ​ |
| Research and development expenditure                | ​ | ​ | ​                                     | ​ | ​   | ​              |
| GW-funded research and development                  | ​ | ​ | ​                                     | ​ | (142,460) | ​              | ​ | ​ | ​ | ​ | (106,650) | ​ | ​ | ​ | ​ | ​ | (91,234) | ​ | ​ | ​ | ​ | ​ | (15,416) | ​ | ​ | ​ | ​ | ​ | 17% | ​ | ​ |
| Development partner-funded research and development | ​ | ​ | ​                                     | ​ | (573)     | ​              | ​ | ​ | ​ | ​ | (428) | ​ | ​ | ​ | ​ | ​ | (337) | ​ | ​ | ​ | ​ | ​ | (91) | ​ | ​ | ​ | ​ | ​ | 27% | ​ | ​ |
| Total research and development expenditure          | ​ | ​ | ​                                     | ​ | (143,033) | ​              | ​ | ​ | ​ | ​ | (107,078) | ​ | ​ | ​ | ​ | ​ | (91,571) | ​ | ​ | ​ | ​ | ​ | (15,507) | ​ | ​ | ​ | ​ | ​ | 17% | ​ | ​ |
| Segmental result                                    | ​ | ​ | ​                                     | ​ | (142,460) | ​              | ​ | ​ | ​ | ​ | (106,650) | ​ | ​ | ​ | ​ | ​ | (91,234) | ​ | ​ | ​ | ​ | ​ | (15,416) | ​ | ​ | ​ | ​ | ​ | 17% | ​ | ​ |
| ​                                             |

----

TABLE OF CONTENTS

| ​                                    | ​ | ​ | Year Ended September 30,               | ​ | ​  | Change 2016 vs. 2015 | ​ |
|--------------------------------------------|---------|---------|---------------------------------------------|---------|----------|----------------------|---------|
| ​                                    | ​ | ​ | 2016                                        | ​ | ​  | 2015                 | ​ | ​ | Increase/(Decrease) | ​ |
| ​                                    | ​ | ​ | £                                      | ​ | ​  | £               | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                    | ​ | ​ | (in thousands, except for percentages) | ​ |
| Revenue                                    | ​ | ​ | ​                                     | ​ | 10,315   | ​              | ​ | ​ | ​ | ​ | 28,540 | ​ | ​ | ​ | ​ | ​ | (18,225) | ​ | ​ | ​ | ​ | ​ | (64)% | ​ | ​ |
| Cost of sales                              | ​ | ​ | ​                                     | ​ | (2,719)  | ​              | ​ | ​ | ​ | ​ | (2,618) | ​ | ​ | ​ | ​ | ​ | (101) | ​ | ​ | ​ | ​ | ​ | 4% | ​ | ​ |
| Research and development expenditure       | ​ | ​ | ​                                     | ​ | (99,815) | ​              | ​ | ​ | ​ | ​ | (76,785) | ​ | ​ | ​ | ​ | ​ | (23,030) | ​ | ​ | ​ | ​ | ​ | 30% | ​ | ​ |
| Sales, general and administrative expenses | ​ | ​ | ​                                     | ​ | (19,939) | ​              | ​ | ​ | ​ | ​ | (12,569) | ​ | ​ | ​ | ​ | ​ | (7,370) | ​ | ​ | ​ | ​ | ​ | 59% | ​ | ​ |
| Net foreign exchange gains                 | ​ | ​ | ​                                     | ​ | 25,551   | ​              | ​ | ​ | ​ | ​ | 6,202 | ​ | ​ | ​ | ​ | ​ | 19,349 | ​ | ​ | ​ | ​ | ​ | 312% | ​ | ​ |
| Operating loss                             | ​ | ​ | ​                                     | ​ | (86,607) | ​              | ​ | ​ | ​ | ​ | (57,230) | ​ | ​ | ​ | ​ | ​ | (29,377) | ​ | ​ | ​ | ​ | ​ | 51% | ​ | ​ |
| Interest expense                           | ​ | ​ | ​                                     | ​ | (173)    | ​              | ​ | ​ | ​ | ​ | (75) | ​ | ​ | ​ | ​ | ​ | (98) | ​ | ​ | ​ | ​ | ​ | 131% | ​ | ​ |
| Interest and other income                  | ​ | ​ | ​                                     | ​ | 608      | ​              | ​ | ​ | ​ | ​ | 244 | ​ | ​ | ​ | ​ | ​ | 364 | ​ | ​ | ​ | ​ | ​ | 149% | ​ | ​ |
| Loss before tax                            | ​ | ​ | ​                                     | ​ | (86,172) | ​              | ​ | ​ | ​ | ​ | (57,061) | ​ | ​ | ​ | ​ | ​ | (29,111) | ​ | ​ | ​ | ​ | ​ | 51% | ​ | ​ |
| Tax benefit                                | ​ | ​ | ​                                     | ​ | 22,515   | ​              | ​ | ​ | ​ | ​ | 12,498 | ​ | ​ | ​ | ​ | ​ | 10,017 | ​ | ​ | ​ | ​ | ​ | 80% | ​ | ​ |
| Loss for the year                          | ​ | ​ | ​                                     | ​ | (63,657) | ​              | ​ | ​ | ​ | ​ | (44,563) | ​ | ​ | ​ | ​ | ​ | (19,094) | ​ | ​ | ​ | ​ | ​ | 43% | ​ | ​ |
| ​                                    |
| ​                                          | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2016 vs. 2015 | ​ |
|--------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                          | ​ | ​ | 2016                                        | ​ | ​ | 2015                 | ​ | ​ | Increase/(Decrease) | ​ |
| ​                                          | ​ | ​ | £                                      | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                          | ​ | ​ | (in thousands, except for percentages) | ​ |
| Product sales                                    | ​ | ​ | ​                                     | ​ | 5,208   | ​              | ​ | ​ | ​ | ​ | 4,255 | ​ | ​ | ​ | ​ | ​ | 953 | ​ | ​ | ​ | ​ | ​ | 22% | ​ | ​ |
| Research and development fees                    | ​ | ​ | ​                                     | ​ | 3,837   | ​              | ​ | ​ | ​ | ​ | 22,810 | ​ | ​ | ​ | ​ | ​ | (18,973) | ​ | ​ | ​ | ​ | ​ | (83)% | ​ | ​ |
| License, collaboration and technical access fees | ​ | ​ | ​                                     | ​ | 1,172   | ​              | ​ | ​ | ​ | ​ | 1,287 | ​ | ​ | ​ | ​ | ​ | (115) | ​ | ​ | ​ | ​ | ​ | (9)% | ​ | ​ |
| Development and approval milestone fees          | ​ | ​ | ​                                     | ​ | 98      | ​              | ​ | ​ | ​ | ​ | 188 | ​ | ​ | ​ | ​ | ​ | (90) | ​ | ​ | ​ | ​ | ​ | (48)% | ​ | ​ |
| Total revenue                                    | ​ | ​ | ​                                     | ​ | 10,315  | ​              | ​ | ​ | ​ | ​ | 28,540 | ​ | ​ | ​ | ​ | ​ | (18,225) | ​ | ​ | ​ | ​ | ​ | (64)% | ​ | ​ |
| ​                                          |

----

TABLE OF CONTENTS

| ​                                             | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2016 vs. 2015 | ​ |
|-----------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                             | ​ | ​ | 2016                                        | ​ | ​ | 2015                 | ​ | ​ | Increase/ (Decrease) | ​ |
| ​                                             | ​ | ​ | £                                      | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                             | ​ | ​ | (in thousands, except for percentages) | ​ |
| GW-funded research and development                  | ​ | ​ | ​                                     | ​ | 95,978  | ​              | ​ | ​ | ​ | ​ | 53,975 | ​ | ​ | ​ | ​ | ​ | 42,003 | ​ | ​ | ​ | ​ | ​ | 78% | ​ | ​ |
| Development partner-funded research and development | ​ | ​ | ​                                     | ​ | 3,837   | ​              | ​ | ​ | ​ | ​ | 22,810 | ​ | ​ | ​ | ​ | ​ | (18,973) | ​ | ​ | ​ | ​ | ​ | (83)% | ​ | ​ |
| Total research and development expenditure          | ​ | ​ | ​                                     | ​ | 99,815  | ​              | ​ | ​ | ​ | ​ | 76,785 | ​ | ​ | ​ | ​ | ​ | 23,030 | ​ | ​ | ​ | ​ | ​ | 30% | ​ | ​ |
| ​                                             |

----

TABLE OF CONTENTS

| ​                                                   | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2016 vs. 2015 | ​ |
|-----------------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                                   | ​ | ​ | 2016                                        | ​ | ​ | 2015                 | ​ | ​ | Increase/(Decrease) | ​ |
| ​                                                   | ​ | ​ | £                                      | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                                   | ​ | ​ | (in thousands, except for percentages) | ​ |
| Sativex U.S. development program                          | ​ | ​ | ​                                     | ​ | 3,500   | ​              | ​ | ​ | ​ | ​ | 22,275 | ​ | ​ | ​ | ​ | ​ | (18,775) | ​ | ​ | ​ | ​ | ​ | (84)% | ​ | ​ |
| Otsuka research collaboration expenses                    | ​ | ​ | ​                                     | ​ | 337     | ​              | ​ | ​ | ​ | ​ | 535 | ​ | ​ | ​ | ​ | ​ | (198) | ​ | ​ | ​ | ​ | ​ | (37)% | ​ | ​ |
| Total development partner-funded research and development | ​ | ​ | ​                                     | ​ | 3,837   | ​              | ​ | ​ | ​ | ​ | 22,810 | ​ | ​ | ​ | ​ | ​ | (18,973) | ​ | ​ | ​ | ​ | ​ | (83)% | ​ | ​ |
| ​                                                   |

----

TABLE OF CONTENTS

| ​                                          | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2016 vs. 2015 | ​ |
|--------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                          | ​ | ​ | 2016                                        | ​ | ​ | 2015                 | ​ | ​ | Increase/Decrease | ​ |
| ​                                          | ​ | ​ | £                                      | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                          | ​ | ​ | (in thousands, except for percentages) | ​ |
| Product sales                                    | ​ | ​ | ​                                     | ​ | 5,208   | ​              | ​ | ​ | ​ | ​ | 4,255 | ​ | ​ | ​ | ​ | ​ | 953 | ​ | ​ | ​ | ​ | ​ | 22% | ​ | ​ |
| License, collaboration and technical access fees | ​ | ​ | ​                                     | ​ | 1,172   | ​              | ​ | ​ | ​ | ​ | 1,287 | ​ | ​ | ​ | ​ | ​ | (115) | ​ | ​ | ​ | ​ | ​ | (9)% | ​ | ​ |
| Development and approval milestone fees          | ​ | ​ | ​                                     | ​ | 98      | ​              | ​ | ​ | ​ | ​ | 188 | ​ | ​ | ​ | ​ | ​ | (90) | ​ | ​ | ​ | ​ | ​ | (48)% | ​ | ​ |
| Total revenue                                    | ​ | ​ | ​                                     | ​ | 6,478   | ​              | ​ | ​ | ​ | ​ | 5,730 | ​ | ​ | ​ | ​ | ​ | 748 | ​ | ​ | ​ | ​ | ​ | 13% | ​ | ​ |
| Cost of sales                                    | ​ | ​ | ​                                     | ​ | (2,719) | ​              | ​ | ​ | ​ | ​ | (2,618) | ​ | ​ | ​ | ​ | ​ | (101) | ​ | ​ | ​ | ​ | ​ | 4% | ​ | ​ |
| Segmental result                                 | ​ | ​ | ​                                     | ​ | 3,759   | ​              | ​ | ​ | ​ | ​ | 3,112 | ​ | ​ | ​ | ​ | ​ | 647 | ​ | ​ | ​ | ​ | ​ | 21% | ​ | ​ |
| ​                                          |

----

TABLE OF CONTENTS

| ​                                             | ​ | ​ | Year Ended September 30,               | ​ | ​ | Change 2016 vs. 2015 | ​ |
|-----------------------------------------------------|---------|---------|---------------------------------------------|---------|---------|----------------------|---------|
| ​                                             | ​ | ​ | 2016                                        | ​ | ​ | 2015                 | ​ | ​ | Increase/(Decrease) | ​ |
| ​                                             | ​ | ​ | £                                      | ​ | ​ | £               | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                             | ​ | ​ | (in thousands, except for percentages) | ​ |
| Research and development fees                       | ​ | ​ | ​                                     | ​ | 3,500   | ​              | ​ | ​ | ​ | ​ | 22,275 | ​ | ​ | ​ | ​ | ​ | (18,775) | ​ | ​ | ​ | ​ | ​ | (84)% | ​ | ​ |
| Research and development expenditure:               | ​ | ​ | ​                                     | ​ | ​ | ​              | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| GW-funded research and development                  | ​ | ​ | ​                                     | ​ | (625)   | ​              | ​ | ​ | ​ | ​ | (4,123) | ​ | ​ | ​ | ​ | ​ | 3,498 | ​ | ​ | ​ | ​ | ​ | (85)% | ​ | ​ |
| Development partner-funded research and development | ​ | ​ | ​                                     | ​ | (3,500) | ​              | ​ | ​ | ​ | ​ | (22,275) | ​ | ​ | ​ | ​ | ​ | 18,775 | ​ | ​ | ​ | ​ | ​ | (84)% | ​ | ​ |
| Total research and development expenditure          | ​ | ​ | ​                                     | ​ | (4,125) | ​              | ​ | ​ | ​ | ​ | (26,398) | ​ | ​ | ​ | ​ | ​ | 22,273 | ​ | ​ | ​ | ​ | ​ | (84)% | ​ | ​ |
| Segmental result                                    | ​ | ​ | ​                                     | ​ | (625)   | ​              | ​ | ​ | ​ | ​ | (4,123) | ​ | ​ | ​ | ​ | ​ | 3,498 | ​ | ​ | ​ | ​ | ​ | (85)% | ​ | ​ |
| ​                                             |
| ​                                             | ​ | ​ | Year Ended September 30,               | ​ | ​  | Change 2016 vs. 2015 | ​ |
|-----------------------------------------------------|---------|---------|---------------------------------------------|---------|----------|----------------------|---------|
| ​                                             | ​ | ​ | 2016                                        | ​ | ​  | 2015                 | ​ | ​ | Increase/(Decrease) | ​ |
| ​                                             | ​ | ​ | £                                      | ​ | ​  | £               | ​ | ​ | £ | ​ | ​ | % | ​ |
| ​                                             | ​ | ​ | (in thousands, except for percentages) | ​ |
| Research and development fees                       | ​ | ​ | ​                                     | ​ | 337      | ​              | ​ | ​ | ​ | ​ | 535 | ​ | ​ | ​ | ​ | ​ | (198) | ​ | ​ | ​ | ​ | ​ | (37)% | ​ | ​ |
| Research and development expenditure                | ​ | ​ | ​                                     | ​ | ​  | ​              | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| GW-funded research and development                  | ​ | ​ | ​                                     | ​ | (91,234) | ​              | ​ | ​ | ​ | ​ | (48,327) | ​ | ​ | ​ | ​ | ​ | (42,907) | ​ | ​ | ​ | ​ | ​ | 89% | ​ | ​ |
| Development partner-funded research and development | ​ | ​ | ​                                     | ​ | (337)    | ​              | ​ | ​ | ​ | ​ | (535) | ​ | ​ | ​ | ​ | ​ | 198 | ​ | ​ | ​ | ​ | ​ | (37)% | ​ | ​ |
| Total research and development expenditure          | ​ | ​ | ​                                     | ​ | (91,571) | ​              | ​ | ​ | ​ | ​ | (48,862) | ​ | ​ | ​ | ​ | ​ | (42,709) | ​ | ​ | ​ | ​ | ​ | 87% | ​ | ​ |
| Segmental result                                    | ​ | ​ | ​                                     | ​ | (91,234) | ​              | ​ | ​ | ​ | ​ | (48,327) | ​ | ​ | ​ | ​ | ​ | (42,907) | ​ | ​ | ​ | ​ | ​ | 89% | ​ | ​ |
| ​                                             |

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS​

| ​                                             | ​ | ​ | Year Ended September 30, | ​ |
|-----------------------------------------------------|---------|---------|-------------------------------|---------|
| ​                                             | ​ | ​ | 2017                          | ​ | ​ | 2017 | ​ | ​ | 2016 | ​ | ​ | 2015 | ​ |
| ​                                             | ​ | ​ | $                             | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ |
| ​                                             | ​ | ​ | (in thousands)                | ​ |
| Net cash outflow from operating activities          | ​ | ​ | ​                       | ​ | (147,261) | ​ | ​ | ​ | ​ | ​ | (110,245) | ​ | ​ | ​ | ​ | ​ | (84,594) | ​ | ​ | ​ | ​ | ​ | (46,471) | ​ | ​ |
| Net cash outflow from investing activities          | ​ | ​ | ​                       | ​ | (20,387) | ​ | ​ | ​ | ​ | ​ | (15,262) | ​ | ​ | ​ | ​ | ​ | (8,756) | ​ | ​ | ​ | ​ | ​ | (17,791) | ​ | ​ |
| Net cash (outflow)/inflow from financing activities | ​ | ​ | ​                       | ​ | (2,742) | ​ | ​ | ​ | ​ | ​ | (2,053) | ​ | ​ | ​ | ​ | ​ | 206,807 | ​ | ​ | ​ | ​ | ​ | 128,419 | ​ | ​ |
| Cash and cash equivalents at end of the year        | ​ | ​ | ​                       | ​ | 322,154 | ​ | ​ | ​ | ​ | ​ | 241,175 | ​ | ​ | ​ | ​ | ​ | 374,392 | ​ | ​ | ​ | ​ | ​ | 234,872 | ​ | ​ |

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS​​

| ​                        | ​ | ​ | Payments Due by Period | ​ |
|--------------------------------|---------|---------|------------------------|---------|
| ​                        | ​ | ​ | Total                  | ​ | ​ | Less than 1 year | ​ | ​ | 1 – 3 years | ​ | ​ | 3 – 5 years | ​ | ​ | More than 5 years | ​ |
| ​                        | ​ | ​ | £                 | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ | ​ | £ | ​ |
| ​                        | ​ | ​ | (in thousands)         | ​ |
| Operating lease obligations(1) | ​ | ​ | ​                | ​ | 14,310 | ​ | ​ | ​ | ​ | ​ | 3,628 | ​ | ​ | ​ | ​ | ​ | 5,364 | ​ | ​ | ​ | ​ | ​ | 3,381 | ​ | ​ | ​ | ​ | ​ | 1,937 | ​ | ​ |
| Finance lease obligations(2)   | ​ | ​ | ​                | ​ | 8,735 | ​ | ​ | ​ | ​ | ​ | 556 | ​ | ​ | ​ | ​ | ​ | 1,110 | ​ | ​ | ​ | ​ | ​ | 1,110 | ​ | ​ | ​ | ​ | ​ | 5,959 | ​ | ​ |
| Purchase obligations(3)        | ​ | ​ | ​                | ​ | 7,583 | ​ | ​ | ​ | ​ | ​ | 7,583 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Borrowings(4)                  | ​ | ​ | ​                | ​ | 12,953 | ​ | ​ | ​ | ​ | ​ | 965 | ​ | ​ | ​ | ​ | ​ | 1,930 | ​ | ​ | ​ | ​ | ​ | 1,930 | ​ | ​ | ​ | ​ | ​ | 8,128 | ​ | ​ |
| Growing operations(5)          | ​ | ​ | ​                | ​ | 38,914 | ​ | ​ | ​ | ​ | ​ | 8,973 | ​ | ​ | ​ | ​ | ​ | 18,323 | ​ | ​ | ​ | ​ | ​ | 11,618 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Total contractual obligations  | ​ | ​ | ​                | ​ | 82,495 | ​ | ​ | ​ | ​ | ​ | 21,705 | ​ | ​ | ​ | ​ | ​ | 26,727 | ​ | ​ | ​ | ​ | ​ | 18,039 | ​ | ​ | ​ | ​ | ​ | 16,024 | ​ | ​ |
| ​                        |

32

32

----

TABLE OF CONTENTS​​

| Name                     | ​ | ​ | Age     | ​ | ​ | Position                                                            | ​ |
|--------------------------|---------|---------|---------|---------|---------|---------------------------------------------------------------------|---------|
| Executive Directors      | ​ | ​ | ​ | ​ | ​ | ​                                                             | ​ |
| Dr. Geoffrey Guy(3) | ​ | ​ | 63      | ​ | ​ | Chairman of the Board of Directors and member of Board of Directors | ​ |
| Justin Gover             | ​ | ​ | 46      | ​ | ​ | Chief Executive Officer and member of Board of Directors            | ​ |
| Non-Employee Directors   | ​ | ​ | ​ |
| James Noble(1)(2)(3)(4)  | ​ | ​ | 58      | ​ | ​ | Deputy Chairman and member of Board of Directors                    | ​ |
| Cabot Brown(1)(2)(3)(4)  | ​ | ​ | 56      | ​ | ​ | Non-Executive Director and member of Board of Directors             | ​ |
| Thomas Lynch(1)(2)(3)(4) | ​ | ​ | 61      | ​ | ​ | Non-Executive Director and member of Board of Directors             | ​ |
| Executive Officers       | ​ | ​ | ​ |
| Scott Giacobello         | ​ | ​ | 47      | ​ | ​ | Chief Financial Officer                                             | ​ |
| Adam George              | ​ | ​ | 47      | ​ | ​ | Managing Director, UK and Company Secretary                         | ​ |
| Chris Tovey              | ​ | ​ | 52      | ​ | ​ | Chief Operating Officer                                             | ​ |
| Julian Gangolli          | ​ | ​ | 59      | ​ | ​ | President, North America                                            | ​ |
| Volker Knappertz         | ​ | ​ | 52      | ​ | ​ | Chief Medical Officer                                               | ​ |
| Doug Snyder              | ​ | ​ | 53      | ​ | ​ | Chief Legal Officer                                                 | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​

| Name                                                                 | ​ | ​ | Salary/Fees | ​ | ​ | Annual Bonus | ​ | ​ | Benefit Excluding Pension(2) | ​ | ​ | Pension Benefit(3) | ​ | ​ | Total   | ​ |
|----------------------------------------------------------------------|---------|---------|-------------|---------|---------|--------------|---------|---------|------------------------------|---------|---------|--------------------|---------|---------|---------|---------|
| ​                                                              | ​ | ​ | £      | ​ | ​ | £       | ​ | ​ | £                       | ​ | ​ | £             | ​ | ​ | £  | ​ |
| Dr. Geoffrey GuyExecutive DirectorChairman                      | ​ | ​ | ​     | ​ | 421,027 | ​      | ​ | ​ | ​                      | ​ | 355,603 | ​            | ​ | ​ | ​ | ​ | 11,878 | ​ | ​ | ​ | ​ | ​ | 18,228 | ​ | ​ | ​ | ​ | ​ | 806,736 | ​ | ​ |
| Justin Gover(4)Executive DirectorChief Executive Officer             | ​ | ​ | ​     | ​ | 406,765 | ​      | ​ | ​ | ​                      | ​ | 362,329 | ​            | ​ | ​ | ​ | ​ | 38,393 | ​ | ​ | ​ | ​ | ​ | 15,492 | ​ | ​ | ​ | ​ | ​ | 822,979 | ​ | ​ |
| Scott GiacobelloExecutive OfficerChief Financial Officer             | ​ | ​ | ​     | ​ | 162,337 | ​      | ​ | ​ | ​                      | ​ | — | ​            | ​ | ​ | ​ | ​ | 10,530 | ​ | ​ | ​ | ​ | ​ | 4,309 | ​ | ​ | ​ | ​ | ​ | 177,176 | ​ | ​ |
| Adam GeorgeExecutive OfficerManaging Director – UK | ​ | ​ | ​     | ​ | 251,132 | ​      | ​ | ​ | ​                      | ​ | 198,248 | ​            | ​ | ​ | ​ | ​ | 7,200 | ​ | ​ | ​ | ​ | ​ | 10,162 | ​ | ​ | ​ | ​ | ​ | 466,742 | ​ | ​ |
| Dr. Stephen Wright(5)Executive OfficerChief Medical Officer     | ​ | ​ | ​     | ​ | 159,095 | ​      | ​ | ​ | ​                      | ​ | 243,564 | ​            | ​ | ​ | ​ | ​ | 7,804 | ​ | ​ | ​ | ​ | ​ | 12,485 | ​ | ​ | ​ | ​ | ​ | 422,948 | ​ | ​ |
| Chris ToveyExecutive OfficerChief Operating Officer                  | ​ | ​ | ​     | ​ | 255,161 | ​      | ​ | ​ | ​                      | ​ | 215,234 | ​            | ​ | ​ | ​ | ​ | 7,355 | ​ | ​ | ​ | ​ | ​ | 11,033 | ​ | ​ | ​ | ​ | ​ | 488,783 | ​ | ​ |
| Julian GangolliExecutive OfficerPresident, North America             | ​ | ​ | ​     | ​ | 329,658 | ​      | ​ | ​ | ​                      | ​ | 324,830 | ​            | ​ | ​ | ​ | ​ | 3,567 | ​ | ​ | ​ | ​ | ​ | 11,395 | ​ | ​ | ​ | ​ | ​ | 669,450 | ​ | ​ |
| Volker KnappertzExecutive OfficerChief Medical Officer               | ​ | ​ | ​     | ​ | 117,936 | ​      | ​ | ​ | ​                      | ​ | 38,433  | ​            | ​ | ​ | ​ | ​ | 6,077 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 162,446 | ​ | ​ |
| Doug SnyderExecutive OfficerChief Legal Officer                      | ​ | ​ | ​     | ​ | 54,115  | ​      | ​ | ​ | ​                      | ​ | — | ​            | ​ | ​ | ​ | ​ | 18,296 | ​ | ​ | ​ | ​ | ​ | 712 | ​ | ​ | ​ | ​ | ​ | 73,123 | ​ | ​ |
| James NobleNon-Executive DirectorDeputy Chairman                     | ​ | ​ | ​     | ​ | 69,600  | ​      | ​ | ​ | ​                      | ​ | — | ​            | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 69,600 | ​ | ​ |
| Cabot Brown Non-Executive Director                                   | ​ | ​ | ​     | ​ | 68,181  | ​      | ​ | ​ | ​                      | ​ | — | ​            | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 68,181 | ​ | ​ |
| Thomas Lynch(6)Non-Executive Director                                | ​ | ​ | ​     | ​ | — | ​      | ​ | ​ | ​                      | ​ | — | ​            | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |

----

TABLE OF CONTENTS

| Name of Director         | ​ | ​ | Type of Plan | ​ | ​ | Granted | ​ | ​ | Nominal value | ​ | ​ | Exercise price | ​ | ​ | Date of exercise       | ​ | ​ | Date of expiry              | ​ |
|--------------------------|---------|---------|--------------|---------|---------|---------|---------|---------|---------------|---------|---------|----------------|---------|---------|------------------------|---------|---------|-----------------------------|---------|
| Dr. Geoffrey W. Guy | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 138,672 | ​       | ​ | ​ | 0.1p​    | ​ | ​ | $100.52 per ADS​ | ​ | ​ | August 10, 2020​ | ​ | ​ | August 10, 2025​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 15,336  | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2018​ | ​ | ​ | August 10, 2025​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 15,336  | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2019​ | ​ | ​ | August 10, 2026​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 15,336  | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2020​ | ​ | ​ | August 10, 2027​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 15,336  | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2021​ | ​ | ​ | August 10, 2028​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 204,552 | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2020​ | ​ | ​ | August 10, 2027​ | ​ |
| Justin Gover             | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 142,344 | ​       | ​ | ​ | 0.1p​    | ​ | ​ | $117.74 per ADS​ | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 17,517  | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2018​ | ​ | ​ | March 15, 2019​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 17,517  | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2019​ | ​ | ​ | March 15, 2020​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 17,517  | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | March 15, 2021​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 17,517  | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2021​ | ​ | ​ | March 15, 2022​ | ​ |
| ​                  | ​ | ​ | LTIP         | ​ | ​ | ​ | ​ | 233,568 | ​       | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | March 15, 2021​ | ​ |

----

TABLE OF CONTENTS

| Name of Director | ​ | ​ | Type ofPlan | ​ | ​ | Granted | ​ | ​ | Nominalvalue | ​ | ​ | Exercise price | ​ | ​ | Date of exercise       | ​ | ​ | Date of expiry              | ​ |
|------------------|---------|---------|-------------|---------|---------|---------|---------|---------|--------------|---------|---------|----------------|---------|---------|------------------------|---------|---------|-----------------------------|---------|
| Scott Giacobello | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 67,161  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | $103.72 per ADS​ | ​ | ​ | May 18, 2020​    | ​ | ​ | May 18, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 8,135   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2018​    | ​ | ​ | March 15, 2019​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 8,135   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2019​    | ​ | ​ | March 15, 2020​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 8,135   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2020​    | ​ | ​ | March 15, 2021​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 8,135   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2021​    | ​ | ​ | March 15, 2022​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 108,465 | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2020​    | ​ | ​ | March 15, 2021​ | ​ |
| Adam George      | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 52,560  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | $117.40 per ADS​ | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 6,468   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2018​ | ​ | ​ | January 6, 2025​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 6,468   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2019​ | ​ | ​ | January 6, 2026​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 6,468   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 6,468   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2021​ | ​ | ​ | January 6, 2028​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 86,244  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| Chris Tovey      | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 52,560  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | $117.40 per ADS​ | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 6,468   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2018​ | ​ | ​ | January 6, 2025​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 6,468   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2019​ | ​ | ​ | January 6, 2026​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 6,468   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 6,468   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2021​ | ​ | ​ | January 6, 2028​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 86,244  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| Julian Gangolli  | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 87,660  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | $117.74 per ADS​ | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 10,788  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2018​ | ​ | ​ | March 15, 2019​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 10,788  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2019​ | ​ | ​ | March 15, 2020​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 10,788  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | March 15, 2021​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 10,788  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2021​ | ​ | ​ | March 15, 2022​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 143,832 | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | March 15, 2021​ | ​ |
| Volker Knappertz | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 150,442 | ​      | ​ | ​ | 0.1p​    | ​ | ​ | $103.72 per ADS​ | ​ | ​ | May 18, 2020​    | ​ | ​ | May 18, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 12,148  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2018​    | ​ | ​ | March 15, 2019​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 12,148  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2019​    | ​ | ​ | March 15, 2020​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 12,148  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2020​    | ​ | ​ | March 15, 2021​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 12,148  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2021​    | ​ | ​ | March 15, 2022​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 121,481 | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | May 18, 2020​    | ​ | ​ | March 15, 2021​ | ​ |
| Doug Snyder      | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 82,956  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | $117.40 per ADS​ | ​ | ​ | August 10, 2020​ | ​ | ​ | August 10, 2025​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 9,180   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2018​ | ​ | ​ | March 15, 2019​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 9,180   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2019​ | ​ | ​ | March 15, 2020​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 9,180   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2020​ | ​ | ​ | March 15, 2021​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 9,180   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2021​ | ​ | ​ | March 15, 2022​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 122,364 | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | August 10, 2020​ | ​ | ​ | March 15, 2021​ | ​ |
| James Noble      | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 18,636  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | $117.40 per ADS​ | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 9,168   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| Cabot Brown      | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 18,636  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | $117.40 per ADS​ | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 9,168   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| Thomas Lynch     | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 18,636  | ​      | ​ | ​ | 0.1p​    | ​ | ​ | $117.40 per ADS​ | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |
| ​          | ​ | ​ | LTIP        | ​ | ​ | ​ | ​ | 9,168   | ​      | ​ | ​ | 0.1p​    | ​ | ​ | 0.1p​            | ​ | ​ | January 6, 2020​ | ​ | ​ | January 6, 2027​ | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​​

| ​                       | ​ | ​ | 2017    | ​ | ​ | 2016    | ​ | ​ | 2015    |
|-------------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| By Function:                  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Research and development      | ​ | ​ | ​ | ​ | 271     | ​ | ​ | ​ | ​ | ​ | 268 | ​ | ​ | ​ | ​ | ​ | 207 |
| Manufacturing and operations  | ​ | ​ | ​ | ​ | 118     | ​ | ​ | ​ | ​ | ​ | 80 | ​ | ​ | ​ | ​ | ​ | 56 |
| Quality control and assurance | ​ | ​ | ​ | ​ | 69      | ​ | ​ | ​ | ​ | ​ | 61 | ​ | ​ | ​ | ​ | ​ | 51 |
| Commercial                    | ​ | ​ | ​ | ​ | 41      | ​ | ​ | ​ | ​ | ​ | 15 | ​ | ​ | ​ | ​ | ​ | 7 |
| Management and administrative | ​ | ​ | ​ | ​ | 84      | ​ | ​ | ​ | ​ | ​ | 72 | ​ | ​ | ​ | ​ | ​ | 48 |
| Total                         | ​ | ​ | ​ | ​ | 583     | ​ | ​ | ​ | ​ | ​ | 496 | ​ | ​ | ​ | ​ | ​ | 369 |
| By Geography:                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| United Kingdom                | ​ | ​ | ​ | ​ | 475     | ​ | ​ | ​ | ​ | ​ | 425 | ​ | ​ | ​ | ​ | ​ | 342 |
| North America                 | ​ | ​ | ​ | ​ | 108     | ​ | ​ | ​ | ​ | ​ | 71 | ​ | ​ | ​ | ​ | ​ | 27 |
| Total                         | ​ | ​ | ​ | ​ | 583     | ​ | ​ | ​ | ​ | ​ | 496 | ​ | ​ | ​ | ​ | ​ | 369 |
| ​                       |

----

TABLE OF CONTENTS​​

| ​                                                            | ​ | ​ | Ordinary Shares Beneficially Owned(2) | ​ |
|--------------------------------------------------------------------|---------|---------|---------------------------------------|---------|
| Name of Beneficial Owner(1)                                        | ​ | ​ | Number                                | ​ | ​ | Percent | ​ |
| Greater than 5% Shareholders                                       | ​ | ​ | ​                               | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Capital Research and Management Company(3)                         | ​ | ​ | ​                               | ​ | 44,594,160 | ​ | ​ | ​ | ​ | ​ | 14.7 | ​ | ​ |
| Scopia Capital Management LP(4)                                    | ​ | ​ | ​                               | ​ | 35,856,228 | ​ | ​ | ​ | ​ | ​ | 11.8 | ​ | ​ |
| Prudential plc group of companies(5)                               | ​ | ​ | ​                               | ​ | 23,972,808 | ​ | ​ | ​ | ​ | ​ | 7.9 | ​ | ​ |
| Janus Henderson Group plc(6)                                       | ​ | ​ | ​                               | ​ | 16,251,564 | ​ | ​ | ​ | ​ | ​ | 5.3 | ​ | ​ |
| Named Executive Officers and Directors                             | ​ | ​ | ​                               | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Dr. Geoffrey Guy(7)                                           | ​ | ​ | ​                               | ​ | 10,775,909 | ​ | ​ | ​ | ​ | ​ | 3.5 | ​ | ​ |
| Mr. Justin Gover(8)                                           | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Mr. Thomas Lynch                                              | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Mr. James Noble                                               | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Mr. Adam George(9)                                            | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Mr. Julian Gangolli                                           | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Mr. Chris Tovey                                               | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Mr. Cabot Brown                                               | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Mr. Scott Giacobello                                          | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Dr. Volker Knappertz                                          | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| Mr. Doug Snyder                                               | ​ | ​ | ​                               | ​ | — | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |
| All Named Executive Officers and Directors as a Group (11 persons) | ​ | ​ | ​                               | ​ | ​ | ​ | ​ | ​ | ​ | ​ | * | ​ | ​ |

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS​​​​​​

| ​                                                 | ​ | ​ | Price Per ADS | ​ |
|---------------------------------------------------------|---------|---------|---------------|---------|
| ​                                                 | ​ | ​ | High          | ​ | ​ | Low | ​ |
| Annual (Year Ended September 30):                  | ​ | ​ | ​       | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| 2013 (May 1, 2013 through September 30, 2013) | ​ | ​ | ​       | $       | 17.75 | ​ | ​ | ​ | ​ | $ | 8.51 | ​ | ​ |
| 2014                                                    | ​ | ​ | ​       | $       | 107.35 | ​ | ​ | ​ | ​ | $ | 17.01 | ​ | ​ |
| 2015                                                    | ​ | ​ | ​       | $       | 129.69 | ​ | ​ | ​ | ​ | $ | 61.55 | ​ | ​ |
| 2016                                                    | ​ | ​ | ​       | $       | 132.73 | ​ | ​ | ​ | ​ | $ | 36.64 | ​ | ​ |
| 2017                                                    | ​ | ​ | ​       | $       | 134.02 | ​ | ​ | ​ | ​ | $ | 94.14 | ​ | ​ |
| 2018 (through December 1, 2017)                         | ​ | ​ | ​       | $       | 128.15 | ​ | ​ | ​ | ​ | $ | 98.51 | ​ | ​ |
| Quarterly:                                              | ​ | ​ | ​       | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| First Quarter 2015                                      | ​ | ​ | ​       | $       | 82.33 | ​ | ​ | ​ | ​ | $ | 61.55 | ​ | ​ |
| Second Quarter 2015                                     | ​ | ​ | ​       | $       | 100.48 | ​ | ​ | ​ | ​ | $ | 69.61 | ​ | ​ |
| Third Quarter 2015                                      | ​ | ​ | ​       | $       | 129.69 | ​ | ​ | ​ | ​ | $ | 90.58 | ​ | ​ |
| Fourth Quarter 2015                                     | ​ | ​ | ​       | $       | 129.01 | ​ | ​ | ​ | ​ | $ | 88.78 | ​ | ​ |
| First Quarter 2016                                      | ​ | ​ | ​       | $       | 92.27 | ​ | ​ | ​ | ​ | $ | 64.96 | ​ | ​ |
| Second Quarter 2016                                     | ​ | ​ | ​       | $       | 85.24 | ​ | ​ | ​ | ​ | $ | 36.64 | ​ | ​ |
| Third Quarter 2016                                      | ​ | ​ | ​       | $       | 94.19 | ​ | ​ | ​ | ​ | $ | 73.64 | ​ | ​ |
| Fourth Quarter 2016                                     | ​ | ​ | ​       | $       | 132.73 | ​ | ​ | ​ | ​ | $ | 80.65 | ​ | ​ |
| First Quarter 2017                                      | ​ | ​ | ​       | $       | 134.02 | ​ | ​ | ​ | ​ | $ | 109.28 | ​ | ​ |
| Second Quarter 2017                                     | ​ | ​ | ​       | $       | 132.51 | ​ | ​ | ​ | ​ | $ | 112.38 | ​ | ​ |
| Third Quarter 2017                                      | ​ | ​ | ​       | $       | 120.81 | ​ | ​ | ​ | ​ | $ | 94.14 | ​ | ​ |
| Fourth Quarter 2017                                     | ​ | ​ | ​       | $       | 117.16 | ​ | ​ | ​ | ​ | $ | 98.75 | ​ | ​ |
| First Quarter 2018 (through December 1, 2017)           | ​ | ​ | ​       | $       | 128.15 | ​ | ​ | ​ | ​ | $ | 98.51 | ​ | ​ |

----

TABLE OF CONTENTS​​​​​​​​​​

| ​                                       | ​ | ​ | Price Per ADS | ​ |
|-----------------------------------------------|---------|---------|---------------|---------|
| ​                                       | ​ | ​ | High          | ​ | ​ | Low | ​ |
| Most Recent Six Months:                       | ​ | ​ | ​       | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| June 2017                                | ​ | ​ | ​       | $       | 104.72 | ​ | ​ | ​ | ​ | $ | 94.14 | ​ | ​ |
| July 2017                                | ​ | ​ | ​       | $       | 117.21 | ​ | ​ | ​ | ​ | $ | 100.10 | ​ | ​ |
| August 2017                              | ​ | ​ | ​       | $       | 117.61 | ​ | ​ | ​ | ​ | $ | 98.75 | ​ | ​ |
| September 2017                           | ​ | ​ | ​       | $       | 112.27 | ​ | ​ | ​ | ​ | $ | 101.49 | ​ | ​ |
| October 2017                             | ​ | ​ | ​       | $       | 114.54 | ​ | ​ | ​ | ​ | $ | 98.51 | ​ | ​ |
| November 2017                            | ​ | ​ | ​       | $       | 128.15 | ​ | ​ | ​ | ​ | $ | 110.24 | ​ | ​ |
| December 2017 (through December 1, 2017) | ​ | ​ | ​       | $       | 122.95 | ​ | ​ | ​ | ​ | $ | 122.95 | ​ | ​ |

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​​​​​

----

TABLE OF CONTENTS​​​​​

| Service                                                                                          | ​ | ​ | Fees                                                                                                | ​ |
|--------------------------------------------------------------------------------------------------|---------|---------|-----------------------------------------------------------------------------------------------------|---------|
| Issuance of ADSs                                                                                 | ​ | ​ | Up to U.S. 5¢ per ADS issued                                                                   | ​ |
| Cancellation of ADSs                                                                             | ​ | ​ | Up to U.S. 5¢ per ADS canceled                                                                 | ​ |
| Distribution of cash dividends or other cash distributions                                       | ​ | ​ | Up to U.S. 5¢ per ADS held                                                                     | ​ |
| Distribution of ADSs pursuant to stock dividends, free stock distributions or exercise of rights | ​ | ​ | Up to U.S. 5¢ per ADS held                                                                     | ​ |
| Distribution of securities other than ADSs or rights to purchase additional ADSs                 | ​ | ​ | Up to U.S. 5¢ per ADS held                                                                     | ​ |
| Depositary Services                                                                              | ​ | ​ | Up to U.S. 5¢ per ADS held on the applicable record date(s) established by the depositary bank | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​​​​​

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS​​​​

| ​               | ​ | ​ | Year ended September 30, | ​ |
|-----------------------|---------|---------|-------------------------------|---------|
| ​               | ​ | ​ | 2017                          | ​ | ​ | 2016 | ​ |
| ​               | ​ | ​ | (in thousands)                | ​ |
| Audit Fees            | ​ | ​ | ​                       | £  | 533 | ​ | ​ | ​ | ​ | £ | 450 | ​ | ​ |
| Audit-Related Fees(1) | ​ | ​ | ​                       | ​ | 122 | ​ | ​ | ​ | ​ | ​ | 184 | ​ | ​ |
| All Other Fees(2)     | ​ | ​ | ​                       | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Total                 | ​ | ​ | ​                       | £  | 655 | ​ | ​ | ​ | ​ | £ | 634 | ​ | ​ |
| ​               |

----

TABLE OF CONTENTS​​​​​

----

TABLE OF CONTENTS​​​

1
| Exhibit Number | ​ | ​ | Description of Exhibit                                                                                                                                                                                                                                                                                                                                                                      | ​ |
|---------------------|---------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 1.1*                | ​ | ​ | Memorandum & Articles of Association of GW Pharmaceuticals plc. (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                                                                  | ​ |
| 2.1*                | ​ | ​ | Form of specimen certificate evidencing ordinary shares (incorporated by reference to Exhibit 4.1 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                                                                              | ​ |
| 2.2(1)*             | ​ | ​ | Form of Deposit Agreement among GW Pharmaceuticals plc, Citibank, N.A., as the depositary bank and all Holders and Beneficial Owners of ADSs issued thereunder (incorporated by reference to Exhibit 4.2 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                  | ​ |
| 2.3(1)*             | ​ | ​ | Form of American Depositary Receipt (included in Exhibit 2.2) (incorporated by reference to Exhibit 4.3 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                                                                   | ​ |
| 4.1†*         | ​ | ​ | Licence and Distribution Agreement between Bayer AG Division Pharma and GW Pharma Limited., dated May 20, 2003 (incorporated by reference to Exhibit 10.1 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                 | ​ |
| 4.2†*         | ​ | ​ | Amendment Number 1 to the Licence and Distribution Agreement, dated November 4, 2003 (incorporated by reference to Exhibit 10.2 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                                           | ​ |
| 4.3*                | ​ | ​ | Amendment Number 2 to the Licence and Distribution Agreement between GW Pharma Limited. and Bayer Healthcare AG Division Pharma, dated January 14, 2004 (incorporated by reference to Exhibit 10.3 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                        | ​ |
| 4.4†*         | ​ | ​ | Amendment Number 3 to the Licence and Distribution Agreement between GW Pharma Limited. and Bayer Healthcare AG Division Pharma, dated March 1, 2005 (incorporated by reference to Exhibit 10.4 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                           | ​ |
| 4.5†*         | ​ | ​ | Amendment Number 4 to the Licence and Distribution Agreement between GW Pharma Limited. and Bayer Healthcare AG Division Pharma, dated May 10, 2005 (incorporated by reference to Exhibit 10.5 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                            | ​ |
| 4.6*                | ​ | ​ | Amendment Number 5 to the Licence and Distribution Agreement between GW Pharma Limited. and Bayer Schering Pharma AG (f/k/a Bayer AG, Bayer HealthCare, Division Pharma), dated March 10, 2010 (incorporated by reference to Exhibit 10.6 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013). | ​ |
| 4.7†*         | ​ | ​ | Supply Agreement between Bayer AG and GW Pharma Limited, dated May 20, 2003 (incorporated by reference to Exhibit 10.7 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                                               | ​ |

----

TABLE OF CONTENTS

| Exhibit Number | ​ | ​ | Description of Exhibit                                                                                                                                                                                                                                                                                                                                                                             | ​ |
|---------------------|---------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 4.8†*         | ​ | ​ | Amendment Number 1 to the Supply Agreement between GW Pharma Limited. and Bayer Healthcare AG, dated November 4, 2003 (incorporated by reference to Exhibit 10.8 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                 | ​ |
| 4.9†*         | ​ | ​ | Amendment Number 2 to the Supply Agreement between GW Pharma Limited. and Bayer Healthcare AG, dated May 10, 2005 (incorporated by reference to Exhibit 10.9 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                     | ​ |
| 4.10†*        | ​ | ​ | Amendment Number 3 to the Supply Agreement between GW Pharma Limited. and Bayer Schering Pharma AG (f/k/a Bayer AG, Bayer HealthCare, Division Pharma), dated March 10, 2010 (incorporated by reference to Exhibit 10.10 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                    | ​ |
| 4.11†*        | ​ | ​ | Product Commercialisation and Supply Consolidated Agreement between GW Pharma Limited and Almirall Prodesfarma, S.A., dated June 6, 2006 (incorporated by reference to Exhibit 10.11 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                             | ​ |
| 4.12†*        | ​ | ​ | Amendment No. 1 to the Product Commercialisation and Supply Consolidated Agreement between GW Pharma Limited. and Laboratorios Almirall S.A., dated March 4, 2009 (incorporated by reference to Exhibit 10.12 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                               | ​ |
| 4.13†*        | ​ | ​ | Amendment to the Product Commercialisation and Supply Consolidated Agreement, dated June 6, 2006 between GW Pharma Limited. and Almirall S.A., dated July 23, 2010 (incorporated by reference to Exhibit 10.13 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                         | ​ |
| 4.14†*        | ​ | ​ | Supplementary Agreement to the Product Commercialisation and Supply Consolidated Agreement, dated June 6, 2006 between GW Pharma Limited. and Almirall S.A., dated November 17, 2011 (incorporated by reference to Exhibit 10.14 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).            | ​ |
| 4.15†*        | ​ | ​ | Amendment and Supplementary Agreement to the Product Commercialisation and Supply Consolidated Agreement, dated June 6, 2006 between GW Pharma Limited. and Almirall S.A., dated March 13, 2012 (incorporated by reference to Exhibit 10.15 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013). | ​ |
| 4.16†*        | ​ | ​ | Research Collaboration and Licence Agreement between GW Pharma Limited. and GW Pharmaceuticals plc and Otsuka Pharmaceutical Co., Ltd., dated July 9, 2007 (incorporated by reference to Exhibit 10.16 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                | ​ |
| 4.17†*        | ​ | ​ | Amendment No. 1 to Research Collaboration and Licence Agreement, dated March 14, 2008 (incorporated by reference to Exhibit 10.17 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                                                | ​ |
| 4.18†*        | ​ | ​ | Amendment No. 2 to Research Collaboration and Licence Agreement, dated June 29, 2010 (incorporated by reference to Exhibit 10.18 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                                            | ​ |
| 4.19†*        | ​ | ​ | Development and Licence Agreement between GW Pharma Limited. and GW Pharmaceuticals Plc and Otsuka Pharmaceutical Co., Ltd., dated February 14, 2007 (incorporated by reference to Exhibit 10.19 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                            | ​ |

----

TABLE OF CONTENTS

| Exhibit Number | ​ | ​ | Description of Exhibit                                                                                                                                                                                                                                                                                             | ​ |
|---------------------|---------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 4.20†*        | ​ | ​ | Amendment No. 1 to Development and Licence Agreement, dated November 1, 2008 (incorporated by reference to Exhibit 10.20 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                    | ​ |
| 4.21†*        | ​ | ​ | Letter amending Development and Licence Agreement, dated October 21, 2010 (incorporated by reference to Exhibit 10.21 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                       | ​ |
| 4.22†*        | ​ | ​ | Distribution and Licence Agreement, dated April 8, 2011, by and between GW Pharma Limited. and Novartis Pharma AG (incorporated by reference to Exhibit 10.22 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).    | ​ |
| 4.23†*        | ​ | ​ | Manufacturing and Supply Agreement, dated November 9, 2011, by and between Novartis Pharma AG and GW Pharma Limited. (incorporated by reference to Exhibit 10.23 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013). | ​ |
| 4.24†*        | ​ | ​ | Production Supply Agreement, dated March 7, 2007 (incorporated by reference to Exhibit 10.24 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                     | ​ |
| 4.25†*        | ​ | ​ | Lease, dated July 6, 2009 (incorporated by reference to Exhibit 10.25 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                            | ​ |
| 4.26†*        | ​ | ​ | Lease, dated October 9, 2009 (incorporated by reference to Exhibit 10.26 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                         | ​ |
| 4.27†*        | ​ | ​ | Lease, dated April 6, 2011 (incorporated by reference to Exhibit 10.27 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                           | ​ |
| 4.28†*        | ​ | ​ | Lease, dated October 12, 2011 (incorporated by reference to Exhibit 10.28 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                        | ​ |
| 4.29†*        | ​ | ​ | Lease, dated January 6, 2012 (incorporated by reference to Exhibit 10.29 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                         | ​ |
| 4.30†*        | ​ | ​ | Agreement for Lease, dated April 4, 2012 (incorporated by reference to Exhibit 10.30 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                             | ​ |
| 4.31*               | ​ | ​ | Occupational Underlease, dated August 11, 2010 (incorporated by reference to Exhibit 10.31 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                       | ​ |
| 4.32*               | ​ | ​ | Lease, dated May 24, 2011 (incorporated by reference to Exhibit 10.32 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                                            | ​ |
| 4.33*               | ​ | ​ | Tenancy Agreement, dated November 19, 2012 (incorporated by reference to Exhibit 10.33 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                           | ​ |
| 4.34*               | ​ | ​ | Service Agreement by and between GW Pharma Limited, and Adam George, dated June 1, 2012 (incorporated by reference to Exhibit 10.34 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                              | ​ |

----

TABLE OF CONTENTS

| Exhibit Number | ​ | ​ | Description of Exhibit                                                                                                                                                                                                                                                                                   | ​ |
|---------------------|---------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 4.35†*        | ​ | ​ | Service Agreement by and between GW Pharma Limited, and Chris Tovey, dated July 11, 2012 (incorporated by reference to Exhibit 10.35 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                   | ​ |
| 4.36*               | ​ | ​ | Service Agreement by and between GW Research Limited and Dr. Geoffrey Guy, dated March 14, 2013 (incorporated by reference to Exhibit 10.36 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).       | ​ |
| 4.37*               | ​ | ​ | Service Agreement by and between GW Research Limited and Justin Gover, dated February 26, 2013 (incorporated by reference to Exhibit 10.37 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).        | ​ |
| 4.38*               | ​ | ​ | Service Agreement by and between GW Research Limited and Dr. Stephen Wright, dated January 18, 2013 (incorporated by reference to Exhibit 10.38 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).   | ​ |
| 4.39*               | ​ | ​ | Letter of Appointment by and between GW Pharmaceuticals plc and James Noble, dated February 26, 2013 (incorporated by reference to Exhibit 10.39 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).  | ​ |
| 4.40*               | ​ | ​ | Letter of Appointment by and between GW Pharmaceuticals plc and Thomas Lynch, dated February 26, 2013 (incorporated by reference to Exhibit 10.40 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013). | ​ |
| 4.41*               | ​ | ​ | Service Agreement by and between Greenwich Biosciences, Inc. (formerly GW Pharmaceuticals Inc.) and Cabot Brown, dated November 7, 2013 (incorporated by reference to Exhibit 10.41 to our Annual Report (file no. 001-35892), filed with the SEC on November 25, 2013).             | ​ |
| 4.42*               | ​ | ​ | Long Term Incentive Plan (incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-8 (file no. 333-204389), filed with the SEC on May 22, 2015).                                                                                                                  | ​ |
| 4.43*               | ​ | ​ | GW Pharmaceuticals All Employee Share Scheme (incorporated by reference to Exhibit 10.43 to our Registration Statement on Form F-1 (file no. 333-187356), as amended, initially filed with the SEC on March 19, 2013).                                                                    | ​ |
| 4.44*               | ​ | ​ | GW Pharmaceuticals Approved Share Option Scheme 2001, as amended.                                                                                                                                                                                                                                        | ​ |
| 4.45*               | ​ | ​ | GW Pharmaceuticals Unapproved Share Option Scheme 2001, as amended.                                                                                                                                                                                                                                      | ​ |
| 4.46†*        | ​ | ​ | Lease, dated May 24, 2013 (incorporated by reference to Exhibit 4.46 to our Annual Report (file no. 001-35892), as amended, originally filed with the SEC on November 25, 2013).                                                                                                     | ​ |
| 4.47†*        | ​ | ​ | Lease, dated May 24, 2013 (incorporated by reference to Exhibit 4.47 to our Annual Report (file no. 001-35892), as amended, originally filed with the SEC on November 25, 2013).                                                                                                     | ​ |
| 4.48†*        | ​ | ​ | Lease, dated May 24, 2013 (incorporated by reference to Exhibit 4.48 to our Annual Report (file no. 001-35892), as amended, originally filed with the SEC on November 25, 2013).                                                                                                     | ​ |
| 4.49*               | ​ | ​ | Lease, dated August 1, 2013 (incorporated by reference to Exhibit 4.49 to our Annual Report (file no. 001-35892), as amended, originally filed with the SEC on November 25, 2013).                                                                                              | ​ |
| 4.50*               | ​ | ​ | Lease, dated July 16, 2013 (incorporated by reference to Exhibit 4.50 to our Annual Report (file no. 001-35892), as amended, originally filed with the SEC on November 25, 2013).                                                                                                    | ​ |
| 4.51*               | ​ | ​ | Amendment to the Distribution and Licence Agreement, dated May 5, 2014 between Novartis Pharma AG and GW Pharma Limited (incorporated by reference to Exhibit 99.4 to our Report on Form 6-K, filed with the SEC on May 7, 2014).                                                         | ​ |
| 4.52*†        | ​ | ​ | Amendment and Supplementary Agreement to the Product Commercialisation and Supply Consolidated Agreement dated June 6, 2006, between GW Pharma Limited and Almirall, S.A., dated September 30, 2014.                                                                                           | ​ |
| 4.53*               | ​ | ​ | Transfer of Contract, dated July 20, 2015 among GW Pharmaceuticals plc, GW Research Limited and Justin Gover.                                                                                                                                                                                  | ​ |

----

TABLE OF CONTENTS

| Exhibit Number  | ​ | ​ | Description of Exhibit                                                                                                                                         | ​ |
|----------------------|---------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 4.54*                | ​ | ​ | Offer Letter, dated July 17, 2015 between Greenwich Biosciences, Inc. (formerly GW Pharmaceuticals Inc.) and Justin Gover.                                | ​ |
| 4.55*                | ​ | ​ | Offer Letter, dated May 5, 2015 between Greenwich Biosciences, Inc. (formerly GW Pharmaceuticals Inc.) and Julian Gangolli.                               | ​ |
| 4.56*                | ​ | ​ | Discretionary Benefits Letter, dated May 5, 2015 between Greenwich Biosciences, Inc. (formerly GW Pharmaceuticals Inc.) and Julian Gangolli.              | ​ |
| 4.57*                | ​ | ​ | Service Agreement by and between GW Pharmaceuticals plc and Julian Gangolli, effective July 21, 2015.                                                     | ​ |
| 4.58*†         | ​ | ​ | Lease, dated May 27, 2016.                                                                                                                                | ​ |
| 4.59*†         | ​ | ​ | Amended and Restated Production and Supply Agreement, dated August 31, 2016, among GW Pharma Limited, GW Pharmaceuticals plc and British Sugar plc.       | ​ |
| 4.60*                | ​ | ​ | Mutual Termination Agreement, dated November 24, 2016 between Novartis Pharma AG and GW Pharma Ltd.                                                       | ​ |
| 4.61*                | ​ | ​ | Letter of Appointment by and between GW Pharmaceuticals plc and Cabot Brown, effective January 1, 2016.                                                   | ​ |
| 4.62*                | ​ | ​ | Letter of Appointment by and between GW Pharmaceuticals plc and James Noble, effective February 1, 2016.                                                  | ​ |
| 4.63**               | ​ | ​ | Fee Letter, dated April 10, 2017 from GW Pharmaceuticals plc to Cabot Brown.                                                                              | ​ |
| 4.64**               | ​ | ​ | Fee Letter, dated April 10, 2017 from GW Pharmaceuticals plc to James Noble.                                                                              | ​ |
| 4.65**               | ​ | ​ | Salary and Bonus Letter, dated April 13, 2017 from GW Pharmaceuticals plc to Chris Tovey.                                                                 | ​ |
| 4.66**               | ​ | ​ | Salary and Bonus Letter, dated April 13, 2017 from GW Pharmaceuticals plc to Geoffrey Guy.                                                                | ​ |
| 4.67**               | ​ | ​ | Salary and Bonus Letter, dated April 13, 2017 from GW Pharmaceuticals plc to Stephen Wright.                                                              | ​ |
| 4.68**               | ​ | ​ | Salary and Bonus Letter, dated April 13, 2017 from GW Pharmaceuticals plc to Adam George.                                                                 | ​ |
| 4.69**               | ​ | ​ | Greenwich Biosciences, Inc. Compensation Memo, dated February 21, 2017 to Justin Gover.                                                                   | ​ |
| 4.70**               | ​ | ​ | Greenwich Biosciences, Inc. Compensation Memo, dated February 22, 2017 to Julian Gangolli.                                                                | ​ |
| 4.71**               | ​ | ​ | Offer Letter, dated February 20, 2017 between Greenwich Biosciences, Inc. and Scott Giacobello.                                                           | ​ |
| 4.72**               | ​ | ​ | Offer Letter, dated April 20, 2017 between Greenwich Biosciences, Inc. and Volker Knappertz.                                                              | ​ |
| 4.73**               | ​ | ​ | Offer Letter, dated May 5, 2017 between Greenwich Biosciences, Inc. and Douglas Snyder.                                                                   | ​ |
| 4.74**               | ​ | ​ | Relocation Assistance Agreement, dated May 8, 2017 between Greenwich Biosciences, Inc. and Douglas Snyder.                                                | ​ |
| 4.75**               | ​ | ​ | Greenwich Biosciences, Inc. Change in Control and Severance Benefit Plan.                                                                                      | ​ |
| 4.76**               | ​ | ​ | Change in Control and Severance Benefit Plan Participation Agreement, dated July 12, 2017 between Greenwich Biosciences, Inc. and Julian Gangolli.   | ​ |
| 4.77**               | ​ | ​ | Change in Control and Severance Benefit Plan Participation Agreement, dated July 13, 2017 between Greenwich Biosciences, Inc. and Volker Knappertz.  | ​ |
| 4.78**               | ​ | ​ | Change in Control and Severance Benefit Plan Participation Agreement, dated August 2, 2017 between Greenwich Biosciences, Inc. and Scott Giacobello. | ​ |
| 4.79**               | ​ | ​ | Change in Control and Severance Benefit Plan Participation Agreement, dated August 9, 2017 between Greenwich Biosciences, Inc. and Douglas Snyder.   | ​ |
| 4.80**               | ​ | ​ | Master Services Agreement, dated April 1, 2017 between GW Research Ltd and inVentiv Health Commercial Europe Limited.                                     | ​ |
| 4.81**†† | ​ | ​ | Master Statement of Work, dated June 15, 2017 between GW Research Ltd and inVentiv Health Commercial Europe Limited.                                      | ​ |

----

TABLE OF CONTENTS

| Exhibit Number  | ​ | ​ | Description of Exhibit                                                                                                                                                                                                                          | ​ |
|----------------------|---------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 4.82**†† | ​ | ​ | Purchase Agreement, dated March 1, 2017 between GW Pharma Limited and Natex Prozesstechnologie GesmbH.                                                                                                                                     | ​ |
| 4.83**†† | ​ | ​ | Contract for the Design, Construction, Testing and Commissioning of GW Pharma Building 750B and Process Equipment at Kent Science Park, dated September 7, 2017 between GW Pharma Limited and The Austin Company of  (U.K.) Limited. | ​ |
| 8.1**                | ​ | ​ | List of Subsidiaries.                                                                                                                                                                                                                           | ​ |
| 12.1**               | ​ | ​ | Certificate of Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.                                                                    | ​ |
| 12.2**               | ​ | ​ | Certificate of Chief Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.                                                                    | ​ |
| 13.1**               | ​ | ​ | Certificate of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.                                                                                                    | ​ |
| 13.2**               | ​ | ​ | Certificate of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.                                                                                                    | ​ |
| 15.1**               | ​ | ​ | Consent of Deloitte LLP.                                                                                                                                                                                                                        | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS​​

| ​ | Report of Independent Registered Public Accounting Firm                                                            | ​ | ​ | ​ | ​ | F-2 | ​ | ​ |
|---------|--------------------------------------------------------------------------------------------------------------------|---------|---------|---------|---------|-----|---------|---------|
| ​ | Consolidated Income Statements for the years ended September 30, 2017, 2016 and 2015                     | ​ | ​ | ​ | ​ | F-3 | ​ | ​ |
| ​ | Consolidated Statements of Comprehensive Loss for the years ended September 30, 2017, 2016 and 2015 | ​ | ​ | ​ | ​ | F-4 | ​ | ​ |
| ​ | Consolidated Statements of Changes in Equity for the years ended September 30, 2017, 2016 and 2015  | ​ | ​ | ​ | ​ | F-5 | ​ | ​ |
| ​ | Consolidated Balance Sheets as at September 30, 2017 and 2016                                                 | ​ | ​ | ​ | ​ | F-6 | ​ | ​ |
| ​ | Consolidated Cash Flow Statements for the years ended September 30, 2017, 2016 and 2015                  | ​ | ​ | ​ | ​ | F-7 | ​ | ​ |
| ​ | Notes to the Consolidated Financial Statements                                                                     | ​ | ​ | ​ | ​ | F-8 | ​ | ​ |

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS​

| ​                                    | ​ | ​ | Notes   | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​   | 2015 £000s | ​ |
|--------------------------------------------|---------|---------|---------|---------|---------|-----------------|---------|---------|-----------------|---------|-----------|-----------------|---------|
| Revenue                                    | ​ | ​ | ​ | ​ | 3       | ​         | ​ | ​ | ​         | ​ | 8,238     | ​         | ​ | ​ | ​ | ​ | 10,315 | ​ | ​ | ​ | ​ | ​ | 28,540 | ​ | ​ |
| Cost of sales                              | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | (3,541)   | ​         | ​ | ​ | ​ | ​ | (2,719) | ​ | ​ | ​ | ​ | ​ | (2,618) | ​ | ​ |
| Research and development expenditure       | ​ | ​ | ​ | ​ | 4       | ​         | ​ | ​ | ​         | ​ | (111,229) | ​         | ​ | ​ | ​ | ​ | (99,815) | ​ | ​ | ​ | ​ | ​ | (76,785) | ​ | ​ |
| Sales, general and administrative expenses | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | (41,699)  | ​         | ​ | ​ | ​ | ​ | (19,939) | ​ | ​ | ​ | ​ | ​ | (12,569) | ​ | ​ |
| Net foreign exchange (loss)/gain           | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | (5,045)   | ​         | ​ | ​ | ​ | ​ | 25,551 | ​ | ​ | ​ | ​ | ​ | 6,202 | ​ | ​ |
| Operating loss                             | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | (153,276) | ​         | ​ | ​ | ​ | ​ | (86,607) | ​ | ​ | ​ | ​ | ​ | (57,230) | ​ | ​ |
| Interest expense                           | ​ | ​ | ​ | ​ | 9       | ​         | ​ | ​ | ​         | ​ | (745)     | ​         | ​ | ​ | ​ | ​ | (173) | ​ | ​ | ​ | ​ | ​ | (75) | ​ | ​ |
| Interest and other income                  | ​ | ​ | ​ | ​ | 9       | ​         | ​ | ​ | ​         | ​ | 1,616     | ​         | ​ | ​ | ​ | ​ | 608 | ​ | ​ | ​ | ​ | ​ | 244 | ​ | ​ |
| Loss before tax                            | ​ | ​ | ​ | ​ | 5       | ​         | ​ | ​ | ​         | ​ | (152,405) | ​         | ​ | ​ | ​ | ​ | (86,172) | ​ | ​ | ​ | ​ | ​ | (57,061) | ​ | ​ |
| Tax benefit                                | ​ | ​ | ​ | ​ | 10      | ​         | ​ | ​ | ​         | ​ | 20,717    | ​         | ​ | ​ | ​ | ​ | 22,515 | ​ | ​ | ​ | ​ | ​ | 12,498 | ​ | ​ |
| Loss for the year                          | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | (131,688) | ​         | ​ | ​ | ​ | ​ | (63,657) | ​ | ​ | ​ | ​ | ​ | (44,563) | ​ | ​ |
| Loss per share – basic   | ​ | ​ | ​ | ​ | 11      | ​         | ​ | ​ | ​         | ​ | (43.4)p   | ​         | ​ | ​ | ​ | ​ | (23.5)p | ​ | ​ | ​ | ​ | ​ | (18.1)p | ​ | ​ |
| Loss per share – diluted | ​ | ​ | ​ | ​ | 11      | ​         | ​ | ​ | ​         | ​ | (43.4)p   | ​         | ​ | ​ | ​ | ​ | (23.5)p | ​ | ​ | ​ | ​ | ​ | (18.1)p | ​ | ​ |

----

TABLE OF CONTENTS​

| ​                                                       | ​ | ​ | 2017 £000s | ​ | ​   | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|---------------------------------------------------------------|---------|---------|-----------------|---------|-----------|-----------------|---------|---------|-----------------|---------|
| Loss for the year                                             | ​ | ​ | ​         | ​ | (131,688) | ​         | ​ | ​ | ​         | ​ | (63,657) | ​ | ​ | ​ | ​ | ​ | (44,563) | ​ | ​ |
| Items that may be reclassified subsequently to profit or loss | ​ | ​ | ​         | ​ | ​   | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Exchange differences on translation of foreign operations     | ​ | ​ | ​         | ​ | (716)     | ​         | ​ | ​ | ​         | ​ | 349 | ​ | ​ | ​ | ​ | ​ | (71) | ​ | ​ |
| Other comprehensive (loss)/gain for the year                  | ​ | ​ | ​         | ​ | (716)     | ​         | ​ | ​ | ​         | ​ | 349 | ​ | ​ | ​ | ​ | ​ | (71) | ​ | ​ |
| Total comprehensive loss for the year                         | ​ | ​ | ​         | ​ | (132,404) | ​         | ​ | ​ | ​         | ​ | (63,308) | ​ | ​ | ​ | ​ | ​ | (44,634) | ​ | ​ |

----

TABLE OF CONTENTS​

|                                                                       | ​ | ​ | Share Capital £000s | ​ | ​ | Share Premium Account £000s | ​ | ​ | Other Reserves £000s | ​ | ​ | Accumulated Deficit £000s | ​ | ​ | Total Equity £000s | ​ |
|-----------------------------------------------------------------------|---------|---------|--------------------------|---------|---------|----------------------------------|---------|---------|---------------------------|---------|---------|--------------------------------|---------|---------|-------------------------|---------|
| At 1 October 2014                                                | ​ | ​ | ​                  | ​ | 237     | ​                          | ​ | ​ | ​                   | ​ | 220,551 | ​                        | ​ | ​ | ​                 | ​ | 19,260 | ​ | ​ | ​ | ​ | ​ | (81,464) | ​ | ​ | ​ | ​ | ​ | 158,584 | ​ | ​ |
| Issue of share capital                                                | ​ | ​ | ​                  | ​ | 22      | ​                          | ​ | ​ | ​                   | ​ | 127,812 | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 127,834 | ​ | ​ |
| Expenses of new equity issue                                          | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | (271)   | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (271) | ​ | ​ |
| Exercise of share options                                             | ​ | ​ | ​                  | ​ | 2       | ​                          | ​ | ​ | ​                   | ​ | 1,183   | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,185 | ​ | ​ |
| Share-based payment transactions                                      | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 2,488 | ​ | ​ | ​ | ​ | ​ | 2,488 | ​ | ​ |
| Loss for the year                                                     | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | (44,563) | ​ | ​ | ​ | ​ | ​ | (44,563) | ​ | ​ |
| Deferred tax attributable to unrealised share option gains            | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 84 | ​ | ​ | ​ | ​ | ​ | 84 | ​ | ​ |
| Other comprehensive loss                                              | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | (71) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (71) | ​ | ​ |
| Balance at 30 September 2015                                     | ​ | ​ | ​                  | ​ | 261     | ​                          | ​ | ​ | ​                   | ​ | 349,275 | ​                        | ​ | ​ | ​                 | ​ | 19,189 | ​ | ​ | ​ | ​ | ​ | (123,455) | ​ | ​ | ​ | ​ | ​ | 245,270 | ​ | ​ |
| Issue of share capital (note 22)                                      | ​ | ​ | ​                  | ​ | 39      | ​                          | ​ | ​ | ​                   | ​ | 206,512 | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 206,551 | ​ | ​ |
| Expenses of new equity issue                                          | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | (472)   | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (472) | ​ | ​ |
| Underwriters’ contribution towards expenses of new equity issue | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | 472     | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 472 | ​ | ​ |
| Exercise of share options (note 22)                                   | ​ | ​ | ​                  | ​ | 2       | ​                          | ​ | ​ | ​                   | ​ | 690     | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 692 | ​ | ​ |
| Share-based payment transactions                                      | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 8,152 | ​ | ​ | ​ | ​ | ​ | 8,152 | ​ | ​ |
| Loss for the year                                                     | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | (63,657) | ​ | ​ | ​ | ​ | ​ | (63,657) | ​ | ​ |
| Deferred tax attributable to unrealised share option gains            | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,133 | ​ | ​ | ​ | ​ | ​ | 1,133 | ​ | ​ |
| Other comprehensive gain                                              | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | 349 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 349 | ​ | ​ |
| Balance at 30 September 2016                                     | ​ | ​ | ​                  | ​ | 302     | ​                          | ​ | ​ | ​                   | ​ | 556,477 | ​                        | ​ | ​ | ​                 | ​ | 19,538 | ​ | ​ | ​ | ​ | ​ | (177,827) | ​ | ​ | ​ | ​ | ​ | 398,490 | ​ | ​ |
| Exercise of share options (note 22)                                   | ​ | ​ | ​                  | ​ | 2       | ​                          | ​ | ​ | ​                   | ​ | 93      | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 95 | ​ | ​ |
| Share-based payment transactions                                      | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 11,860 | ​ | ​ | ​ | ​ | ​ | 11,860 | ​ | ​ |
| Loss for the year                                                     | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | (131,688) | ​ | ​ | ​ | ​ | ​ | (131,688) | ​ | ​ |
| Deferred tax attributable to unrealised share option gains            | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 134 | ​ | ​ | ​ | ​ | ​ | 134 | ​ | ​ |
| Other comprehensive loss                                              | ​ | ​ | ​                  | ​ | — | ​                          | ​ | ​ | ​                   | ​ | — | ​                        | ​ | ​ | ​                 | ​ | (716) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (716) | ​ | ​ |
| Balance at 30 September 2017                                     | ​ | ​ | ​                  | ​ | 304     | ​                          | ​ | ​ | ​                   | ​ | 556,570 | ​                        | ​ | ​ | ​                 | ​ | 18,822 | ​ | ​ | ​ | ​ | ​ | (297,521) | ​ | ​ | ​ | ​ | ​ | 278,175 | ​ | ​ |

----

TABLE OF CONTENTS​

| ​                                        | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ |                 | ​ |
|------------------------------------------------|---------|---------|---------|---------|---------|-----------------|---------|---------|-----------------|---------|
| ​                                        | ​ | ​ | Notes   | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
| Non-current assets                             | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Intangible assets – goodwill | ​ | ​ | ​ | ​ | 12      | ​         | ​ | ​ | ​         | ​ | 5,210 | ​ | ​ | ​ | ​ | ​ | 5,210 | ​ | ​ |
| Other intangible assets                        | ​ | ​ | ​ | ​ | 13      | ​         | ​ | ​ | ​         | ​ | 1,049 | ​ | ​ | ​ | ​ | ​ | 629 | ​ | ​ |
| Property, plant and equipment                  | ​ | ​ | ​ | ​ | 14      | ​         | ​ | ​ | ​         | ​ | 43,666 | ​ | ​ | ​ | ​ | ​ | 38,947 | ​ | ​ |
| Deferred tax asset                             | ​ | ​ | ​ | ​ | 10      | ​         | ​ | ​ | ​         | ​ | 6,282 | ​ | ​ | ​ | ​ | ​ | 3,873 | ​ | ​ |
| ​                                        | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | 56,207 | ​ | ​ | ​ | ​ | ​ | 48,659 | ​ | ​ |
| Current assets                                 | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Inventories                                    | ​ | ​ | ​ | ​ | 15      | ​         | ​ | ​ | ​         | ​ | 4,244 | ​ | ​ | ​ | ​ | ​ | 4,248 | ​ | ​ |
| Taxation recoverable                           | ​ | ​ | ​ | ​ | 10      | ​         | ​ | ​ | ​         | ​ | 20,072 | ​ | ​ | ​ | ​ | ​ | 21,322 | ​ | ​ |
| Trade receivables and other current assets     | ​ | ​ | ​ | ​ | 16      | ​         | ​ | ​ | ​         | ​ | 11,217 | ​ | ​ | ​ | ​ | ​ | 4,556 | ​ | ​ |
| Cash and cash equivalents                      | ​ | ​ | ​ | ​ | 21      | ​         | ​ | ​ | ​         | ​ | 241,175 | ​ | ​ | ​ | ​ | ​ | 374,392 | ​ | ​ |
| ​                                        | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | 276,708 | ​ | ​ | ​ | ​ | ​ | 404,518 | ​ | ​ |
| Total assets                                   | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | 332,915 | ​ | ​ | ​ | ​ | ​ | 453,177 | ​ | ​ |
| Current liabilities                            | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Trade and other payables                       | ​ | ​ | ​ | ​ | 17      | ​         | ​ | ​ | ​         | ​ | (33,119) | ​ | ​ | ​ | ​ | ​ | (31,170) | ​ | ​ |
| Current tax liabilities                        | ​ | ​ | ​ | ​ | 10      | ​         | ​ | ​ | ​         | ​ | (838) | ​ | ​ | ​ | ​ | ​ | (883) | ​ | ​ |
| Obligations under finance leases               | ​ | ​ | ​ | ​ | 19      | ​         | ​ | ​ | ​         | ​ | (205) | ​ | ​ | ​ | ​ | ​ | (211) | ​ | ​ |
| Deferred revenue                               | ​ | ​ | ​ | ​ | 20      | ​         | ​ | ​ | ​         | ​ | (2,307) | ​ | ​ | ​ | ​ | ​ | (2,686) | ​ | ​ |
| ​                                        | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | (36,469) | ​ | ​ | ​ | ​ | ​ | (34,950) | ​ | ​ |
| Non-current liabilities                        | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Trade and other payables                       | ​ | ​ | ​ | ​ | 17      | ​         | ​ | ​ | ​         | ​ | (9,256) | ​ | ​ | ​ | ​ | ​ | (9,423) | ​ | ​ |
| Obligations under finance leases               | ​ | ​ | ​ | ​ | 19      | ​         | ​ | ​ | ​         | ​ | (4,755) | ​ | ​ | ​ | ​ | ​ | (4,959) | ​ | ​ |
| Deferred revenue                               | ​ | ​ | ​ | ​ | 20      | ​         | ​ | ​ | ​         | ​ | (4,260) | ​ | ​ | ​ | ​ | ​ | (5,355) | ​ | ​ |
| Total liabilities                              | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | (54,740) | ​ | ​ | ​ | ​ | ​ | (54,687) | ​ | ​ |
| Net assets                                     | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | 278,175 | ​ | ​ | ​ | ​ | ​ | 398,490 | ​ | ​ |
| Equity                                         | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Share capital                                  | ​ | ​ | ​ | ​ | 22      | ​         | ​ | ​ | ​         | ​ | 304 | ​ | ​ | ​ | ​ | ​ | 302 | ​ | ​ |
| Share premium account                          | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | 556,570 | ​ | ​ | ​ | ​ | ​ | 556,477 | ​ | ​ |
| Other reserves                                 | ​ | ​ | ​ | ​ | 24      | ​         | ​ | ​ | ​         | ​ | 18,822 | ​ | ​ | ​ | ​ | ​ | 19,538 | ​ | ​ |
| Accumulated deficit                            | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | (297,521) | ​ | ​ | ​ | ​ | ​ | (177,827) | ​ | ​ |
| Total equity                                   | ​ | ​ | ​ | ​ | ​ | ​         | ​ | ​ | ​         | ​ | 278,175 | ​ | ​ | ​ | ​ | ​ | 398,490 | ​ | ​ |

----

TABLE OF CONTENTS​

| ​                                                               | ​ | ​ |                 | ​ |
|-----------------------------------------------------------------------|---------|---------|-----------------|---------|
| ​                                                               | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
| (Loss)/profit for the year                                            | ​ | ​ | ​         | ​ | (131,688) | ​ | ​ | ​ | ​ | ​ | (63,657) | ​ | ​ | ​ | ​ | ​ | (44,563) | ​ | ​ |
| Adjustments for:                                                      | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Interest expense                                                      | ​ | ​ | ​         | ​ | 745 | ​ | ​ | ​ | ​ | ​ | 173 | ​ | ​ | ​ | ​ | ​ | 75 | ​ | ​ |
| Interest and other income                                             | ​ | ​ | ​         | ​ | (1,616) | ​ | ​ | ​ | ​ | ​ | (608) | ​ | ​ | ​ | ​ | ​ | (244) | ​ | ​ |
| Tax benefit                                                           | ​ | ​ | ​         | ​ | (20,717) | ​ | ​ | ​ | ​ | ​ | (22,515) | ​ | ​ | ​ | ​ | ​ | (12,498) | ​ | ​ |
| Depreciation of property, plant and equipment                         | ​ | ​ | ​         | ​ | 5,276 | ​ | ​ | ​ | ​ | ​ | 3,605 | ​ | ​ | ​ | ​ | ​ | 2,250 | ​ | ​ |
| Impairment of property, plant and equipment                           | ​ | ​ | ​         | ​ | 635 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 606 | ​ | ​ |
| Reversal of impairment of property, plant and equipment               | ​ | ​ | ​         | ​ | (216) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Amortisation of intangible assets                                     | ​ | ​ | ​         | ​ | 245 | ​ | ​ | ​ | ​ | ​ | 62 | ​ | ​ | ​ | ​ | ​ | 52 | ​ | ​ |
| Net foreign exchange losses/(gains)                                   | ​ | ​ | ​         | ​ | 5,045 | ​ | ​ | ​ | ​ | ​ | (25,551) | ​ | ​ | ​ | ​ | ​ | (6,282) | ​ | ​ |
| Increase in provision for inventories                                 | ​ | ​ | ​         | ​ | 100 | ​ | ​ | ​ | ​ | ​ | 72 | ​ | ​ | ​ | ​ | ​ | 33 | ​ | ​ |
| Decrease in deferred signature fees                                   | ​ | ​ | ​         | ​ | (1,370) | ​ | ​ | ​ | ​ | ​ | (1,170) | ​ | ​ | ​ | ​ | ​ | (1,250) | ​ | ​ |
| Share-based payment charge                                            | ​ | ​ | ​         | ​ | 11,860 | ​ | ​ | ​ | ​ | ​ | 8,152 | ​ | ​ | ​ | ​ | ​ | 2,478 | ​ | ​ |
| Loss on disposal of property, plant and equipment                     | ​ | ​ | ​         | ​ | 582 | ​ | ​ | ​ | ​ | ​ | 1 | ​ | ​ | ​ | ​ | ​ | 1 | ​ | ​ |
| ​                                                               | ​ | ​ | ​         | ​ | (131,119) | ​ | ​ | ​ | ​ | ​ | (101,436) | ​ | ​ | ​ | ​ | ​ | (59,342) | ​ | ​ |
| (Increase)/decrease in inventories                                    | ​ | ​ | ​         | ​ | (96) | ​ | ​ | ​ | ​ | ​ | 436 | ​ | ​ | ​ | ​ | ​ | (12) | ​ | ​ |
| Increase in trade receivables and other current assets                | ​ | ​ | ​         | ​ | (2,728) | ​ | ​ | ​ | ​ | ​ | (753) | ​ | ​ | ​ | ​ | ​ | (1,010) | ​ | ​ |
| Increase in trade and other payables and deferred revenue             | ​ | ​ | ​         | ​ | 4,312 | ​ | ​ | ​ | ​ | ​ | 4,761 | ​ | ​ | ​ | ​ | ​ | 8,478 | ​ | ​ |
| Cash used in operations                                               | ​ | ​ | ​         | ​ | (129,631) | ​ | ​ | ​ | ​ | ​ | (96,992) | ​ | ​ | ​ | ​ | ​ | (51,886) | ​ | ​ |
| Income taxes paid                                                     | ​ | ​ | ​         | ​ | (2,293) | ​ | ​ | ​ | ​ | ​ | (883) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Research and development tax credits received                         | ​ | ​ | ​         | ​ | 21,679 | ​ | ​ | ​ | ​ | ​ | 13,281 | ​ | ​ | ​ | ​ | ​ | 5,415 | ​ | ​ |
| Net cash outflow from operating activities                            | ​ | ​ | ​         | ​ | (110,245) | ​ | ​ | ​ | ​ | ​ | (84,594) | ​ | ​ | ​ | ​ | ​ | (46,471) | ​ | ​ |
| Investing activities                                                  | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Interest received                                                     | ​ | ​ | ​         | ​ | 1,433 | ​ | ​ | ​ | ​ | ​ | 434 | ​ | ​ | ​ | ​ | ​ | 236 | ​ | ​ |
| Purchase of property, plant and equipment                             | ​ | ​ | ​         | ​ | (16,059) | ​ | ​ | ​ | ​ | ​ | (8,678) | ​ | ​ | ​ | ​ | ​ | (17,915) | ​ | ​ |
| Purchase of intangible assets                                         | ​ | ​ | ​         | ​ | (636) | ​ | ​ | ​ | ​ | ​ | (512) | ​ | ​ | ​ | ​ | ​ | (114) | ​ | ​ |
| Proceeds from sale of property, plant and equipment                   | ​ | ​ | ​         | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 2 | ​ | ​ |
| Net cash outflow from investing activities                            | ​ | ​ | ​         | ​ | (15,262) | ​ | ​ | ​ | ​ | ​ | (8,756) | ​ | ​ | ​ | ​ | ​ | (17,791) | ​ | ​ |
| Financing activities                                                  | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Proceeds on exercise of share options                                 | ​ | ​ | ​         | ​ | 96 | ​ | ​ | ​ | ​ | ​ | 540 | ​ | ​ | ​ | ​ | ​ | 1,185 | ​ | ​ |
| Proceeds of new equity issue                                          | ​ | ​ | ​         | ​ | — | ​ | ​ | ​ | ​ | ​ | 206,550 | ​ | ​ | ​ | ​ | ​ | 127,834 | ​ | ​ |
| Expenses of new equity issue                                          | ​ | ​ | ​         | ​ | (134) | ​ | ​ | ​ | ​ | ​ | (319) | ​ | ​ | ​ | ​ | ​ | (271) | ​ | ​ |
| Underwriters’ contribution towards expenses of new equity issue | ​ | ​ | ​         | ​ | — | ​ | ​ | ​ | ​ | ​ | 472 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Interest paid                                                         | ​ | ​ | ​         | ​ | (965) | ​ | ​ | ​ | ​ | ​ | (69) | ​ | ​ | ​ | ​ | ​ | (74) | ​ | ​ |
| Repayments of fit out funding                                         | ​ | ​ | ​         | ​ | (841) | ​ | ​ | ​ | ​ | ​ | (240) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Repayments of obligations under finance leases                        | ​ | ​ | ​         | ​ | (209) | ​ | ​ | ​ | ​ | ​ | (127) | ​ | ​ | ​ | ​ | ​ | (255) | ​ | ​ |
| Net cash (outflow)/inflow from financing activities                   | ​ | ​ | ​         | ​ | (2,053) | ​ | ​ | ​ | ​ | ​ | 206,807 | ​ | ​ | ​ | ​ | ​ | 128,419 | ​ | ​ |
| Effect of foreign exchange rate changes                               | ​ | ​ | ​         | ​ | (5,657) | ​ | ​ | ​ | ​ | ​ | 26,063 | ​ | ​ | ​ | ​ | ​ | 6,224 | ​ | ​ |
| Net (decrease)/increase in cash and cash equivalents                  | ​ | ​ | ​         | ​ | (133,217) | ​ | ​ | ​ | ​ | ​ | 139,520 | ​ | ​ | ​ | ​ | ​ | 70,381 | ​ | ​ |
| Cash and cash equivalents at the beginning of the year                | ​ | ​ | ​         | ​ | 374,392 | ​ | ​ | ​ | ​ | ​ | 234,872 | ​ | ​ | ​ | ​ | ​ | 164,491 | ​ | ​ |
| Cash and cash equivalents at end of the year                          | ​ | ​ | ​         | ​ | 241,175 | ​ | ​ | ​ | ​ | ​ | 374,392 | ​ | ​ | ​ | ​ | ​ | 234,872 | ​ | ​ |

----

TABLE OF CONTENTS​

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| ​ | Leasehold buildings                | ​ | ​ | 20 years or term of lease if shorter          | ​ |
|---------|------------------------------------|---------|---------|----------------------------------------------------|---------|
| ​ | Plant, machinery and lab equipment | ​ | ​ | 3 to 20 years                                 | ​ |
| ​ | Office and IT equipment            | ​ | ​ | 3 to 5 years                                  | ​ |
| ​ | Leasehold improvements             | ​ | ​ | 4 to 20 years or term of the lease if shorter | ​ |

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

----

TABLE OF CONTENTS

| ​                                          | ​ | ​ | Commercial £000s | ​ | ​ | Sativex R&D £000s | ​ | ​ | Pipeline R&D £000s | ​ | ​ | Total Reportable Segments £000s | ​ | ​ | Unallocated Costs(1)£000s | ​ | ​   | Consolidated £000s | ​ |
|--------------------------------------------------|---------|---------|-----------------------|---------|---------|----------------------------|---------|---------|-----------------------------|---------|---------|--------------------------------------|---------|---------|--------------------------------|---------|-----------|-------------------------|---------|
| Revenue:                                         | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​   | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Product sales                                    | ​ | ​ | ​               | ​ | 6,232   | ​                    | ​ | ​ | ​                     | ​ | — | ​                              | ​ | ​ | ​                        | ​ | —   | ​                 | ​ | ​ | ​ | ​ | 6,232 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 6,232 | ​ | ​ |
| Research and development fees               | ​ | ​ | ​               | ​ | — | ​                    | ​ | ​ | ​                     | ​ | 95      | ​                              | ​ | ​ | ​                        | ​ | 428       | ​                 | ​ | ​ | ​ | ​ | 523 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 523 | ​ | ​ |
| Licence, collaboration and technical access fees | ​ | ​ | ​               | ​ | 1,373   | ​                    | ​ | ​ | ​                     | ​ | — | ​                              | ​ | ​ | ​                        | ​ | —   | ​                 | ​ | ​ | ​ | ​ | 1,373 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,373 | ​ | ​ |
| Development and approval milestones              | ​ | ​ | ​               | ​ | 110     | ​                    | ​ | ​ | ​                     | ​ | — | ​                              | ​ | ​ | ​                        | ​ | —   | ​                 | ​ | ​ | ​ | ​ | 110 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 110 | ​ | ​ |
| Total revenue                                    | ​ | ​ | ​               | ​ | 7,715   | ​                    | ​ | ​ | ​                     | ​ | 95      | ​                              | ​ | ​ | ​                        | ​ | 428       | ​                 | ​ | ​ | ​ | ​ | 8,238 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 8,238 | ​ | ​ |
| Cost of sales                                    | ​ | ​ | ​               | ​ | (3,541) | ​                    | ​ | ​ | ​                     | ​ | — | ​                              | ​ | ​ | ​                        | ​ | —   | ​                 | ​ | ​ | ​ | ​ | (3,541) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (3,541) | ​ | ​ |
| Research and development expenditure             | ​ | ​ | ​               | ​ | — | ​                    | ​ | ​ | ​                     | ​ | (107)   | ​                              | ​ | ​ | ​                        | ​ | (107,078) | ​                 | ​ | ​ | ​ | ​ | (107,185) | ​ | ​ | ​ | ​ | ​ | (4,044) | ​ | ​ | ​ | ​ | ​ | (111,229) | ​ | ​ |
| Segmental result                                 | ​ | ​ | ​               | ​ | 4,174   | ​                    | ​ | ​ | ​                     | ​ | (12)    | ​                              | ​ | ​ | ​                        | ​ | (106,650) | ​                 | ​ | ​ | ​ | ​ | (102,488) | ​ | ​ | ​ | ​ | ​ | (4,044) | ​ | ​ | ​ | ​ | ​ | (106,532) | ​ | ​ |
| Sales, general and administrative expenses       | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​   | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (41,699) | ​ | ​ |
| Net foreign exchange loss                        | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​   | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (5,045) | ​ | ​ |
| Operating loss                                   | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​   | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (153,276) | ​ | ​ |
| Interest expense                                 | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​   | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (745) | ​ | ​ |
| Interest and other income                        | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​   | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,616 | ​ | ​ |
| Loss before tax                                  | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​   | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (152,405) | ​ | ​ |
| Tax benefit                                      | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​   | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 20,717 | ​ | ​ |
| Loss for the year                                | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​   | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (131,688) | ​ | ​ |

----

TABLE OF CONTENTS

| ​                                          | ​ | ​ | Commercial £000s | ​ | ​ | Sativex R&D £000s | ​ | ​ | Pipeline R&D £000s | ​ | ​ | Total Reportable Segments £000s | ​ | ​ | Unallocated Costs(1)£000s | ​ | ​  | Consolidated £000s | ​ |
|--------------------------------------------------|---------|---------|-----------------------|---------|---------|----------------------------|---------|---------|-----------------------------|---------|---------|--------------------------------------|---------|---------|--------------------------------|---------|----------|-------------------------|---------|
| Revenue:                                         | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Product sales                                    | ​ | ​ | ​               | ​ | 5,208   | ​                    | ​ | ​ | ​                     | ​ | — | ​                              | ​ | ​ | ​                        | ​ | —  | ​                 | ​ | ​ | ​ | ​ | 5,208 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 5,208 | ​ | ​ |
| Research and development fees               | ​ | ​ | ​               | ​ | — | ​                    | ​ | ​ | ​                     | ​ | 3,500   | ​                              | ​ | ​ | ​                        | ​ | 337      | ​                 | ​ | ​ | ​ | ​ | 3,837 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 3,837 | ​ | ​ |
| Licence, collaboration and technical access fees | ​ | ​ | ​               | ​ | 1,172   | ​                    | ​ | ​ | ​                     | ​ | — | ​                              | ​ | ​ | ​                        | ​ | —  | ​                 | ​ | ​ | ​ | ​ | 1,172 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,172 | ​ | ​ |
| Development and approval milestones              | ​ | ​ | ​               | ​ | 98      | ​                    | ​ | ​ | ​                     | ​ | — | ​                              | ​ | ​ | ​                        | ​ | —  | ​                 | ​ | ​ | ​ | ​ | 98 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 98 | ​ | ​ |
| Total revenue                                    | ​ | ​ | ​               | ​ | 6,478   | ​                    | ​ | ​ | ​                     | ​ | 3,500   | ​                              | ​ | ​ | ​                        | ​ | 337      | ​                 | ​ | ​ | ​ | ​ | 10,315 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 10,315 | ​ | ​ |
| Cost of sales                                    | ​ | ​ | ​               | ​ | (2,719) | ​                    | ​ | ​ | ​                     | ​ | — | ​                              | ​ | ​ | ​                        | ​ | —  | ​                 | ​ | ​ | ​ | ​ | (2,719) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (2,719) | ​ | ​ |
| Research and development expenditure             | ​ | ​ | ​               | ​ | — | ​                    | ​ | ​ | ​                     | ​ | (4,125) | ​                              | ​ | ​ | ​                        | ​ | (91,571) | ​                 | ​ | ​ | ​ | ​ | (95,696) | ​ | ​ | ​ | ​ | ​ | (4,119) | ​ | ​ | ​ | ​ | ​ | (99,815) | ​ | ​ |
| Segmental result                                 | ​ | ​ | ​               | ​ | 3,759   | ​                    | ​ | ​ | ​                     | ​ | (625)   | ​                              | ​ | ​ | ​                        | ​ | (91,234) | ​                 | ​ | ​ | ​ | ​ | (88,100) | ​ | ​ | ​ | ​ | ​ | (4,119) | ​ | ​ | ​ | ​ | ​ | (92,219) | ​ | ​ |
| Sales, general and administrative expenses       | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (19,939) | ​ | ​ |
| Net foreign exchange gain                        | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 25,551 | ​ | ​ |
| Operating loss                                   | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (86,607) | ​ | ​ |
| Interest expense                                 | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (173) | ​ | ​ |
| Interest and other income                        | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 608 | ​ | ​ |
| Loss before tax                                  | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (86,172) | ​ | ​ |
| Tax benefit                                      | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 22,515 | ​ | ​ |
| Loss for the year                                | ​ | ​ | ​               | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​ | ​                              | ​ | ​ | ​                        | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (63,657) | ​ | ​ |

----

TABLE OF CONTENTS

| ​                                          | ​ | ​ | Commercial(1)£000s | ​ | ​ | Sativex R&D £000s | ​ | ​ | Pipeline R&D £000s | ​ | ​  | Total Reportable Segments £000s | ​ | ​ | UnallocatedCosts(1)£000s | ​ | ​  | Consolidated £000s | ​ |
|--------------------------------------------------|---------|---------|-------------------------|---------|---------|----------------------------|---------|---------|-----------------------------|---------|----------|--------------------------------------|---------|---------|-------------------------------|---------|----------|-------------------------|---------|
| Revenue:                                         | ​ | ​ | ​                 | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​  | ​                              | ​ | ​ | ​                       | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Product sales                                    | ​ | ​ | ​                 | ​ | 4,255   | ​                    | ​ | ​ | ​                     | ​ | —  | ​                              | ​ | ​ | ​                       | ​ | —  | ​                 | ​ | ​ | ​ | ​ | 4,255 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 4,255 | ​ | ​ |
| Research and development fees                    | ​ | ​ | ​                 | ​ | — | ​                    | ​ | ​ | ​                     | ​ | 22,275   | ​                              | ​ | ​ | ​                       | ​ | 535      | ​                 | ​ | ​ | ​ | ​ | 22,810 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 22,810 | ​ | ​ |
| Licence, collaboration and technical access fees | ​ | ​ | ​                 | ​ | 1,287   | ​                    | ​ | ​ | ​                     | ​ | —  | ​                              | ​ | ​ | ​                       | ​ | —  | ​                 | ​ | ​ | ​ | ​ | 1,287 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,287 | ​ | ​ |
| Development and approval milestones              | ​ | ​ | ​                 | ​ | 188     | ​                    | ​ | ​ | ​                     | ​ | —  | ​                              | ​ | ​ | ​                       | ​ | —  | ​                 | ​ | ​ | ​ | ​ | 188 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 188 | ​ | ​ |
| Total revenue                                    | ​ | ​ | ​                 | ​ | 5,730   | ​                    | ​ | ​ | ​                     | ​ | 22,275   | ​                              | ​ | ​ | ​                       | ​ | 535      | ​                 | ​ | ​ | ​ | ​ | 28,540 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 28,540 | ​ | ​ |
| Cost of sales                                    | ​ | ​ | ​                 | ​ | (2,618) | ​                    | ​ | ​ | ​                     | ​ | —  | ​                              | ​ | ​ | ​                       | ​ | —  | ​                 | ​ | ​ | ​ | ​ | (2,618) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (2,618) | ​ | ​ |
| Research and development expenditure             | ​ | ​ | ​                 | ​ | — | ​                    | ​ | ​ | ​                     | ​ | (26,398) | ​                              | ​ | ​ | ​                       | ​ | (48,862) | ​                 | ​ | ​ | ​ | ​ | (75,260) | ​ | ​ | ​ | ​ | ​ | (1,525) | ​ | ​ | ​ | ​ | ​ | (76,785) | ​ | ​ |
| Segmental result                                 | ​ | ​ | ​                 | ​ | 3,112   | ​                    | ​ | ​ | ​                     | ​ | (4,123)  | ​                              | ​ | ​ | ​                       | ​ | (48,327) | ​                 | ​ | ​ | ​ | ​ | (49,338) | ​ | ​ | ​ | ​ | ​ | (1,525) | ​ | ​ | ​ | ​ | ​ | (50,863) | ​ | ​ |
| Sales, general and administrative expenses       | ​ | ​ | ​                 | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​  | ​                              | ​ | ​ | ​                       | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (12,569) | ​ | ​ |
| Net foreign exchange gain                        | ​ | ​ | ​                 | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​  | ​                              | ​ | ​ | ​                       | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 6,202 | ​ | ​ |
| Operating loss                                   | ​ | ​ | ​                 | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​  | ​                              | ​ | ​ | ​                       | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (57,230) | ​ | ​ |
| Interest expense                                 | ​ | ​ | ​                 | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​  | ​                              | ​ | ​ | ​                       | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (75) | ​ | ​ |
| Interest and other income                        | ​ | ​ | ​                 | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​  | ​                              | ​ | ​ | ​                       | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 244 | ​ | ​ |
| Loss before tax                                  | ​ | ​ | ​                 | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​  | ​                              | ​ | ​ | ​                       | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (57,061) | ​ | ​ |
| Tax benefit                                      | ​ | ​ | ​                 | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​  | ​                              | ​ | ​ | ​                       | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 12,498 | ​ | ​ |
| Loss for the year                                | ​ | ​ | ​                 | ​ | ​ | ​                    | ​ | ​ | ​                     | ​ | ​  | ​                              | ​ | ​ | ​                       | ​ | ​  | ​                 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (44,563) | ​ | ​ |
| ​                           | ​ | ​ | Commercial £000s | ​ | ​ | Sativex R&D£000s | ​ | ​ | Pipeline R&D£000s | ​ | ​ | Total£000s | ​ |
|-----------------------------------|---------|---------|-----------------------|---------|---------|---------------------------|---------|---------|----------------------------|---------|---------|-----------------|---------|
| Year ended 30 September 2017 | ​ | ​ | ​               | ​ | 5,033   | ​                   | ​ | ​ | ​                    | ​ | — | ​         | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 5,033 | ​ | ​ |
| Year ended 30 September 2016 | ​ | ​ | ​               | ​ | 4,310   | ​                   | ​ | ​ | ​                    | ​ | — | ​         | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 4,310 | ​ | ​ |
| Year ended 30 September 2015 | ​ | ​ | ​               | ​ | 3,385   | ​                   | ​ | ​ | ​                    | ​ | — | ​         | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 3,385 | ​ | ​ |
| ​                           | ​ | ​ | Commercial £000s | ​ | ​ | Sativex R&D£000s | ​ | ​ | Pipeline R&D£000s | ​ | ​ | Total£000s | ​ |
|-----------------------------------|---------|---------|-----------------------|---------|---------|---------------------------|---------|---------|----------------------------|---------|---------|-----------------|---------|
| Year ended 30 September 2017 | ​ | ​ | ​               | ​ | 1,559   | ​                   | ​ | ​ | ​                    | ​ | — | ​         | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,559 | ​ | ​ |
| Year ended 30 September 2016 | ​ | ​ | ​               | ​ | 1,419   | ​                   | ​ | ​ | ​                    | ​ | — | ​         | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,419 | ​ | ​ |
| Year ended 30 September 2015 | ​ | ​ | ​               | ​ | 1,474   | ​                   | ​ | ​ | ​                    | ​ | — | ​         | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,474 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                           | ​ | ​ | Commercial £000s | ​ | ​ | Sativex R&D£000s | ​ | ​ | Pipeline R&D£000s | ​ | ​ | Total£000s | ​ |
|-----------------------------------|---------|---------|-----------------------|---------|---------|---------------------------|---------|---------|----------------------------|---------|---------|-----------------|---------|
| Year ended 30 September 2017 | ​ | ​ | ​               | ​ | 280     | ​                   | ​ | ​ | ​                    | ​ | 95      | ​         | ​ | ​ | ​ | ​ | 428 | ​ | ​ | ​ | ​ | ​ | 803 | ​ | ​ |
| Year ended 30 September 2016 | ​ | ​ | ​               | ​ | 280     | ​                   | ​ | ​ | ​                    | ​ | 3,500   | ​         | ​ | ​ | ​ | ​ | 337 | ​ | ​ | ​ | ​ | ​ | 4,117 | ​ | ​ |
| Year ended 30 September 2015 | ​ | ​ | ​               | ​ | 280     | ​                   | ​ | ​ | ​                    | ​ | 22,275  | ​         | ​ | ​ | ​ | ​ | 535 | ​ | ​ | ​ | ​ | ​ | 23,090 | ​ | ​ |
| ​               | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|-----------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| UK                    | ​ | ​ | ​         | ​ | 1,502   | ​         | ​ | ​ | ​         | ​ | 1,082 | ​ | ​ | ​ | ​ | ​ | 1,158 | ​ | ​ |
| Europe (excluding UK) | ​ | ​ | ​         | ​ | 5,342   | ​         | ​ | ​ | ​         | ​ | 4,435 | ​ | ​ | ​ | ​ | ​ | 3,592 | ​ | ​ |
| United States         | ​ | ​ | ​         | ​ | 375     | ​         | ​ | ​ | ​         | ​ | 3,780 | ​ | ​ | ​ | ​ | ​ | 22,555 | ​ | ​ |
| Canada                | ​ | ​ | ​         | ​ | 582     | ​         | ​ | ​ | ​         | ​ | 680 | ​ | ​ | ​ | ​ | ​ | 700 | ​ | ​ |
| Asia/Other            | ​ | ​ | ​         | ​ | 437     | ​         | ​ | ​ | ​         | ​ | 338 | ​ | ​ | ​ | ​ | ​ | 535 | ​ | ​ |
| ​               | ​ | ​ | ​         | ​ | 8,238   | ​         | ​ | ​ | ​         | ​ | 10,315 | ​ | ​ | ​ | ​ | ​ | 28,540 | ​ | ​ |
| ​                                             | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|-----------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| GW-funded research and development                  | ​ | ​ | ​         | ​ | 110,705 | ​         | ​ | ​ | ​         | ​ | 95,978 | ​ | ​ | ​ | ​ | ​ | 53,975 | ​ | ​ |
| Development partner-funded research and development | ​ | ​ | ​         | ​ | 524     | ​         | ​ | ​ | ​         | ​ | 3,837 | ​ | ​ | ​ | ​ | ​ | 22,810 | ​ | ​ |
| ​                                             | ​ | ​ | ​         | ​ | 111,229 | ​         | ​ | ​ | ​         | ​ | 99,815 | ​ | ​ | ​ | ​ | ​ | 76,785 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                                                        | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|----------------------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Operating lease rentals – land and buildings | ​ | ​ | ​         | ​ | 3,602   | ​         | ​ | ​ | ​         | ​ | 2,341 | ​ | ​ | ​ | ​ | ​ | 1,473 | ​ | ​ |
| Operating lease rentals – equipment          | ​ | ​ | ​         | ​ | 25      | ​         | ​ | ​ | ​         | ​ | 20 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Depreciation of property, plant and equipment                  | ​ | ​ | ​         | ​ | 5,276   | ​         | ​ | ​ | ​         | ​ | 3,605 | ​ | ​ | ​ | ​ | ​ | 2,250 | ​ | ​ |
| Impairment of property, plant and equipment                    | ​ | ​ | ​         | ​ | 635     | ​         | ​ | ​ | ​         | ​ | — | ​ | ​ | ​ | ​ | ​ | 606 | ​ | ​ |
| Reversal of impairment of property, plant and equipment        | ​ | ​ | ​         | ​ | (216)   | ​         | ​ | ​ | ​         | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Amortisation of intangible assets                              | ​ | ​ | ​         | ​ | 245     | ​         | ​ | ​ | ​         | ​ | 62 | ​ | ​ | ​ | ​ | ​ | 52 | ​ | ​ |
| Decrease in provision for inventories                          | ​ | ​ | ​         | ​ | 100     | ​         | ​ | ​ | ​         | ​ | 72 | ​ | ​ | ​ | ​ | ​ | 33 | ​ | ​ |
| Foreign exchange loss/(gain)                                   | ​ | ​ | ​         | ​ | 5,045   | ​         | ​ | ​ | ​         | ​ | (25,551) | ​ | ​ | ​ | ​ | ​ | (6,202) | ​ | ​ |
| Staff costs (see note 7)                                       | ​ | ​ | ​         | ​ | 55,328  | ​         | ​ | ​ | ​         | ​ | 40,463 | ​ | ​ | ​ | ​ | ​ | 23,083 | ​ | ​ |
| ​                                                                                     | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|---------------------------------------------------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| The auditor for the years ended 30 September 2017, 2016 and 2015 was Deloitte LLP | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Audit fees:                                                                                 | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
|  –  Audit of the Group’s annual accounts(1)                         | ​ | ​ | ​         | ​ | 475     | ​         | ​ | ​ | ​         | ​ | 400 | ​ | ​ | ​ | ​ | ​ | 400 | ​ | ​ |
|  –  Audit of the Company and subsidiaries pursuant to legislation         | ​ | ​ | ​         | ​ | 58      | ​         | ​ | ​ | ​         | ​ | 50 | ​ | ​ | ​ | ​ | ​ | 50 | ​ | ​ |
| Total audit fees                                                                            | ​ | ​ | ​         | ​ | 533     | ​         | ​ | ​ | ​         | ​ | 450 | ​ | ​ | ​ | ​ | ​ | 450 | ​ | ​ |
| Other services                                                                              | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
|  –  Audit-related assurance(2)                                            | ​ | ​ | ​         | ​ | 102     | ​         | ​ | ​ | ​         | ​ | 75 | ​ | ​ | ​ | ​ | ​ | 53 | ​ | ​ |
|  –  Other assurance services(3)                                           | ​ | ​ | ​         | ​ | 20      | ​         | ​ | ​ | ​         | ​ | 109 | ​ | ​ | ​ | ​ | ​ | 92 | ​ | ​ |
| Total non-audit fees                                                                        | ​ | ​ | ​         | ​ | 122     | ​         | ​ | ​ | ​         | ​ | 184 | ​ | ​ | ​ | ​ | ​ | 145 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                           | ​ | ​ | 2017 Number | ​ | ​ | 2016 Number | ​ | ​ | 2015 Number | ​ |
|-----------------------------------|---------|---------|-------------|---------|---------|-------------|---------|---------|-------------|---------|
| Research and development          | ​ | ​ | ​     | ​ | 433     | ​     | ​ | ​ | ​     | ​ | 391 | ​ | ​ | ​ | ​ | ​ | 288 | ​ | ​ |
| Sales, general and administration | ​ | ​ | ​     | ​ | 100     | ​     | ​ | ​ | ​     | ​ | 53 | ​ | ​ | ​ | ​ | ​ | 34 | ​ | ​ |
| ​                           | ​ | ​ | ​     | ​ | 533     | ​     | ​ | ​ | ​     | ​ | 444 | ​ | ​ | ​ | ​ | ​ | 322 | ​ | ​ |
| ​                                 | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|-----------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Group aggregate remuneration comprised: | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Wages and salaries                      | ​ | ​ | ​         | ​ | 37,517  | ​         | ​ | ​ | ​         | ​ | 25,823 | ​ | ​ | ​ | ​ | ​ | 17,092 | ​ | ​ |
| Social security costs                   | ​ | ​ | ​         | ​ | 4,301   | ​         | ​ | ​ | ​         | ​ | 5,132 | ​ | ​ | ​ | ​ | ​ | 2,748 | ​ | ​ |
| Other pension costs                     | ​ | ​ | ​         | ​ | 1,650   | ​         | ​ | ​ | ​         | ​ | 1,356 | ​ | ​ | ​ | ​ | ​ | 765 | ​ | ​ |
| Share-based payment                     | ​ | ​ | ​         | ​ | 11,860  | ​         | ​ | ​ | ​         | ​ | 8,152 | ​ | ​ | ​ | ​ | ​ | 2,478 | ​ | ​ |
| ​                                 | ​ | ​ | ​         | ​ | 55,328  | ​         | ​ | ​ | ​         | ​ | 40,463 | ​ | ​ | ​ | ​ | ​ | 23,083 | ​ | ​ |
| ​                                                               | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|-----------------------------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Emoluments                                                            | ​ | ​ | ​         | ​ | 3,130   | ​         | ​ | ​ | ​         | ​ | 2,523 | ​ | ​ | ​ | ​ | ​ | 2,395 | ​ | ​ |
| Money purchase contributions to Directors’ pension arrangements | ​ | ​ | ​         | ​ | 79      | ​         | ​ | ​ | ​         | ​ | 215 | ​ | ​ | ​ | ​ | ​ | 211 | ​ | ​ |
| Gain on exercise of share options                                     | ​ | ​ | ​         | ​ | 12,977  | ​         | ​ | ​ | ​         | ​ | 6,453 | ​ | ​ | ​ | ​ | ​ | 7,910 | ​ | ​ |
| ​                                                               | ​ | ​ | ​         | ​ | 16,186  | ​         | ​ | ​ | ​         | ​ | 9,191 | ​ | ​ | ​ | ​ | ​ | 10,516 | ​ | ​ |
| ​                                                       | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|---------------------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Interest expense – finance lease interest   | ​ | ​ | ​         | ​ | (361)   | ​         | ​ | ​ | ​         | ​ | (173) | ​ | ​ | ​ | ​ | ​ | (75) | ​ | ​ |
| Interest expense – fit out funding interest | ​ | ​ | ​         | ​ | (384)   | ​         | ​ | ​ | ​         | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Total interest expense                                        | ​ | ​ | ​         | ​ | (745)   | ​         | ​ | ​ | ​         | ​ | (173) | ​ | ​ | ​ | ​ | ​ | (75) | ​ | ​ |
| Interest income – bank interest             | ​ | ​ | ​         | ​ | 1,616   | ​         | ​ | ​ | ​         | ​ | 435 | ​ | ​ | ​ | ​ | ​ | 244 | ​ | ​ |
| Other income                                                  | ​ | ​ | ​         | ​ | — | ​         | ​ | ​ | ​         | ​ | 173 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Total interest and other income                               | ​ | ​ | ​         | ​ | 1,616   | ​         | ​ | ​ | ​         | ​ | 608 | ​ | ​ | ​ | ​ | ​ | 244 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                                          | ​ | ​ | 2017 £000s | ​ | ​  | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|--------------------------------------------------|---------|---------|-----------------|---------|----------|-----------------|---------|---------|-----------------|---------|
| Current year research and development tax credit | ​ | ​ | ​         | ​ | (19,900) | ​         | ​ | ​ | ​         | ​ | (21,150) | ​ | ​ | ​ | ​ | ​ | (12,641) | ​ | ​ |
| Current period tax (credit)/charge               | ​ | ​ | ​         | ​ | 2,144    | ​         | ​ | ​ | ​         | ​ | 1,175 | ​ | ​ | ​ | ​ | ​ | 366 | ​ | ​ |
| Adjustment in respect of prior year tax credit   | ​ | ​ | ​         | ​ | (468)    | ​         | ​ | ​ | ​         | ​ | (546) | ​ | ​ | ​ | ​ | ​ | (165) | ​ | ​ |
| Deferred tax credit                              | ​ | ​ | ​         | ​ | (2,623)  | ​         | ​ | ​ | ​         | ​ | (2,037) | ​ | ​ | ​ | ​ | ​ | (335) | ​ | ​ |
| Movements on deferred tax assets                 | ​ | ​ | ​         | ​ | 130      | ​         | ​ | ​ | ​         | ​ | 43 | ​ | ​ | ​ | ​ | ​ | 277 | ​ | ​ |
| Tax benefit                                      | ​ | ​ | ​         | ​ | (20,717) | ​         | ​ | ​ | ​         | ​ | (22,515) | ​ | ​ | ​ | ​ | ​ | (12,498) | ​ | ​ |
| ​                                                                     | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|-----------------------------------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Change in estimate of excess tax deductions related to share-based payments | ​ | ​ | ​         | ​ | 134     | ​         | ​ | ​ | ​         | ​ | 1,133 | ​ | ​ | ​ | ​ | ​ | 84 | ​ | ​ |
| Total income tax recognised directly in equity                              | ​ | ​ | ​         | ​ | 134     | ​         | ​ | ​ | ​         | ​ | 1,133 | ​ | ​ | ​ | ​ | ​ | 84 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                                                                                                         | ​ | ​ | 2017 £000s | ​ | ​   | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|-----------------------------------------------------------------------------------------------------------------|---------|---------|-----------------|---------|-----------|-----------------|---------|---------|-----------------|---------|
| Loss before tax                                                                                                 | ​ | ​ | ​         | ​ | (152,405) | ​         | ​ | ​ | ​         | ​ | (86,172) | ​ | ​ | ​ | ​ | ​ | (57,061) | ​ | ​ |
| Tax credit on Group loss before tax at the standard UK corporation tax rate of 19.5% (2016: 20.0%; 2015: 20.5%) | ​ | ​ | ​         | ​ | (29,717)  | ​         | ​ | ​ | ​         | ​ | (17,234) | ​ | ​ | ​ | ​ | ​ | (11,698) | ​ | ​ |
| Effects of:                                                                                                     | ​ | ​ | ​         | ​ | ​   | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Expenses not deductible in determining taxable profit                                                           | ​ | ​ | ​         | ​ | 756       | ​         | ​ | ​ | ​         | ​ | 588 | ​ | ​ | ​ | ​ | ​ | 233 | ​ | ​ |
| Impact of employee share acquisition relief                                                                     | ​ | ​ | ​         | ​ | (2,792)   | ​         | ​ | ​ | ​         | ​ | (1,842) | ​ | ​ | ​ | ​ | ​ | (2,519) | ​ | ​ |
| Current year UK research and development tax credit                                                             | ​ | ​ | ​         | ​ | (19,900)  | ​         | ​ | ​ | ​         | ​ | (21,150) | ​ | ​ | ​ | ​ | ​ | (12,641) | ​ | ​ |
| Current year US tax credits                                                                                     | ​ | ​ | ​         | ​ | (2,016)   | ​         | ​ | ​ | ​         | ​ | (1,766) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| R&D enhanced tax relief and surrender of losses                                                             | ​ | ​ | ​         | ​ | 11,634    | ​         | ​ | ​ | ​         | ​ | 12,679 | ​ | ​ | ​ | ​ | ​ | 7,756 | ​ | ​ |
| Effect of unrecognised losses and temporary differences                                                         | ​ | ​ | ​         | ​ | 21,329    | ​         | ​ | ​ | ​         | ​ | 6,634 | ​ | ​ | ​ | ​ | ​ | 6,536 | ​ | ​ |
| Overseas profits taxed at different rates                                                                       | ​ | ​ | ​         | ​ | 456       | ​         | ​ | ​ | ​         | ​ | 122 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Adjustment in respect of prior year tax credit                                                                  | ​ | ​ | ​         | ​ | (467)     | ​         | ​ | ​ | ​         | ​ | (546) | ​ | ​ | ​ | ​ | ​ | (165) | ​ | ​ |
| Tax                                                                                                             | ​ | ​ | ​         | ​ | (20,717)  | ​         | ​ | ​ | ​         | ​ | (22,515) | ​ | ​ | ​ | ​ | ​ | (12,498) | ​ | ​ |
| ​                              | ​ | ​ | Accelerated Tax Depreciation £000s | ​ | ​ | Tax Losses and Credits £000s | ​ | ​ | Share-Based Payment and Other Compensation £000s | ​ | ​ | Total £000s | ​ |
|--------------------------------------|---------|---------|-----------------------------------------|---------|---------|-----------------------------------|---------|---------|-------------------------------------------------------|---------|---------|------------------|---------|
| At 1 October 2014               | ​ | ​ | ​                                 | ​ | (605)   | ​                           | ​ | ​ | ​                                               | ​ | 882     | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 277 | ​ | ​ |
| (Charged)/credited to profit or loss | ​ | ​ | ​                                 | ​ | (1,290) | ​                           | ​ | ​ | ​                                               | ​ | 1,002   | ​          | ​ | ​ | ​ | ​ | 345 | ​ | ​ | ​ | ​ | ​ | 57 | ​ | ​ |
| Credited to equity                   | ​ | ​ | ​                                 | ​ | — | ​                           | ​ | ​ | ​                                               | ​ | — | ​          | ​ | ​ | ​ | ​ | 84 | ​ | ​ | ​ | ​ | ​ | 84 | ​ | ​ |
| At 1 October 2015               | ​ | ​ | ​                                 | ​ | (1,895) | ​                           | ​ | ​ | ​                                               | ​ | 1,884   | ​          | ​ | ​ | ​ | ​ | 429 | ​ | ​ | ​ | ​ | ​ | 418 | ​ | ​ |
| (Charged)/credited to profit or loss | ​ | ​ | ​                                 | ​ | (23)    | ​                           | ​ | ​ | ​                                               | ​ | (48)    | ​          | ​ | ​ | ​ | ​ | 2,072 | ​ | ​ | ​ | ​ | ​ | 2,001 | ​ | ​ |
| Credited to equity                   | ​ | ​ | ​                                 | ​ | — | ​                           | ​ | ​ | ​                                               | ​ | — | ​          | ​ | ​ | ​ | ​ | 1,454 | ​ | ​ | ​ | ​ | ​ | 1,454 | ​ | ​ |
| At 1 October 2016               | ​ | ​ | ​                                 | ​ | (1,918) | ​                           | ​ | ​ | ​                                               | ​ | 1,836   | ​          | ​ | ​ | ​ | ​ | 3,955 | ​ | ​ | ​ | ​ | ​ | 3,873 | ​ | ​ |
| Credited/(charged) to profit or loss | ​ | ​ | ​                                 | ​ | 107     | ​                           | ​ | ​ | ​                                               | ​ | 220     | ​          | ​ | ​ | ​ | ​ | 2,297 | ​ | ​ | ​ | ​ | ​ | 2,623 | ​ | ​ |
| Credited to equity                   | ​ | ​ | ​                                 | ​ | — | ​                           | ​ | ​ | ​                                               | ​ | — | ​          | ​ | ​ | ​ | ​ | (215) | ​ | ​ | ​ | ​ | ​ | (215) | ​ | ​ |
| At 30 September 2017            | ​ | ​ | ​                                 | ​ | (1,811) | ​                           | ​ | ​ | ​                                               | ​ | 2,056   | ​          | ​ | ​ | ​ | ​ | 6,037 | ​ | ​ | ​ | ​ | ​ | 6,282 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                                                 | ​ | ​ | 2017 £000s | ​ | ​   | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|---------------------------------------------------------|---------|---------|-----------------|---------|-----------|-----------------|---------|---------|-----------------|---------|
| Loss for the year – basic and diluted | ​ | ​ | ​         | ​ | (131,688) | ​         | ​ | ​ | ​         | ​ | (63,657) | ​ | ​ | ​ | ​ | ​ | (44,563) | ​ | ​ |
| ​                                                                               | ​ | ​ | Number of Shares |
|---------------------------------------------------------------------------------------|---------|---------|------------------|
| ​                                                                               | ​ | ​ | 2017Million      | ​ | ​ | 2016Million | ​ | ​ | 2015Million |
| Weighted average number of ordinary shares                                            | ​ | ​ | ​          | ​ | 303.6 | ​ | ​ | ​ | ​ | ​ | 270.4 | ​ | ​ | ​ | ​ | ​ | 246.4 |
| Less ESOP trust ordinary shares(1)                                                    | ​ | ​ | ​          | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — |
| Weighted average number of ordinary shares for purposes of basic earnings per share   | ​ | ​ | ​          | ​ | 303.6 | ​ | ​ | ​ | ​ | ​ | 270.4 | ​ | ​ | ​ | ​ | ​ | 246.4 |
| Effect of potentially dilutive shares arising from share options(2)                   | ​ | ​ | ​          | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — |
| Weighted average number of ordinary shares for purposes of diluted earnings per share | ​ | ​ | ​          | ​ | 303.6 | ​ | ​ | ​ | ​ | ​ | 270.4 | ​ | ​ | ​ | ​ | ​ | 246.4 |
| Loss per share – basic                                              | ​ | ​ | ​          | ​ | (43.4)p | ​ | ​ | ​ | ​ | ​ | (23.5)p | ​ | ​ | ​ | ​ | ​ | (18.1)p |
| Loss per share – diluted                                            | ​ | ​ | ​          | ​ | (43.4)p | ​ | ​ | ​ | ​ | ​ | (23.5)p | ​ | ​ | ​ | ​ | ​ | (18.1)p |
|                                                       | ​ | ​ | 2017£000s | ​ | ​ | 2016£000s | ​ |
|-------------------------------------------------------|---------|---------|----------------|---------|---------|----------------|---------|
| Cost – as at 1 October              | ​ | ​ | ​        | ​ | 5,210   | ​        | ​ | ​ | ​ | ​ | 5,210 | ​ | ​ |
| Net book value – as at 30 September | ​ | ​ | ​        | ​ | 5,210   | ​        | ​ | ​ | ​ | ​ | 5,210 | ​ | ​ |

----

TABLE OF CONTENTS

|                               | ​ | ​ | Intangible Assets Under the Course of Construction £000s | ​ | ​ | Software £000s | ​ | ​ | Licences £000s | ​ | ​ | Total £000s | ​ |
|-------------------------------|---------|---------|---------------------------------------------------------------|---------|---------|---------------------|---------|---------|---------------------|---------|---------|------------------|---------|
| Cost                          | ​ | ​ | ​                                                       | ​ | ​ | ​             | ​ | ​ | ​             | ​ | ​ | ​          | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| At 1 October 2015        | ​ | ​ | ​                                                       | ​ | 66      | ​             | ​ | ​ | ​             | ​ | 220     | ​          | ​ | ​ | ​ | ​ | 59 | ​ | ​ | ​ | ​ | ​ | 345 | ​ | ​ |
| Additions                     | ​ | ​ | ​                                                       | ​ | 387     | ​             | ​ | ​ | ​             | ​ | 35      | ​          | ​ | ​ | ​ | ​ | 24 | ​ | ​ | ​ | ​ | ​ | 446 | ​ | ​ |
| Transfers of completed assets | ​ | ​ | ​                                                       | ​ | (38)    | ​             | ​ | ​ | ​             | ​ | 38      | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| At 1 October 2016        | ​ | ​ | ​                                                       | ​ | 415     | ​             | ​ | ​ | ​             | ​ | 293     | ​          | ​ | ​ | ​ | ​ | 83 | ​ | ​ | ​ | ​ | ​ | 791 | ​ | ​ |
| Additions                     | ​ | ​ | ​                                                       | ​ | 259     | ​             | ​ | ​ | ​             | ​ | 359     | ​          | ​ | ​ | ​ | ​ | 47 | ​ | ​ | ​ | ​ | ​ | 665 | ​ | ​ |
| Reclassifications             | ​ | ​ | ​                                                       | ​ | 41      | ​             | ​ | ​ | ​             | ​ | — | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 41 | ​ | ​ |
| Transfers of completed assets | ​ | ​ | ​                                                       | ​ | (546)   | ​             | ​ | ​ | ​             | ​ | 546     | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Disposals                     | ​ | ​ | ​                                                       | ​ | (41)    | ​             | ​ | ​ | ​             | ​ | — | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (41) | ​ | ​ |
| At 30 September 2017     | ​ | ​ | ​                                                       | ​ | 128     | ​             | ​ | ​ | ​             | ​ | 1,198   | ​          | ​ | ​ | ​ | ​ | 130 | ​ | ​ | ​ | ​ | ​ | 1,456 | ​ | ​ |
| Accumulated amortisation      | ​ | ​ | ​                                                       | ​ | ​ | ​             | ​ | ​ | ​             | ​ | ​ | ​          | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| At 1 October 2015        | ​ | ​ | ​                                                       | ​ | — | ​             | ​ | ​ | ​             | ​ | 96      | ​          | ​ | ​ | ​ | ​ | 4 | ​ | ​ | ​ | ​ | ​ | 100 | ​ | ​ |
| Charge for the year           | ​ | ​ | ​                                                       | ​ | — | ​             | ​ | ​ | ​             | ​ | 57      | ​          | ​ | ​ | ​ | ​ | 5 | ​ | ​ | ​ | ​ | ​ | 62 | ​ | ​ |
| At 1 October 2016        | ​ | ​ | ​                                                       | ​ | — | ​             | ​ | ​ | ​             | ​ | 153     | ​          | ​ | ​ | ​ | ​ | 9 | ​ | ​ | ​ | ​ | ​ | 162 | ​ | ​ |
| Charge for the year           | ​ | ​ | ​                                                       | ​ | — | ​             | ​ | ​ | ​             | ​ | 233     | ​          | ​ | ​ | ​ | ​ | 12 | ​ | ​ | ​ | ​ | ​ | 245 | ​ | ​ |
| At 30 September 2017     | ​ | ​ | ​                                                       | ​ | — | ​             | ​ | ​ | ​             | ​ | 386     | ​          | ​ | ​ | ​ | ​ | 21 | ​ | ​ | ​ | ​ | ​ | 407 | ​ | ​ |
| Net book value                | ​ | ​ | ​                                                       | ​ | ​ | ​             | ​ | ​ | ​             | ​ | ​ | ​          | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| At 30 September 2017     | ​ | ​ | ​                                                       | ​ | 128     | ​             | ​ | ​ | ​             | ​ | 812     | ​          | ​ | ​ | ​ | ​ | 109 | ​ | ​ | ​ | ​ | ​ | 1,049 | ​ | ​ |
| At 30 September 2016     | ​ | ​ | ​                                                       | ​ | 415     | ​             | ​ | ​ | ​             | ​ | 140     | ​          | ​ | ​ | ​ | ​ | 74 | ​ | ​ | ​ | ​ | ​ | 629 | ​ | ​ |

----

TABLE OF CONTENTS​

|                                           | ​ | ​ | Assets Under the Course of Construction £000s | ​ | ​  | Leasehold Buildings £000s | ​ | ​ | Plant, Machinery and Lab Equipment £000s | ​ | ​ | Office and IT Equipment £000s | ​ | ​ | Leasehold Improvements £000s | ​ | ​ | Total £000s | ​ |
|-------------------------------------------|---------|---------|----------------------------------------------------|---------|----------|--------------------------------|---------|---------|-----------------------------------------------|---------|---------|------------------------------------|---------|---------|-----------------------------------|---------|---------|------------------|---------|
| Cost                                      | ​ | ​ | ​                                            | ​ | ​  | ​                        | ​ | ​ | ​                                       | ​ | ​ | ​                            | ​ | ​ | ​                           | ​ | ​ | ​          | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| At 1 October 2015                    | ​ | ​ | ​                                            | ​ | 17,283   | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | 7,915   | ​          | ​ | ​ | ​ | ​ | 3,347 | ​ | ​ | ​ | ​ | ​ | 8,164 | ​ | ​ | ​ | ​ | ​ | 36,709 | ​ | ​ |
| Additions                                 | ​ | ​ | ​                                            | ​ | 7,698    | ​                        | ​ | ​ | ​                                       | ​ | 3,603   | ​                            | ​ | ​ | ​                           | ​ | 1,754   | ​          | ​ | ​ | ​ | ​ | 273 | ​ | ​ | ​ | ​ | ​ | 473 | ​ | ​ | ​ | ​ | ​ | 13,801 | ​ | ​ |
| Reclassifications                         | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | 1,463   | ​          | ​ | ​ | ​ | ​ | (1,463) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Transfers of completed assets             | ​ | ​ | ​                                            | ​ | (3,623)  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | 1,809   | ​          | ​ | ​ | ​ | ​ | 29 | ​ | ​ | ​ | ​ | ​ | 1,785 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Disposals                                 | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | (112)   | ​          | ​ | ​ | ​ | ​ | (789) | ​ | ​ | ​ | ​ | ​ | (122) | ​ | ​ | ​ | ​ | ​ | (1,023) | ​ | ​ |
| Exchange differences                      | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | — | ​          | ​ | ​ | ​ | ​ | 20 | ​ | ​ | ​ | ​ | ​ | 1 | ​ | ​ | ​ | ​ | ​ | 21 | ​ | ​ |
| At 1 October 2016                    | ​ | ​ | ​                                            | ​ | 21,358   | ​                        | ​ | ​ | ​                                       | ​ | 3,603   | ​                            | ​ | ​ | ​                           | ​ | 12,829  | ​          | ​ | ​ | ​ | ​ | 1,417 | ​ | ​ | ​ | ​ | ​ | 10,301 | ​ | ​ | ​ | ​ | ​ | 49,508 | ​ | ​ |
| Additions                                 | ​ | ​ | ​                                            | ​ | 11,090   | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | 470     | ​          | ​ | ​ | ​ | ​ | 72 | ​ | ​ | ​ | ​ | ​ | 418 | ​ | ​ | ​ | ​ | ​ | 12,050 | ​ | ​ |
| Reclassifications                         | ​ | ​ | ​                                            | ​ | (41)     | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | — | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (41) | ​ | ​ |
| Transfers of completed assets             | ​ | ​ | ​                                            | ​ | (26,566) | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | 9,944   | ​          | ​ | ​ | ​ | ​ | 131 | ​ | ​ | ​ | ​ | ​ | 16,491 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Transfers to assets held for sale in year | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | (1,249) | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (1,249) | ​ | ​ |
| Disposals                                 | ​ | ​ | ​                                            | ​ | (390)    | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | (770)   | ​          | ​ | ​ | ​ | ​ | (33) | ​ | ​ | ​ | ​ | ​ | (225) | ​ | ​ | ​ | ​ | ​ | (1,418) | ​ | ​ |
| Exchange differences                      | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | — | ​          | ​ | ​ | ​ | ​ | (6) | ​ | ​ | ​ | ​ | ​ | (5) | ​ | ​ | ​ | ​ | ​ | (11) | ​ | ​ |
| At 30 September 2017                 | ​ | ​ | ​                                            | ​ | 5,451    | ​                        | ​ | ​ | ​                                       | ​ | 3,603   | ​                            | ​ | ​ | ​                           | ​ | 21,224  | ​          | ​ | ​ | ​ | ​ | 1,581 | ​ | ​ | ​ | ​ | ​ | 26,980 | ​ | ​ | ​ | ​ | ​ | 58,839 | ​ | ​ |
| Accumulated depreciation and impairment   | ​ | ​ | ​                                            | ​ | ​  | ​                        | ​ | ​ | ​                                       | ​ | ​ | ​                            | ​ | ​ | ​                           | ​ | ​ | ​          | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| At 1 October 2015                    | ​ | ​ | ​                                            | ​ | 606      | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | 3,765   | ​          | ​ | ​ | ​ | ​ | 1,339 | ​ | ​ | ​ | ​ | ​ | 2,266 | ​ | ​ | ​ | ​ | ​ | 7,976 | ​ | ​ |
| Charge for the year                       | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | 63      | ​                            | ​ | ​ | ​                           | ​ | 1,654   | ​          | ​ | ​ | ​ | ​ | 338 | ​ | ​ | ​ | ​ | ​ | 1,550 | ​ | ​ | ​ | ​ | ​ | 3,605 | ​ | ​ |
| Reclassifications                         | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | 216     | ​          | ​ | ​ | ​ | ​ | (216) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ |
| Disposals                                 | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | (112)   | ​          | ​ | ​ | ​ | ​ | (788) | ​ | ​ | ​ | ​ | ​ | (122) | ​ | ​ | ​ | ​ | ​ | (1,022) | ​ | ​ |
| Exchange differences                      | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | — | ​          | ​ | ​ | ​ | ​ | 1 | ​ | ​ | ​ | ​ | ​ | 1 | ​ | ​ | ​ | ​ | ​ | 2 | ​ | ​ |
| At 1 October 2016                    | ​ | ​ | ​                                            | ​ | 606      | ​                        | ​ | ​ | ​                                       | ​ | 63      | ​                            | ​ | ​ | ​                           | ​ | 5,523   | ​          | ​ | ​ | ​ | ​ | 674 | ​ | ​ | ​ | ​ | ​ | 3,695 | ​ | ​ | ​ | ​ | ​ | 10,561 | ​ | ​ |
| Charge for the year                       | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | 180     | ​                            | ​ | ​ | ​                           | ​ | 2,166   | ​          | ​ | ​ | ​ | ​ | 331 | ​ | ​ | ​ | ​ | ​ | 2,599 | ​ | ​ | ​ | ​ | ​ | 5,276 | ​ | ​ |
| Transfers to assets held for sale in year | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | (340)   | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (340) | ​ | ​ |
| Impairment of assets                      | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | 635     | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 635 | ​ | ​ |
| Reversal of impairment of assets          | ​ | ​ | ​                                            | ​ | (216)    | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | — | ​          | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (216) | ​ | ​ |
| Disposals                                 | ​ | ​ | ​                                            | ​ | (390)    | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | (168)   | ​          | ​ | ​ | ​ | ​ | (32) | ​ | ​ | ​ | ​ | ​ | (150) | ​ | ​ | ​ | ​ | ​ | (740) | ​ | ​ |
| Exchange differences                      | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | — | ​                            | ​ | ​ | ​                           | ​ | — | ​          | ​ | ​ | ​ | ​ | (2) | ​ | ​ | ​ | ​ | ​ | (1) | ​ | ​ | ​ | ​ | ​ | (3) | ​ | ​ |
| At 30 September 2017                 | ​ | ​ | ​                                            | ​ | —  | ​                        | ​ | ​ | ​                                       | ​ | 243     | ​                            | ​ | ​ | ​                           | ​ | 7,816   | ​          | ​ | ​ | ​ | ​ | 971 | ​ | ​ | ​ | ​ | ​ | 6,143 | ​ | ​ | ​ | ​ | ​ | 15,173 | ​ | ​ |
| Net book value                            | ​ | ​ | ​                                            | ​ | ​  | ​                        | ​ | ​ | ​                                       | ​ | ​ | ​                            | ​ | ​ | ​                           | ​ | ​ | ​          | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| At 30 September 2017                 | ​ | ​ | ​                                            | ​ | 5,451    | ​                        | ​ | ​ | ​                                       | ​ | 3,360   | ​                            | ​ | ​ | ​                           | ​ | 13,408  | ​          | ​ | ​ | ​ | ​ | 610 | ​ | ​ | ​ | ​ | ​ | 20,837 | ​ | ​ | ​ | ​ | ​ | 43,666 | ​ | ​ |
| At 30 September 2016                 | ​ | ​ | ​                                            | ​ | 20,752   | ​                        | ​ | ​ | ​                                       | ​ | 3,540   | ​                            | ​ | ​ | ​                           | ​ | 7,306   | ​          | ​ | ​ | ​ | ​ | 743 | ​ | ​ | ​ | ​ | ​ | 6,606 | ​ | ​ | ​ | ​ | ​ | 38,947 | ​ | ​ |

----

TABLE OF CONTENTS

|                                     | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
|-------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Raw materials                       | ​ | ​ | ​         | ​ | 199     | ​         | ​ | ​ | ​ | ​ | 252 | ​ | ​ |
| Work in progress                    | ​ | ​ | ​         | ​ | 3,379   | ​         | ​ | ​ | ​ | ​ | 3,226 | ​ | ​ |
| Finished goods                      | ​ | ​ | ​         | ​ | 666     | ​         | ​ | ​ | ​ | ​ | 770 | ​ | ​ |
| Total inventories, net of provision | ​ | ​ | ​         | ​ | 4,244   | ​         | ​ | ​ | ​ | ​ | 4,248 | ​ | ​ |
| ​                                            | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
|----------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Opening balance as at 1 October                    | ​ | ​ | ​         | ​ | 118     | ​         | ​ | ​ | ​ | ​ | 66 | ​ | ​ |
| Write down of inventories                          | ​ | ​ | ​         | ​ | 159     | ​         | ​ | ​ | ​ | ​ | 129 | ​ | ​ |
| Write off of inventories included in the provision | ​ | ​ | ​         | ​ | (177)   | ​         | ​ | ​ | ​ | ​ | (20) | ​ | ​ |
| Reversal of write down of inventories              | ​ | ​ | ​         | ​ | (59)    | ​         | ​ | ​ | ​ | ​ | (57) | ​ | ​ |
| Closing balance as at 30 September                 | ​ | ​ | ​         | ​ | 41      | ​         | ​ | ​ | ​ | ​ | 118 | ​ | ​ |
|                                     | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
|-------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Amounts falling due within one year | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Trade receivables                   | ​ | ​ | ​         | ​ | 1,023   | ​         | ​ | ​ | ​ | ​ | 778 | ​ | ​ |
| Prepayments and accrued income      | ​ | ​ | ​         | ​ | 7,481   | ​         | ​ | ​ | ​ | ​ | 2,637 | ​ | ​ |
| Other receivables                   | ​ | ​ | ​         | ​ | 2,713   | ​         | ​ | ​ | ​ | ​ | 1,141 | ​ | ​ |
| ​                             | ​ | ​ | ​         | ​ | 11,217  | ​         | ​ | ​ | ​ | ​ | 4,556 | ​ | ​ |

----

TABLE OF CONTENTS

|                                     | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
|-------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Amounts falling due within one year | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Other creditors and accruals        | ​ | ​ | ​         | ​ | 19,335  | ​         | ​ | ​ | ​ | ​ | 15,899 | ​ | ​ |
| Trade payables                      | ​ | ​ | ​         | ​ | 5,807   | ​         | ​ | ​ | ​ | ​ | 3,433 | ​ | ​ |
| Clinical trial accruals             | ​ | ​ | ​         | ​ | 5,520   | ​         | ​ | ​ | ​ | ​ | 9,503 | ​ | ​ |
| Other taxation and social security  | ​ | ​ | ​         | ​ | 2,032   | ​         | ​ | ​ | ​ | ​ | 1,490 | ​ | ​ |
| Fit out funding (see note 18)       | ​ | ​ | ​         | ​ | 389     | ​         | ​ | ​ | ​ | ​ | 845 | ​ | ​ |
| Onerous lease provision             | ​ | ​ | ​         | ​ | 36      | ​         | ​ | ​ | ​ | ​ | — | ​ | ​ |
| ​                             | ​ | ​ | ​         | ​ | 33,119  | ​         | ​ | ​ | ​ | ​ | 31,170 | ​ | ​ |
| Amounts falling due after one year  | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Fit out funding (see note 18)       | ​ | ​ | ​         | ​ | 7,957   | ​         | ​ | ​ | ​ | ​ | 8,342 | ​ | ​ |
| Other creditors and accruals        | ​ | ​ | ​         | ​ | 1,288   | ​         | ​ | ​ | ​ | ​ | 1,081 | ​ | ​ |
| Onerous lease provision             | ​ | ​ | ​         | ​ | 11      | ​         | ​ | ​ | ​ | ​ | — | ​ | ​ |
| ​                             | ​ | ​ | ​         | ​ | 9,256   | ​         | ​ | ​ | ​ | ​ | 9,423 | ​ | ​ |
| ​                             | ​ | ​ | ​         | ​ | 42,375  | ​         | ​ | ​ | ​ | ​ | 40,593 | ​ | ​ |

----

TABLE OF CONTENTS​​

| Forward projection of cash flows as at 30 September 2017 | ​ | ​ | <1 year£000s | ​ | ​ | 1 – 2 years £000s | ​ | ​ | 2 – 3 years £000s | ​ | ​ | 3 – 4 years £000s | ​ | ​ | 4 – 5 years £000s | ​ | ​ | 5+ years £000s | ​ | ​ | Total£000s | ​ |
|--------------------------------------------------------------------|---------|---------|----------------------|---------|---------|-----------------------------------------------|---------|---------|-----------------------------------------------|---------|---------|-----------------------------------------------|---------|---------|-----------------------------------------------|---------|---------|---------------------|---------|---------|-----------------|---------|
| Principal                                                          | ​ | ​ | ​              | ​ | 389     | ​                                       | ​ | ​ | ​                                       | ​ | 417     | ​                                       | ​ | ​ | ​                                       | ​ | 446     | ​             | ​ | ​ | ​         | ​ | 480 | ​ | ​ | ​ | ​ | ​ | 514 | ​ | ​ | ​ | ​ | ​ | 6,100 | ​ | ​ | ​ | ​ | ​ | 8,346 | ​ | ​ |
| Interest                                                           | ​ | ​ | ​              | ​ | 576     | ​                                       | ​ | ​ | ​                                       | ​ | 548     | ​                                       | ​ | ​ | ​                                       | ​ | 519     | ​             | ​ | ​ | ​         | ​ | 485 | ​ | ​ | ​ | ​ | ​ | 451 | ​ | ​ | ​ | ​ | ​ | 2,028 | ​ | ​ | ​ | ​ | ​ | 4,607 | ​ | ​ |
| Total                                                              | ​ | ​ | ​              | ​ | 965     | ​                                       | ​ | ​ | ​                                       | ​ | 965     | ​                                       | ​ | ​ | ​                                       | ​ | 965     | ​             | ​ | ​ | ​         | ​ | 965 | ​ | ​ | ​ | ​ | ​ | 965 | ​ | ​ | ​ | ​ | ​ | 8,128 | ​ | ​ | ​ | ​ | ​ | 12,953 | ​ | ​ |
| Forward projection of cash flows as at 30 September 2016 | ​ | ​ | <1 year£000s | ​ | ​ | 1 – 2 years £000s | ​ | ​ | 2 – 3 years £000s | ​ | ​ | 3 – 4 years £000s | ​ | ​ | 4 – 5 years £000s | ​ | ​ | 5+ years £000s | ​ | ​ | Total£000s | ​ |
|---------------------------------------------------------------|---------|---------|----------------------|---------|---------|-----------------------------------------------|---------|---------|-----------------------------------------------|---------|---------|-----------------------------------------------|---------|---------|-----------------------------------------------|---------|---------|---------------------|---------|---------|-----------------|---------|
| Principal                                                     | ​ | ​ | ​              | ​ | 845     | ​                                       | ​ | ​ | ​                                       | ​ | 389     | ​                                       | ​ | ​ | ​                                       | ​ | 417     | ​             | ​ | ​ | ​         | ​ | 446 | ​ | ​ | ​ | ​ | ​ | 479 | ​ | ​ | ​ | ​ | ​ | 6,611 | ​ | ​ | ​ | ​ | ​ | 9,187 | ​ | ​ |
| Interest                                                      | ​ | ​ | ​              | ​ | 603     | ​                                       | ​ | ​ | ​                                       | ​ | 576     | ​                                       | ​ | ​ | ​                                       | ​ | 548     | ​             | ​ | ​ | ​         | ​ | 519 | ​ | ​ | ​ | ​ | ​ | 486 | ​ | ​ | ​ | ​ | ​ | 2,480 | ​ | ​ | ​ | ​ | ​ | 5,212 | ​ | ​ |
| Total                                                         | ​ | ​ | ​              | ​ | 1,448   | ​                                       | ​ | ​ | ​                                       | ​ | 965     | ​                                       | ​ | ​ | ​                                       | ​ | 965     | ​             | ​ | ​ | ​         | ​ | 965 | ​ | ​ | ​ | ​ | ​ | 965 | ​ | ​ | ​ | ​ | ​ | 9,091 | ​ | ​ | ​ | ​ | ​ | 14,399 | ​ | ​ |
| ​                                     | ​ | ​ | Minimum Lease Payments | ​ |
|---------------------------------------------|---------|---------|------------------------|---------|
|                                             | ​ | ​ | 2017 £000s        | ​ | ​ | 2016 £000s | ​ |
| Amounts payable under finance leases:       | ​ | ​ | ​                | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Within one year                             | ​ | ​ | ​                | ​ | 556 | ​ | ​ | ​ | ​ | ​ | 571 | ​ | ​ |
| In the second to fifth years inclusive | ​ | ​ | ​                | ​ | 2,220 | ​ | ​ | ​ | ​ | ​ | 2,223 | ​ | ​ |
| After five years                       | ​ | ​ | ​                | ​ | 5,959 | ​ | ​ | ​ | ​ | ​ | 6,511 | ​ | ​ |
| ​                                     | ​ | ​ | ​                | ​ | 8,735 | ​ | ​ | ​ | ​ | ​ | 9,305 | ​ | ​ |
| Less: future finance charges                | ​ | ​ | ​                | ​ | (3,775) | ​ | ​ | ​ | ​ | ​ | (4,135) | ​ | ​ |
| Present value of lease obligations          | ​ | ​ | ​                | ​ | 4,960 | ​ | ​ | ​ | ​ | ​ | 5,170 | ​ | ​ |
| ​                                          | ​ | ​ | Present Value of Lease Payments | ​ |
|--------------------------------------------------|---------|---------|---------------------------------|---------|
| ​                                          | ​ | ​ | 2017 £000s                 | ​ | ​ | 2016 £000s | ​ |
| Amounts payable under finance leases:            | ​ | ​ | ​                         | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Amounts due for settlement within 12 months | ​ | ​ | ​                         | ​ | 205 | ​ | ​ | ​ | ​ | ​ | 211 | ​ | ​ |
| Amounts due for settlement after 12 months  | ​ | ​ | ​                         | ​ | 4,755 | ​ | ​ | ​ | ​ | ​ | 4,959 | ​ | ​ |
| ​                                          | ​ | ​ | ​                         | ​ | 4,960 | ​ | ​ | ​ | ​ | ​ | 5,170 | ​ | ​ |

----

TABLE OF CONTENTS

|                                                                    | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
|--------------------------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Amounts falling due within one year                                | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Deferred licence, collaboration and technical access fee income(1) | ​ | ​ | ​         | ​ | 1,166   | ​         | ​ | ​ | ​ | ​ | 1,451 | ​ | ​ |
| Advance research and development fees(2)                           | ​ | ​ | ​         | ​ | 1,141   | ​         | ​ | ​ | ​ | ​ | 1,235 | ​ | ​ |
| ​                                                            | ​ | ​ | ​         | ​ | 2,307   | ​         | ​ | ​ | ​ | ​ | 2,686 | ​ | ​ |
| Amounts falling due after one year                                 | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Deferred licence, collaboration and technical access fee income(1) | ​ | ​ | ​         | ​ | 4,260   | ​         | ​ | ​ | ​ | ​ | 5,355 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                                                    | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
|------------------------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Financial assets – loans and receivables | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Cash and cash equivalents                                  | ​ | ​ | ​         | ​ | 241,175 | ​         | ​ | ​ | ​ | ​ | 374,392 | ​ | ​ |
| Trade receivables – at amortised cost    | ​ | ​ | ​         | ​ | 1,023   | ​         | ​ | ​ | ​ | ​ | 778 | ​ | ​ |
| Other receivables                                          | ​ | ​ | ​         | ​ | 1,699   | ​         | ​ | ​ | ​ | ​ | 385 | ​ | ​ |
| Total financial assets                                     | ​ | ​ | ​         | ​ | 243,897 | ​         | ​ | ​ | ​ | ​ | 375,555 | ​ | ​ |
| Financial liabilities – amortised cost   | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Other creditors and accruals                               | ​ | ​ | ​         | ​ | 16,546  | ​         | ​ | ​ | ​ | ​ | 12,401 | ​ | ​ |
| Clinical trial accruals                                    | ​ | ​ | ​         | ​ | 5,520   | ​         | ​ | ​ | ​ | ​ | 9,503 | ​ | ​ |
| Trade payables                                             | ​ | ​ | ​         | ​ | 5,807   | ​         | ​ | ​ | ​ | ​ | 3,433 | ​ | ​ |
| Fit out funding                                            | ​ | ​ | ​         | ​ | 8,346   | ​         | ​ | ​ | ​ | ​ | 9,187 | ​ | ​ |
| Obligations under finance leases                           | ​ | ​ | ​         | ​ | 4,960   | ​         | ​ | ​ | ​ | ​ | 5,170 | ​ | ​ |
| Total financial liabilities                                | ​ | ​ | ​         | ​ | 41,179  | ​         | ​ | ​ | ​ | ​ | 39,694 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                                       | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
|-----------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Cash at bank and in hand:                     | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Pounds Sterling                               | ​ | ​ | ​         | ​ | 57,246  | ​         | ​ | ​ | ​ | ​ | 73,277 | ​ | ​ |
| Euro                                          | ​ | ​ | ​         | ​ | 1,848   | ​         | ​ | ​ | ​ | ​ | 1,582 | ​ | ​ |
| US Dollar                                     | ​ | ​ | ​         | ​ | 25,681  | ​         | ​ | ​ | ​ | ​ | 169,738 | ​ | ​ |
| Canadian Dollar                               | ​ | ​ | ​         | ​ | 1,002   | ​         | ​ | ​ | ​ | ​ | 448 | ​ | ​ |
| Total                                         | ​ | ​ | ​         | ​ | 85,777  | ​         | ​ | ​ | ​ | ​ | 245,045 | ​ | ​ |
| Short-term deposits (less than 30 days): | ​ | ​ | ​         | ​ | ​ | ​         | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| Pounds Sterling                               | ​ | ​ | ​         | ​ | — | ​         | ​ | ​ | ​ | ​ | 31,564 | ​ | ​ |
| US Dollar                                     | ​ | ​ | ​         | ​ | 155,398 | ​         | ​ | ​ | ​ | ​ | 97,783 | ​ | ​ |
| Total cash and cash equivalents               | ​ | ​ | ​         | ​ | 241,175 | ​         | ​ | ​ | ​ | ​ | 374,392 | ​ | ​ |

----

TABLE OF CONTENTS

| ​         | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| US Dollar       | ​ | ​ | ​         | ​ | 171,375 | ​         | ​ | ​ | ​ | ​ | 263,094 | ​ | ​ |
| Euro            | ​ | ​ | ​         | ​ | 420     | ​         | ​ | ​ | ​ | ​ | 1,665 | ​ | ​ |
| Canadian Dollar | ​ | ​ | ​         | ​ | 1,002   | ​         | ​ | ​ | ​ | ​ | 649 | ​ | ​ |
| Other           | ​ | ​ | ​         | ​ | (276)   | ​         | ​ | ​ | ​ | ​ | (38) | ​ | ​ |
| ​         | ​ | ​ | ​         | ​ | 172,521 | ​         | ​ | ​ | ​ | ​ | 265,370 | ​ | ​ |
| Year Ended 30 September 2017 | ​ | ​ | Euro £000s | ​ | ​ | US Dollar £000s | ​ | ​ | Can Dollar £000s | ​ | ​ | Other £000s | ​ |
|-----------------------------------|---------|---------|-----------------|---------|---------|----------------------|---------|---------|-----------------------|---------|---------|------------------|---------|
| Loss before tax                   | ​ | ​ | ​         | ​ | 42      | ​              | ​ | ​ | ​               | ​ | 17,138  | ​          | ​ | ​ | ​ | ​ | 100 | ​ | ​ | ​ | ​ | ​ | (28) | ​ | ​ |
| Equity                            | ​ | ​ | ​         | ​ | 42      | ​              | ​ | ​ | ​               | ​ | 17,138  | ​          | ​ | ​ | ​ | ​ | 100 | ​ | ​ | ​ | ​ | ​ | (28) | ​ | ​ |
| Year Ended 30 September 2016 | ​ | ​ | Euro £000s | ​ | ​ | US Dollar £000s | ​ | ​ | Can Dollar £000s | ​ | ​ | Other £000s | ​ |
|-----------------------------------|---------|---------|-----------------|---------|---------|----------------------|---------|---------|-----------------------|---------|---------|------------------|---------|
| Loss before tax                   | ​ | ​ | ​         | ​ | 167     | ​              | ​ | ​ | ​               | ​ | 26,309  | ​          | ​ | ​ | ​ | ​ | 65 | ​ | ​ | ​ | ​ | ​ | (4) | ​ | ​ |
| Equity                            | ​ | ​ | ​         | ​ | 167     | ​              | ​ | ​ | ​               | ​ | 26,309  | ​          | ​ | ​ | ​ | ​ | 65 | ​ | ​ | ​ | ​ | ​ | (4) | ​ | ​ |
| Year Ended 30 September 2015 | ​ | ​ | Euro £000s | ​ | ​ | US Dollar £000s | ​ | ​ | Can Dollar £000s | ​ | ​ | Other £000s | ​ |
|-----------------------------------|---------|---------|-----------------|---------|---------|----------------------|---------|---------|-----------------------|---------|---------|------------------|---------|
| Loss before tax                   | ​ | ​ | ​         | ​ | 77      | ​              | ​ | ​ | ​               | ​ | 17,780  | ​          | ​ | ​ | ​ | ​ | 95 | ​ | ​ | ​ | ​ | ​ | (6) | ​ | ​ |
| Equity                            | ​ | ​ | ​         | ​ | 77      | ​              | ​ | ​ | ​               | ​ | 17,780  | ​          | ​ | ​ | ​ | ​ | 95 | ​ | ​ | ​ | ​ | ​ | (6) | ​ | ​ |

----

TABLE OF CONTENTS

| ​                            | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
|------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Allotted, called-up and fully paid | ​ | ​ | ​         | ​ | 304     | ​         | ​ | ​ | ​ | ​ | 302 | ​ | ​ |
| ​                                     | ​ | ​ | Number of Shares | ​ | ​     | Total Nominal Value £000s | ​ | ​ | Total Share Premium £000s | ​ | ​ | Total Consideration £000s | ​ |
|---------------------------------------------|---------|---------|------------------|---------|-------------|--------------------------------|---------|---------|--------------------------------|---------|---------|--------------------------------|---------|
| As at 1 October 2015                   | ​ | ​ | ​          | ​ | 261,180,173 | ​                        | ​ | ​ | ​                        | ​ | 261     | ​                        | ​ | ​ | ​ | ​ | 349,275 | ​ | ​ | ​ | ​ | ​ | 349,536 | ​ | ​ |
| Issue of new shares (net of issuance costs) | ​ | ​ | ​          | ​ | 38,640,000  | ​                        | ​ | ​ | ​                        | ​ | 39      | ​                        | ​ | ​ | ​ | ​ | 206,512 | ​ | ​ | ​ | ​ | ​ | 206,551 | ​ | ​ |
| Exercise of share options                   | ​ | ​ | ​          | ​ | 2,272,966   | ​                        | ​ | ​ | ​                        | ​ | 2       | ​                        | ​ | ​ | ​ | ​ | 690 | ​ | ​ | ​ | ​ | ​ | 692 | ​ | ​ |
| As at 1 October 2016                   | ​ | ​ | ​          | ​ | 302,093,139 | ​                        | ​ | ​ | ​                        | ​ | 302     | ​                        | ​ | ​ | ​ | ​ | 556,477 | ​ | ​ | ​ | ​ | ​ | 556,779 | ​ | ​ |
| Exercise of share options                   | ​ | ​ | ​          | ​ | 2,346,601   | ​                        | ​ | ​ | ​                        | ​ | 2       | ​                        | ​ | ​ | ​ | ​ | 93 | ​ | ​ | ​ | ​ | ​ | 95 | ​ | ​ |
| As at 30 September 2017                | ​ | ​ | ​          | ​ | 304,439,740 | ​                        | ​ | ​ | ​                        | ​ | 304     | ​                        | ​ | ​ | ​ | ​ | 556,570 | ​ | ​ | ​ | ​ | ​ | 556,874 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                       | ​ | ​ | 30 Sept 2017 Number of Share Options | ​ | ​    | 30 Sept 2016 Number of Share Options | ​ |
|-------------------------------|---------|---------|--------------------------------------|---------|------------|--------------------------------------|---------|
| Employee share option schemes | ​ | ​ | ​                              | ​ | —    | ​                              | ​ | ​ | ​ | ​ | 107,542 | ​ | ​ |
| Employee LTIP awards          | ​ | ​ | ​                              | ​ | 11,925,948 | ​                              | ​ | ​ | ​ | ​ | 10,525,630 | ​ | ​ |
| Options outstanding           | ​ | ​ | ​                              | ​ | 11,925,948 | ​                              | ​ | ​ | ​ | ​ | 10,633,172 | ​ | ​ |
| ​                               | ​ | ​ | Employee Options        | ​ | ​   | Employee LTIP                          | ​ | ​ | Total Options           | ​ |
|---------------------------------------|---------|---------|-------------------------|---------|-----------|----------------------------------------|---------|---------|-------------------------|---------|
| ​                               | ​ | ​ | Number of Share Options | ​ | ​   | Weighted Average Exercise Price £ | ​ | ​ | Number of Share Options | ​ | ​ | Weighted Average Exercise Price £ | ​ | ​ | Number of Share Options | ​ | ​ | Weighted Average Exercise Price £ | ​ |
| Outstanding at 1 October 2015    | ​ | ​ | ​                 | ​ | 770,936   | ​                                | ​ | ​ | ​                 | ​ | 1.02 | ​ | ​ | ​ | ​ | ​ | 7,660,564 | ​ | ​ | ​ | ​ | ​ | 0.29 | ​ | ​ | ​ | ​ | ​ | 8,431,500 | ​ | ​ | ​ | ​ | ​ | 0.35 | ​ | ​ |
| Granted during the year               | ​ | ​ | ​                 | ​ | —   | ​                                | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 4,767,106 | ​ | ​ | ​ | ​ | ​ | 0.60 | ​ | ​ | ​ | ​ | ​ | 4,767,106 | ​ | ​ | ​ | ​ | ​ | 0.60 | ​ | ​ |
| Exercised during the year             | ​ | ​ | ​                 | ​ | (663,394) | ​                                | ​ | ​ | ​                 | ​ | 1.04 | ​ | ​ | ​ | ​ | ​ | (1,609,572) | ​ | ​ | ​ | ​ | ​ | 0.001 | ​ | ​ | ​ | ​ | ​ | (2,272,966) | ​ | ​ | ​ | ​ | ​ | 0.305 | ​ | ​ |
| Lapsed during the year                | ​ | ​ | ​                 | ​ | —   | ​                                | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | (292,468) | ​ | ​ | ​ | ​ | ​ | 0.001 | ​ | ​ | ​ | ​ | ​ | (292,468) | ​ | ​ | ​ | ​ | ​ | 0.001 | ​ | ​ |
| Outstanding at 1 October 2016    | ​ | ​ | ​                 | ​ | 107,542   | ​                                | ​ | ​ | ​                 | ​ | 0.868 | ​ | ​ | ​ | ​ | ​ | 10,525,630 | ​ | ​ | ​ | ​ | ​ | 0.482 | ​ | ​ | ​ | ​ | ​ | 10,633,172 | ​ | ​ | ​ | ​ | ​ | 0.61 | ​ | ​ |
| Granted during the year               | ​ | ​ | ​                 | ​ | —   | ​                                | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 3,927,368 | ​ | ​ | ​ | ​ | ​ | 1.525 | ​ | ​ | ​ | ​ | ​ | 3,927,368 | ​ | ​ | ​ | ​ | ​ | 1.525 | ​ | ​ |
| Exercised during the year             | ​ | ​ | ​                 | ​ | (107,538) | ​                                | ​ | ​ | ​                 | ​ | 0.868 | ​ | ​ | ​ | ​ | ​ | (2,239,063) | ​ | ​ | ​ | ​ | ​ | 0.001 | ​ | ​ | ​ | ​ | ​ | (2,346,601) | ​ | ​ | ​ | ​ | ​ | 0.041 | ​ | ​ |
| Lapsed during the year                | ​ | ​ | ​                 | ​ | (4)       | ​                                | ​ | ​ | ​                 | ​ | 0.540 | ​ | ​ | ​ | ​ | ​ | (287,987) | ​ | ​ | ​ | ​ | ​ | 0.001 | ​ | ​ | ​ | ​ | ​ | (287,991) | ​ | ​ | ​ | ​ | ​ | 0.001 | ​ | ​ |
| Outstanding at 30 September 2017 | ​ | ​ | ​                 | ​ | —   | ​                                | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 11,925,948 | ​ | ​ | ​ | ​ | ​ | 0.927 | ​ | ​ | ​ | ​ | ​ | 11,925,948 | ​ | ​ | ​ | ​ | ​ | 0.927 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                                   | ​ | ​ | Employee Options        | ​ | ​ | Employee LTIP                                     | ​ | ​ | Total Options           | ​ |
|-------------------------------------------|---------|---------|-------------------------|---------|---------|---------------------------------------------------|---------|---------|-------------------------|---------|
| ​                                   | ​ | ​ | Number of Share Options | ​ | ​ | Weighted Average Remaining Contractual Life/Years | ​ | ​ | Number of Share Options | ​ | ​ | Weighted Average Remaining Contractual Life/Years | ​ | ​ | Number of Share Options | ​ | ​ | Weighted Average Remaining Contractual Life/Years | ​ |
| £0.00 – £0.50 | ​ | ​ | ​                 | ​ | — | ​                                           | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 9,752,126 | ​ | ​ | ​ | ​ | ​ | 5.34 | ​ | ​ | ​ | ​ | ​ | 9,752,126 | ​ | ​ | ​ | ​ | ​ | 5.34 | ​ | ​ |
| £2.50+                               | ​ | ​ | ​                 | ​ | — | ​                                           | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 2,173,822 | ​ | ​ | ​ | ​ | ​ | 8.70 | ​ | ​ | ​ | ​ | ​ | 2,173,822 | ​ | ​ | ​ | ​ | ​ | 8.70 | ​ | ​ |
| Outstanding at 30 September 2017     | ​ | ​ | ​                 | ​ | — | ​                                           | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 11,925,948 | ​ | ​ | ​ | ​ | ​ | 5.95 | ​ | ​ | ​ | ​ | ​ | 11,925,948 | ​ | ​ | ​ | ​ | ​ | 5.95 | ​ | ​ |
| Exercisable at 30 September 2017     | ​ | ​ | ​                 | ​ | — | ​                                           | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,986,029 | ​ | ​ | ​ | ​ | ​ | 4.87 | ​ | ​ | ​ | ​ | ​ | 1,986,029 | ​ | ​ | ​ | ​ | ​ | 4.87 | ​ | ​ |
| ​                                   | ​ | ​ | Employee Options        | ​ | ​ | Employee LTIP                                     | ​ | ​ | Total Options           | ​ |
|-------------------------------------------|---------|---------|-------------------------|---------|---------|---------------------------------------------------|---------|---------|-------------------------|---------|
| ​                                   | ​ | ​ | Number of Share Options | ​ | ​ | Weighted Average Remaining Contractual Life/Years | ​ | ​ | Number of Share Options | ​ | ​ | Weighted Average Remaining Contractual Life/Years | ​ | ​ | Number of Share Options | ​ | ​ | Weighted Average Remaining Contractual Life/Years | ​ |
| £0.00 – £0.50 | ​ | ​ | ​                 | ​ | 4,000   | ​                                           | ​ | ​ | ​                 | ​ | 1.97 | ​ | ​ | ​ | ​ | ​ | 9,182,071 | ​ | ​ | ​ | ​ | ​ | 6.26 | ​ | ​ | ​ | ​ | ​ | 9,186,071 | ​ | ​ | ​ | ​ | ​ | 6.25 | ​ | ​ |
| £0.51 – £1.00 | ​ | ​ | ​                 | ​ | 103,542 | ​                                           | ​ | ​ | ​                 | ​ | 0.59 | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | 103,542 | ​ | ​ | ​ | ​ | ​ | 0.59 | ​ | ​ |
| £1.00+                               | ​ | ​ | ​                 | ​ | — | ​                                           | ​ | ​ | ​                 | ​ | — | ​ | ​ | ​ | ​ | ​ | 1,343,559 | ​ | ​ | ​ | ​ | ​ | 7.24 | ​ | ​ | ​ | ​ | ​ | 1,343,559 | ​ | ​ | ​ | ​ | ​ | 7.24 | ​ | ​ |
| Outstanding at 30 September 2016     | ​ | ​ | ​                 | ​ | 107,542 | ​                                           | ​ | ​ | ​                 | ​ | 0.64 | ​ | ​ | ​ | ​ | ​ | 10,525,630 | ​ | ​ | ​ | ​ | ​ | 6.38 | ​ | ​ | ​ | ​ | ​ | 10,633,172 | ​ | ​ | ​ | ​ | ​ | 6.32 | ​ | ​ |
| Exercisable at 30 September 2016     | ​ | ​ | ​                 | ​ | 107,542 | ​                                           | ​ | ​ | ​                 | ​ | 0.64 | ​ | ​ | ​ | ​ | ​ | 3,057,821 | ​ | ​ | ​ | ​ | ​ | 6.12 | ​ | ​ | ​ | ​ | ​ | 3,165,363 | ​ | ​ | ​ | ​ | ​ | 5.93 | ​ | ​ |
| ​                                    | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|--------------------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Research and development expenditure       | ​ | ​ | ​         | ​ | 4,044   | ​         | ​ | ​ | ​         | ​ | 4,119 | ​ | ​ | ​ | ​ | ​ | 1,525 | ​ | ​ |
| Sales, general and administrative expenses | ​ | ​ | ​         | ​ | 7,816   | ​         | ​ | ​ | ​         | ​ | 4,033 | ​ | ​ | ​ | ​ | ​ | 953 | ​ | ​ |
| ​                                    | ​ | ​ | ​         | ​ | 11,860  | ​         | ​ | ​ | ​         | ​ | 8,152 | ​ | ​ | ​ | ​ | ​ | 2,478 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                         | ​ | ​ | 2017            | ​ | ​ | 2016           | ​ | ​ | 2015           | ​ |
|---------------------------------|---------|---------|-----------------|---------|---------|----------------|---------|---------|----------------|---------|
| Weighted average share price    | ​ | ​ | 744p            | ​ | ​ | 298p           | ​ | ​ | 579p           | ​ |
| Weighted average exercise price | ​ | ​ | 152p            | ​ | ​ | 60p            | ​ | ​ | 109p           | ​ |
| Expected volatility             | ​ | ​ | 67%             | ​ | ​ | 58%            | ​ | ​ | 59%            | ​ |
| Expected life                   | ​ | ​ | 3.26 years | ​ | ​ | 3.3 years | ​ | ​ | 3.6 years | ​ |
| Risk-free rate                  | ​ | ​ | 1.25%           | ​ | ​ | 1.09%          | ​ | ​ | 1.32%          | ​ |
| Expected dividend yield         | ​ | ​ | Nil             | ​ | ​ | Nil            | ​ | ​ | Nil            | ​ |
| ​                                               | ​ | ​ | 2017 Number | ​ | ​ | 2016 Number | ​ |
|-------------------------------------------------------|---------|---------|-------------|---------|---------|-------------|---------|
| Unconditionally vested in employees                   | ​ | ​ | ​     | ​ | 69,119  | ​     | ​ | ​ | ​ | ​ | 90,043 | ​ | ​ |
| Shares available for future distribution to employees | ​ | ​ | ​     | ​ | 33,054  | ​     | ​ | ​ | ​ | ​ | 33,054 | ​ | ​ |
| Total                                                 | ​ | ​ | ​     | ​ | 102,173 | ​     | ​ | ​ | ​ | ​ | 123,097 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                         | ​ | ​ | Group           | ​ |
|---------------------------------|---------|---------|-----------------|---------|
| ​                         | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
| Within one year                 | ​ | ​ | ​         | ​ | 3,628 | ​ | ​ | ​ | ​ | ​ | 2,723 | ​ | ​ |
| Between two and five years | ​ | ​ | ​         | ​ | 8,745 | ​ | ​ | ​ | ​ | ​ | 8,117 | ​ | ​ |
| After five years           | ​ | ​ | ​         | ​ | 1,937 | ​ | ​ | ​ | ​ | ​ | 2,198 | ​ | ​ |
| ​                         | ​ | ​ | ​         | ​ | 14,310 | ​ | ​ | ​ | ​ | ​ | 13,038 | ​ | ​ |
| ​                         | ​ | ​ | Group           | ​ |
|---------------------------------|---------|---------|-----------------|---------|
| ​                         | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ |
| Within one year                 | ​ | ​ | ​         | ​ | 8,973 | ​ | ​ | ​ | ​ | ​ | 6,755 | ​ | ​ |
| Between two and five years | ​ | ​ | ​         | ​ | 29,942 | ​ | ​ | ​ | ​ | ​ | 36,667 | ​ | ​ |
| After five years           | ​ | ​ | ​         | ​ | — | ​ | ​ | ​ | ​ | ​ | 2,248 | ​ | ​ |
| ​                         | ​ | ​ | ​         | ​ | 38,915 | ​ | ​ | ​ | ​ | ​ | 45,670 | ​ | ​ |

----

TABLE OF CONTENTS

| ​                      | ​ | ​ | 2017 £000s | ​ | ​ | 2016 £000s | ​ | ​ | 2015 £000s | ​ |
|------------------------------|---------|---------|-----------------|---------|---------|-----------------|---------|---------|-----------------|---------|
| Short-term employee benefits | ​ | ​ | ​         | ​ | 4,144   | ​         | ​ | ​ | ​         | ​ | 2,523 | ​ | ​ | ​ | ​ | ​ | 2,395 | ​ | ​ |
| Post-employment benefits     | ​ | ​ | ​         | ​ | 84      | ​         | ​ | ​ | ​         | ​ | 215 | ​ | ​ | ​ | ​ | ​ | 211 | ​ | ​ |
| Share-based payments         | ​ | ​ | ​         | ​ | 7,237   | ​         | ​ | ​ | ​         | ​ | 4,556 | ​ | ​ | ​ | ​ | ​ | 1,164 | ​ | ​ |
| ​                      | ​ | ​ | ​         | ​ | 11,465  | ​         | ​ | ​ | ​         | ​ | 7,294 | ​ | ​ | ​ | ​ | ​ | 3,770 | ​ | ​ |

----